US20210186555A1 - Balloon assemblies having controllably variable topographies - Google Patents
Balloon assemblies having controllably variable topographies Download PDFInfo
- Publication number
- US20210186555A1 US20210186555A1 US17/136,570 US202017136570A US2021186555A1 US 20210186555 A1 US20210186555 A1 US 20210186555A1 US 202017136570 A US202017136570 A US 202017136570A US 2021186555 A1 US2021186555 A1 US 2021186555A1
- Authority
- US
- United States
- Prior art keywords
- balloon
- template
- assembly
- aperture
- inflated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012876 topography Methods 0.000 title description 62
- 230000000712 assembly Effects 0.000 title description 38
- 238000000429 assembly Methods 0.000 title description 38
- 230000000670 limiting effect Effects 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 41
- 229940124597 therapeutic agent Drugs 0.000 claims description 38
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 33
- 206010000060 Abdominal distension Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 description 56
- 239000010408 film Substances 0.000 description 40
- 238000000034 method Methods 0.000 description 32
- 230000001427 coherent effect Effects 0.000 description 23
- 230000001788 irregular Effects 0.000 description 23
- -1 filaments Substances 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 239000012530 fluid Substances 0.000 description 21
- 238000002399 angioplasty Methods 0.000 description 16
- 239000002245 particle Substances 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 229920001169 thermoplastic Polymers 0.000 description 10
- 239000000853 adhesive Substances 0.000 description 9
- 230000001070 adhesive effect Effects 0.000 description 9
- 239000004416 thermosoftening plastic Substances 0.000 description 9
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 8
- 229920009441 perflouroethylene propylene Polymers 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 229920002313 fluoropolymer Polymers 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 240000007817 Olea europaea Species 0.000 description 5
- 210000003484 anatomy Anatomy 0.000 description 5
- 229910052785 arsenic Inorganic materials 0.000 description 5
- 229940091658 arsenic Drugs 0.000 description 5
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000004811 fluoropolymer Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000013151 thrombectomy Methods 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000007669 thermal treatment Methods 0.000 description 4
- 206010002329 Aneurysm Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- MSKQYWJTFPOQAV-UHFFFAOYSA-N fluoroethene;prop-1-ene Chemical group CC=C.FC=C MSKQYWJTFPOQAV-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- MUMCCPUVOAUBAN-UHFFFAOYSA-N liriodenine Chemical compound C1=NC(C(=O)C=2C3=CC=CC=2)=C2C3=C(OCO3)C3=CC2=C1 MUMCCPUVOAUBAN-UHFFFAOYSA-N 0.000 description 3
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000003746 surface roughness Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- DGSRXKGBZHMWTF-UHFFFAOYSA-N (12-hydroxy-5-methoxy-2,2,9-trimethyl-11-oxo-8,10-dihydronaphtho[3,2-h]chromen-9-yl) acetate Chemical compound O1C(C)(C)C=CC2=C1C1=C(O)C(C(=O)CC(C)(C3)OC(C)=O)=C3C=C1C=C2OC DGSRXKGBZHMWTF-UHFFFAOYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- BGGIZHKHJBQRTI-VTYGAKHASA-N (3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-[(2r,3r,4s,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde Chemical compound O1[C@H](C)[C@@H](O)[C@H](OC)[C@@H](OC)[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 BGGIZHKHJBQRTI-VTYGAKHASA-N 0.000 description 2
- BGGIZHKHJBQRTI-HJKWRMQUSA-N (3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-[(2r,3r,4s,5s,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](OC)[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 BGGIZHKHJBQRTI-HJKWRMQUSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VGXICZIFUHMPMS-UHFFFAOYSA-N 1,11-dimethoxy-6h-indolo[3,2,1-de][1,5]naphthyridin-6-one Chemical compound C1=2C3=C(OC)C=NC=2C=CC(=O)N1C1=C3C(OC)=CC=C1 VGXICZIFUHMPMS-UHFFFAOYSA-N 0.000 description 2
- GCNSBSLHQZFIMO-UHFFFAOYSA-N 1-[3-[(8-acetyl-3,5,7-trihydroxy-2,2-dimethyl-3,4-dihydrochromen-6-yl)methyl]-2,6-dihydroxy-4-methoxy-5-methylphenyl]ethanone Chemical compound COC1=C(C)C(O)=C(C(C)=O)C(O)=C1CC(C(=C1C(C)=O)O)=C(O)C2=C1OC(C)(C)C(O)C2 GCNSBSLHQZFIMO-UHFFFAOYSA-N 0.000 description 2
- LEPXKGXTXIACRO-UHFFFAOYSA-N 1-methoxycanthinone Chemical compound C1=CC(=O)N2C3=CC=CC=C3C3=C2C1=NC=C3OC LEPXKGXTXIACRO-UHFFFAOYSA-N 0.000 description 2
- MTVOSXTZNVKGIF-UHFFFAOYSA-N 2,3-dimethoxy-12-methyl-13h-[1,3]benzodioxolo[5,6-c]phenanthridine Chemical compound C1=C2C(N(C)CC=3C=C(C(=CC=33)OC)OC)=C3C=CC2=CC2=C1OCO2 MTVOSXTZNVKGIF-UHFFFAOYSA-N 0.000 description 2
- KKWJCGCIAHLFNE-UHFFFAOYSA-N 22R-hydroxylanosterol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C(O)CC=C(C)C)C)CCC21C KKWJCGCIAHLFNE-UHFFFAOYSA-N 0.000 description 2
- FXZKDRVSINFUOY-GNFMRZGLSA-N 3-[(3s,5r,8r,9s,10r,13r,14s,17r)-14-hydroxy-3-[(2r,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10-(hydroxymethyl)-13-methyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(CC[C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)O)[C@]3(CO)CC1 FXZKDRVSINFUOY-GNFMRZGLSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 102000012421 C-Type Natriuretic Peptide Human genes 0.000 description 2
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- CSYGXJQNODZRQO-UHFFFAOYSA-N Inotodiol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CC(O)C12C)C4(C)CCC(O)C(C)(C)C4CC3 CSYGXJQNODZRQO-UHFFFAOYSA-N 0.000 description 2
- ANFSXHKDCKWWDB-UHFFFAOYSA-N Justicidin A Chemical compound C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C(OC)=C3C=C(C(=CC3=2)OC)OC)=C1 ANFSXHKDCKWWDB-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BGGIZHKHJBQRTI-UHFFFAOYSA-N UNPD92725 Natural products O1C(C)C(O)C(OC)C(OC)C1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CCC3C2(C=O)CC1 BGGIZHKHJBQRTI-UHFFFAOYSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYYBXMVTBWYBDY-UOBFQKKOSA-N baccharinoids B2 Natural products O1C(=O)C=C\C=C\C(C(O)C)OCC(O)C(C)CC(=O)OCC23CC(O)C(C)=CC2OC2CC1C3(C)C21CO1 PYYBXMVTBWYBDY-UOBFQKKOSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- NPHHLSOQKLWOCK-AHIYZFNLSA-N chembl499134 Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(CO)C[C@H]5O[C@@]6(O)[C@H](O)C[C@@H](CO)O[C@H]6O[C@@H]5C[C@@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 NPHHLSOQKLWOCK-AHIYZFNLSA-N 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 2
- 229960001585 dicloxacillin Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
- 238000013156 embolectomy Methods 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- NPHHLSOQKLWOCK-UHFFFAOYSA-N ghalakinoside Natural products C1CC(C2C(C3(CO)CC4OC5(O)C(O)CC(CO)OC5OC4CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 NPHHLSOQKLWOCK-UHFFFAOYSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- KKWJCGCIAHLFNE-KFPHZHIMSA-N inotodiol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H]([C@H](O)CC=C(C)C)C)CC[C@]21C KKWJCGCIAHLFNE-KFPHZHIMSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- RTDRYYULUYRTAN-UHFFFAOYSA-N justicidin B Natural products C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C=C3C=C(C(=CC3=2)OC)OC)=C1 RTDRYYULUYRTAN-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000001349 mammary artery Anatomy 0.000 description 2
- 239000009014 mansonin Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960001237 podophyllotoxin Drugs 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RNYZJZKPGHQTJR-UHFFFAOYSA-N protoanemonin Chemical compound C=C1OC(=O)C=C1 RNYZJZKPGHQTJR-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- MFKPWBJXKCSPGK-KNORBDTNSA-N sinococuline Chemical compound C([C@@H]1NCC2)C3=CC=C(OC)C(O)=C3[C@@]32C1=C(OC)[C@@H](O)[C@@H](O)C3 MFKPWBJXKCSPGK-KNORBDTNSA-N 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- RWMIDFKXUZOZMK-UHFFFAOYSA-N strebloside Natural products COC1C(O)C(C)OC(OC2CCC3(C=O)C(CCC4C3CCC5(C)C(CCC45O)C6=CC(=O)OC6)C2)C1OC RWMIDFKXUZOZMK-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 2
- 229960005342 tranilast Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- LGSDYQBPJKYJCT-UHFFFAOYSA-N (-)-Akagerine Natural products OC1CC(C(C=O)=CC)CC2N(C)CCC3=C2N1C1=CC=CC=C31 LGSDYQBPJKYJCT-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- XNWZKGMGEINBJE-NIEJHYDOSA-N (1r,4z,6r,8e,10s,12e,14s)-6,10-dihydroxy-4,8,12,15,15-pentamethylbicyclo[12.1.0]pentadeca-4,8,12-trien-11-one Chemical compound C1CC(/C)=C\[C@H](O)C\C(C)=C\[C@H](O)C(=O)\C(C)=C\[C@@H]2C(C)(C)[C@H]12 XNWZKGMGEINBJE-NIEJHYDOSA-N 0.000 description 1
- FEOSJHQSWIDLGT-INJUBXAJSA-N (1s,4z,6r,8z,10r,12z,14r,15s)-6,10-dihydroxy-15-(hydroxymethyl)-4,8,12,15-tetramethylbicyclo[12.1.0]pentadeca-4,8,12-trien-11-one Chemical compound C1CC(/C)=C\[C@H](O)C\C(C)=C/[C@@H](O)C(=O)\C(C)=C/[C@H]2[C@](CO)(C)[C@@H]12 FEOSJHQSWIDLGT-INJUBXAJSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- IWQKGRNFKYKJHS-UHFFFAOYSA-N (2alpha,3beta,12beta)-2,3,12-Trihydroxypregna-4,7,16-trien-20-one Natural products OC1C(O)CC2(C)C(CC(O)C3(C(C(=O)C)=CCC33)C)C3=CCC2=C1 IWQKGRNFKYKJHS-UHFFFAOYSA-N 0.000 description 1
- KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 1
- KJTPWUVVLPCPJD-AUWJEWJLSA-N (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C\C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-AUWJEWJLSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- LLNJYWAPDLBDRC-DKNITUKRSA-N (3r,6's,7'r,8'as)-6'-ethenyl-7-[(2r)-1-methylpyrrolidin-2-yl]-7'-[[(1s)-2-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]methyl]spiro[1,2-dihydroindole-3,1'-3,5,6,7,8,8a-hexahydro-2h-indolizine]-6-ol Chemical compound CN1CCC[C@@H]1C1=C(NC[C@]23[C@@H]4C[C@H](C[C@H]5C6=C(C7=CC=CC=C7N6)CCN5C)[C@H](C=C)CN4CC3)C2=CC=C1O LLNJYWAPDLBDRC-DKNITUKRSA-N 0.000 description 1
- YNZXLMPHTZVKJN-VBKCWIKWSA-N (3z,5e,7r,8r,9s,10s,11r,13e,15e,17s,18r)-18-[(2s,3r,4s)-4-[(2r,4r,5s,6r)-2,4-dihydroxy-5-methyl-6-[(e)-prop-1-enyl]oxan-2-yl]-3-hydroxypentan-2-yl]-9-ethyl-8,10-dihydroxy-3,17-dimethoxy-5,7,11,13-tetramethyl-1-oxacyclooctadeca-3,5,13,15-tetraen-2-one Chemical compound O1C(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@H](OC)[C@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](\C=C\C)[C@@H](C)[C@H](O)C1 YNZXLMPHTZVKJN-VBKCWIKWSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 description 1
- GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
- IWQKGRNFKYKJHS-KQFCJCSDSA-N 1-[(2r,3r,9s,10r,12r,13s,14s)-2,3,12-trihydroxy-10,13-dimethyl-2,3,6,9,11,12,14,15-octahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound O[C@H]1[C@H](O)C[C@]2(C)[C@@H](C[C@@H](O)[C@@]3(C(C(=O)C)=CC[C@H]33)C)C3=CCC2=C1 IWQKGRNFKYKJHS-KQFCJCSDSA-N 0.000 description 1
- YOQKJYPYVSGRAG-UHFFFAOYSA-N 1-[6-[(3-acetyl-2,4-dihydroxy-6-methoxy-5-methylphenyl)methyl]-3,5,7-trihydroxy-2,2-dimethyl-3,4-dihydrochromen-8-yl]-2-methylpropan-1-one Chemical compound COC1=C(C)C(O)=C(C(C)=O)C(O)=C1CC(C(=C1C(=O)C(C)C)O)=C(O)C2=C1OC(C)(C)C(O)C2 YOQKJYPYVSGRAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- SOLIIYNRSAWTSQ-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 SOLIIYNRSAWTSQ-UHFFFAOYSA-N 0.000 description 1
- SJSCBAFROHXGCX-MAVWQDHUSA-N 3,16,21,28-Tetrahydroxyolean-12-en-22-yl (2Z)-2-methyl-2-butenoate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@@H](O)[C@@]5(CO)[C@@H](O)[C@H](OC(=O)C(\C)=C/C)C(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C SJSCBAFROHXGCX-MAVWQDHUSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- AJNRNTOMAOOUFZ-UHFFFAOYSA-N 4,7-Oxycycloanisomelic acid Natural products CC1=C/C2OC(=O)C(=C)C2CCC3(C)CCC(O3)C(=CCC1)C(=O)O AJNRNTOMAOOUFZ-UHFFFAOYSA-N 0.000 description 1
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 1
- TUGAUFMQYWZJAB-FPLPWBNLSA-N 5-[(8Z)-pentadec-8-enyl]resorcinol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC(O)=CC(O)=C1 TUGAUFMQYWZJAB-FPLPWBNLSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- GVZIONLFUHXCGG-UOBFQKKOSA-N 8beta-Hydroxy-Roridin A Natural products O1C(=O)C=C\C=C\C(C(O)C)OCCC(C)C(O)C(=O)OCC23CC(O)C(C)=CC2OC2CC1C3(C)C21CO1 GVZIONLFUHXCGG-UOBFQKKOSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- OSSDUQKWVVZIGP-UHFFFAOYSA-N Aromaticin Natural products CC1CC2OC(=O)C(=C)C2CC2(C)C(=O)C=CC12 OSSDUQKWVVZIGP-UHFFFAOYSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- SRLTUZDQBFYLQI-FPLPWBNLSA-N Bilobol Natural products Oc1c(CCCCCCC/C=C\CCCCCC)ccc(O)c1 SRLTUZDQBFYLQI-FPLPWBNLSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- NIPCMFQXEPLEQI-UHFFFAOYSA-N Bruceantinoside C Natural products COC(=O)C12OCC34C(CC5C(C)C=C(OC6OC(CO)C(O)C(O)C6O)C(=O)C5(C)C3C(O)C1O)OC(=O)C(OC(=O)C=C(/C)C(C)COC(=O)C)C24 NIPCMFQXEPLEQI-UHFFFAOYSA-N 0.000 description 1
- BMRNQSAXDJQXEL-ALGYPFNYSA-N Bryophyllin A Natural products O=C[C@@]12[C@H]3[C@H](O)C[C@]4(C)[C@H](C5=COC(=O)C=C5)CC[C@]4(O)[C@@H]3CC[C@]31O[C@]1(C)O[C@@H]2C[C@H](O1)C3 BMRNQSAXDJQXEL-ALGYPFNYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- XQCGNURMLWFQJR-ZNDDOCHDSA-N Cymarin Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 XQCGNURMLWFQJR-ZNDDOCHDSA-N 0.000 description 1
- XQCGNURMLWFQJR-UESCRGIISA-N Cymarin Natural products O=C[C@@]12[C@@](O)(C[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CC[C@H]21 XQCGNURMLWFQJR-UESCRGIISA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- JMUOPRSXUVOHFE-GZZMZBIISA-N Deoxyelephantopin Chemical compound C1\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2[C@@H](OC(=O)C(=C)C)CC2=C[C@@H]1OC2=O JMUOPRSXUVOHFE-GZZMZBIISA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010015543 Eustachian tube dysfunction Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
- ZVLOPMNVFLSSAA-UHFFFAOYSA-N Heleanalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C2(C)C(=O)C=CC12 ZVLOPMNVFLSSAA-UHFFFAOYSA-N 0.000 description 1
- RFBYGVGDYMSKTD-UHFFFAOYSA-N Helenalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C3C(C)C(=O)C=C13 RFBYGVGDYMSKTD-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LZRUVOHMFJDCOH-UHFFFAOYSA-N Hydroxyanopterin Natural products CC=C(/C)C(=O)OC1C(OC(=O)C(=CC)C)C2C34CC(O)C5(O)C6(C)CN(C)C(C3C1C(=C)C4)C25CC(O)C6O LZRUVOHMFJDCOH-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- SFVVQRJOGUKCEG-CQROYNQRSA-N Indicine Natural products C1C[C@H](O)[C@H]2C(COC(=O)[C@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-CQROYNQRSA-N 0.000 description 1
- OONXNTUZEDPBLV-UHFFFAOYSA-N Indicine+ Natural products C1CC2(C)C3CCC4(C)C(C(O)C)CCC4(O)C3CC=C2CC1OC1CC(O)C(O)C(C)O1 OONXNTUZEDPBLV-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- AMTATQQZOONDAP-UHFFFAOYSA-N Isostrychnophylline Natural products CN1CCc2c([nH]c3ccccc23)C1CC4CC5N(CCC56C(=O)Nc7c(C8CCCN8C)c(O)ccc67)CC4C=C AMTATQQZOONDAP-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 description 1
- BSBUOIJYJTWEHV-UHFFFAOYSA-N Leukamenin A Natural products C12CCC(C3O)C(=C)C(=O)C23C(O)CC2C1(C)CC(O)C(OC(=O)C)C2(C)C BSBUOIJYJTWEHV-UHFFFAOYSA-N 0.000 description 1
- ZUYCXZKSCBNOSX-UHFFFAOYSA-N Leukamenin B Natural products C12CCC(C3O)C(=C)C(=O)C23C(O)CC2C1(C)CC(OC(=O)C)C(OC(C)=O)C2(C)C ZUYCXZKSCBNOSX-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- MEPSBMMZQBMKHM-UHFFFAOYSA-N Lomatiol Natural products CC(=C/CC1=C(O)C(=O)c2ccccc2C1=O)CO MEPSBMMZQBMKHM-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- LLMFFOXSSQHNFR-UHFFFAOYSA-N Marchantin A Chemical compound O1C2=C(O)C=CC=C2CCC(C=C2)=CC=C2OC(C=2)=C(O)C(O)=CC=2CCC2=CC=CC1=C2 LLMFFOXSSQHNFR-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFTUDGRDUWDYHE-UHFFFAOYSA-N Mexicanin I Natural products CC1CC2OC(=O)C(=C)C2C(O)C3(C)C1CC=C3C AFTUDGRDUWDYHE-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- RTMAZVHPRZLMEU-WPLROGRBSA-N Periplocoside A Natural products O=C(O[C@H]1[C@H](OC)[C@@H](O)[C@@H](C)O[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](C)O[C@@H](O[C@H]3[C@@H](C)O[C@H](O[C@H]4[C@H](C)O[C@@]5(OO[C@@H]6[C@@H](C)O[C@H](O[C@H](C)[C@]7(O)[C@]8(C)[C@@H]([C@@H]9[C@H]([C@@]%10(C)C(=CC9)C[C@H](O[C@H]9C(=O)C(OC)=C[C@H](C)O9)CC%10)CC8)CC7)C[C@H]6OC5)C[C@@H]4OC)C[C@H]3OC)C[C@@H]2OC)C[C@H]1OC)C RTMAZVHPRZLMEU-WPLROGRBSA-N 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- CIEYTVIYYGTCCI-UHFFFAOYSA-N SJ000286565 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1 CIEYTVIYYGTCCI-UHFFFAOYSA-N 0.000 description 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
- JWBVQJZXSQDXKU-DOAWMXAISA-N Sculponeatin C Chemical compound C([C@@H]1C[C@]2(C(C1=C)=O)C(=O)OC1)[C@@H](O)[C@H]2[C@@]1([C@@H]12)[C@H]3O[C@H]2OC[C@]1(C)CC3 JWBVQJZXSQDXKU-DOAWMXAISA-N 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- PHLJPJICTIGOKC-XKYMZAEISA-N Strychnopentamine Chemical compound CN1CCC[C@@H]1C1=C(O)C=CC2=C1NC1=C2CCN2[C@H]1C[C@H](C[C@H]1C3=C(C4=CC=CC=C4N3)CCN1C)[C@@H](C=C)C2 PHLJPJICTIGOKC-XKYMZAEISA-N 0.000 description 1
- PHLJPJICTIGOKC-UHFFFAOYSA-N Strychnopentamine Natural products CN1CCCC1C1=C(O)C=CC2=C1NC1=C2CCN2C1CC(CC1C3=C(C4=CC=CC=C4N3)CCN1C)C(C=C)C2 PHLJPJICTIGOKC-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229920009638 Tetrafluoroethylene-Hexafluoropropylene-Vinylidenefluoride Copolymer Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- QGGGTLQHMHIOKZ-GQJGGXIMSA-N Tomenphantopin A Natural products O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2[C@](C)(O2)C[C@@H]2O[C@@H](OC)C(=C2)C1)C(=C)C QGGGTLQHMHIOKZ-GQJGGXIMSA-N 0.000 description 1
- HAZJAYURMWWXAM-OFGAZGMUSA-N Tomenphantopin B Natural products O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2[C@](C)(O2)C[C@@H]2O[C@@H](O)C(=C2)C1)C(=C)C HAZJAYURMWWXAM-OFGAZGMUSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930187911 Tubeimoside Natural products 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- VUMZOPMHFVDIMF-NLLHOBBWSA-N Usambarensine Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C[C@H]1C[C@H]2C(NC=3C4=CC=CC=3)=C4CCN2C/C1=C/C VUMZOPMHFVDIMF-NLLHOBBWSA-N 0.000 description 1
- JICXOAIUPFUZPK-DXBSEXLMSA-N Usambarine Chemical compound N1C2=CC=CC=C2C(CCN2C[C@@H]3C=C)=C1[C@@H]2C[C@@H]3C[C@H]1C(NC=2C3=CC=CC=2)=C3CCN1C JICXOAIUPFUZPK-DXBSEXLMSA-N 0.000 description 1
- JICXOAIUPFUZPK-UHFFFAOYSA-N Usambarine Natural products N1C2=CC=CC=C2C(CCN2CC3C=C)=C1C2CC3CC1C(NC=2C3=CC=CC=2)=C3CCN1C JICXOAIUPFUZPK-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 229930182763 Yadanzioside Natural products 0.000 description 1
- PISLVTVZMHAKFK-LHBKFWKVSA-N [(1S,3S,4S,5S,7S,9S,12R,13R,14R,15R,16S,17R)-3,4,7-trihydroxy-9,11-dimethyl-16-[(E)-2-methylbut-2-enoyl]oxy-19-methylidene-11-azahexacyclo[12.3.2.01,13.04,9.05,12.05,17]nonadecan-15-yl] (E)-2-methylbut-2-enoate Chemical compound C([C@@]12CC3=C)[C@H](O)[C@]4(O)[C@]5(C)CN(C)[C@@H]6[C@@H]1[C@H]3[C@@H](OC(=O)C(/C)=C/C)[C@@H](OC(=O)C(\C)=C\C)[C@H]2[C@@]64C[C@@H](O)C5 PISLVTVZMHAKFK-LHBKFWKVSA-N 0.000 description 1
- FWXLVXABZRYLST-XUOZYSPWSA-N [(3r,4r,4ar,5s,6r,6ar,6as,6br,8ar,10s,12ar,14bs)-5,6,10-trihydroxy-4a-(hydroxymethyl)-2,2,6a,6b,9,9,12a-heptamethyl-4-[(z)-2-methylbut-2-enoyl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicen-3-yl] (e)-2-methylbut-2-enoate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)[C@@H](O)[C@@H](O)[C@@]5(CO)[C@@H](OC(=O)C(\C)=C/C)[C@H](OC(=O)C(/C)=C/C)C(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C FWXLVXABZRYLST-XUOZYSPWSA-N 0.000 description 1
- DNAWGBOKUFFVMB-PZIGJSDBSA-N [(7r,8r)-7-hydroxy-4-oxido-5,6,7,8-tetrahydro-3h-pyrrolizin-4-ium-1-yl]methyl (2r)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@](O)([C@H](C)O)C(C)C)=CC[N+]21[O-] DNAWGBOKUFFVMB-PZIGJSDBSA-N 0.000 description 1
- RTMAZVHPRZLMEU-UHFFFAOYSA-N [5-hydroxy-2-[6-[6-[6-[7-[1-[17-hydroxy-3-[(4-methoxy-2-methyl-5-oxo-2h-pyran-6-yl)oxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethoxy]-4'-methoxy-2',9-dimethylspiro[4,5a,6,7,9,9a-hexahydropyrano[3,4-c][1,2,5] Chemical compound O1C(C)C(OC2OC(C)C(OC3C(C(OC)C(O)C(C)O3)OC(C)=O)C(OC)C2)C(OC)CC1OC(C(C1)OC)C(C)OC1OC(C(C1)OC)C(C)OC1(OOC1C(C)O2)COC1CC2OC(C)C(C1(CCC2C3(C)CC4)C)(O)CCC1C2CC=C3CC4OC1OC(C)C=C(OC)C1=O RTMAZVHPRZLMEU-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- XNWZKGMGEINBJE-UHFFFAOYSA-N agrostistachin Natural products C1CC(C)=CC(O)CC(C)=CC(O)C(=O)C(C)=CC2C(C)(C)C12 XNWZKGMGEINBJE-UHFFFAOYSA-N 0.000 description 1
- LGSDYQBPJKYJCT-YTLNUPAMSA-N akagerine Chemical compound O[C@H]1C[C@H](C(\C=O)=C/C)C[C@@H]2N(C)CCC3=C2N1C1=CC=CC=C31 LGSDYQBPJKYJCT-YTLNUPAMSA-N 0.000 description 1
- YQIYGKCKHVXNPT-UHFFFAOYSA-N akagerine Natural products CC=C(C=O)/C1CC(O)n2c3C(C1)NCCc3c4ccccc24 YQIYGKCKHVXNPT-UHFFFAOYSA-N 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000710 anti-hyperplastic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002769 anti-restenotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229930192649 bafilomycin Natural products 0.000 description 1
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- XJIAVYYCXSQJAZ-SRHNQKLESA-N bruceantinoside c Chemical compound C([C@@H](C)[C@@H]1C[C@H]2OC(=O)[C@H](OC(=O)\C=C(/C)C(C)(C)OC(C)=O)[C@@H]3[C@]22CO[C@]3([C@H]([C@H](O)[C@@H]2[C@@]1(C)C1=O)O)C(=O)OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJIAVYYCXSQJAZ-SRHNQKLESA-N 0.000 description 1
- BMRNQSAXDJQXEL-BGJAGFQLSA-N bryophyllin a Chemical compound C=1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5([C@H]6C[C@H]7C[C@@]5(O[C@](C)(O7)O6)CC4)C=O)[C@H](O)C[C@@]32C)C=CC(=O)OC=1 BMRNQSAXDJQXEL-BGJAGFQLSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- GNEVIACKFGQMHB-UHFFFAOYSA-N carbon suboxide Chemical compound O=C=C=C=O GNEVIACKFGQMHB-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960002328 chloroquine phosphate Drugs 0.000 description 1
- UUAGAQFQZIEFAH-UHFFFAOYSA-N chlorotrifluoroethylene Chemical compound FC(F)=C(F)Cl UUAGAQFQZIEFAH-UHFFFAOYSA-N 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229930184793 concanamycin Natural products 0.000 description 1
- DJZCTUVALDDONK-HQMSUKCRSA-N concanamycin A Chemical compound O1C(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@H](OC)[C@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](\C=C\C)[C@@H](C)[C@H](O[C@@H]2O[C@H](C)[C@@H](OC(N)=O)[C@H](O)C2)C1 DJZCTUVALDDONK-HQMSUKCRSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003083 cymarin Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- JRHMMVBOTXEHGJ-UHFFFAOYSA-N daphnoretin Chemical compound C1=CC(=O)OC2=CC(OC3=CC=4C=C(C(=CC=4OC3=O)O)OC)=CC=C21 JRHMMVBOTXEHGJ-UHFFFAOYSA-N 0.000 description 1
- UJRSXAFBORHKBS-UHFFFAOYSA-N daphnoretin Natural products COC1=CC2C=C(Oc3ccc4C=CC(=O)Oc4c3)C(=O)OC2C=C1O UJRSXAFBORHKBS-UHFFFAOYSA-N 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- NMPPLGMVCCNRTJ-UHFFFAOYSA-N echinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)CCN21 NMPPLGMVCCNRTJ-UHFFFAOYSA-N 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229920006129 ethylene fluorinated ethylene propylene Polymers 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 1
- 229960002435 fasudil Drugs 0.000 description 1
- 230000002615 fibrolytic effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 halofuginone Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- ZVLOPMNVFLSSAA-XEPQRQSNSA-N helenalin Chemical compound C[C@@H]1C[C@H]2OC(=O)C(=C)[C@H]2[C@H](O)[C@]2(C)C(=O)C=C[C@@H]12 ZVLOPMNVFLSSAA-XEPQRQSNSA-N 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- KNOSIOWNDGUGFJ-UHFFFAOYSA-N hydroxysesamone Natural products C1=CC(O)=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1O KNOSIOWNDGUGFJ-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- SFVVQRJOGUKCEG-XTWPYSKKSA-N indicine Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@](O)([C@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-XTWPYSKKSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 description 1
- BBEFSDNXXNECSY-UHFFFAOYSA-N isojusticidin B Natural products C1=C2OCOC2=CC(C2=C3C(=O)OCC3=CC3=CC=C(C(=C32)OC)OC)=C1 BBEFSDNXXNECSY-UHFFFAOYSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- PQFYSRLXICNMSR-UHFFFAOYSA-N justicidine B Natural products COc1ccc(cc1OC)c2c3OCC(=O)c3cc4cc5OCOc5cc24 PQFYSRLXICNMSR-UHFFFAOYSA-N 0.000 description 1
- WHSUEVLJUHPROF-BIGDWJEQSA-N kamebakaurin Chemical compound C1C[C@H]([C@H]2O)C(=C)C(=O)[C@@]32[C@H](O)C[C@@H]2C(C)(C)CC[C@H](O)[C@@]2(CO)[C@@H]31 WHSUEVLJUHPROF-BIGDWJEQSA-N 0.000 description 1
- 229930184156 kamebakaurin Natural products 0.000 description 1
- WHSUEVLJUHPROF-UHFFFAOYSA-N kamebakaurin A Natural products C1CC(C2O)C(=C)C(=O)C32C(O)CC2C(C)(C)CCC(O)C2(CO)C31 WHSUEVLJUHPROF-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- CWPGNVFCJOPXFB-UHFFFAOYSA-N lapachol Chemical compound C1=CC=C2C(=O)C(=O)C(CC=C(C)C)=C(O)C2=C1 CWPGNVFCJOPXFB-UHFFFAOYSA-N 0.000 description 1
- SIUGQQMOYSVTAT-UHFFFAOYSA-N lapachol Natural products CC(=CCC1C(O)C(=O)c2ccccc2C1=O)C SIUGQQMOYSVTAT-UHFFFAOYSA-N 0.000 description 1
- 235000006826 lariciresinol Nutrition 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- QHOZSLCIKHUPSU-PNFBIMPKSA-N lasiocarpine Chemical compound C1C[C@H](OC(=O)C(\C)=C/C)[C@H]2C(COC(=O)[C@](O)([C@H](C)OC)C(C)(C)O)=CCN21 QHOZSLCIKHUPSU-PNFBIMPKSA-N 0.000 description 1
- YHPCSAOULAHGKY-UHFFFAOYSA-N lasiocarpine Natural products CC=C(C)/C(=O)OC1CCN2CC=C(COC(=O)C(O)(C(C)C)C(C)(C)O)C12 YHPCSAOULAHGKY-UHFFFAOYSA-N 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- XVUQHFRQHBLHQD-UHFFFAOYSA-N lonazolac Chemical compound OC(=O)CC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 XVUQHFRQHBLHQD-UHFFFAOYSA-N 0.000 description 1
- 229960003768 lonazolac Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- SCWKUSONPRYOHV-UHFFFAOYSA-N marchantin A Natural products Oc1cccc2CCc3ccc(Oc4cc(CCc5ccccc5Oc12)cc(O)c4O)cc3 SCWKUSONPRYOHV-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- CPTIBDHUFVHUJK-NZYDNVMFSA-N mitopodozide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- BZRYYBWNOUALTQ-HOTGVXAUSA-N myrtecaine Chemical compound CCN(CC)CCOCCC1=CC[C@@H]2C(C)(C)[C@H]1C2 BZRYYBWNOUALTQ-HOTGVXAUSA-N 0.000 description 1
- 229960000739 myrtecaine Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229920006173 natural rubber latex Polymers 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960004036 nonivamide Drugs 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- QGGGTLQHMHIOKZ-UHFFFAOYSA-N orthopappolide methacrylate Natural products C1C2(C)OC2C2OC(=O)C(=C)C2C(OC(=O)C(C)=C)CC2=CC1OC2OC QGGGTLQHMHIOKZ-UHFFFAOYSA-N 0.000 description 1
- 229960005113 oxaceprol Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229920011301 perfluoro alkoxyl alkane Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
- 229960002226 polidocanol Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- VKNAGQVZXQTVMW-UHFFFAOYSA-N retrochinensinaphthol methyl ether Natural products C1=C(OC)C(OC)=CC=C1C(C1=C2)=C(OCC3=O)C3=C(OC)C1=CC1=C2OCO1 VKNAGQVZXQTVMW-UHFFFAOYSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- LFBIHCZSRPAPHS-UHFFFAOYSA-N rutamontine Natural products COc1cc2OC(=O)C(=Cc2cc1O)Oc3ccc4C=CC(=O)Oc4c3 LFBIHCZSRPAPHS-UHFFFAOYSA-N 0.000 description 1
- RLISWLLILOTWGG-UHFFFAOYSA-N salamidacetic acid Chemical compound NC(=O)C1=CC=CC=C1OCC(O)=O RLISWLLILOTWGG-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- JWBVQJZXSQDXKU-UHFFFAOYSA-N sculponeatin C Natural products C1OC(=O)C2(C(C3=C)=O)CC3CC(O)C2C1(C12)C3OC2OCC1(C)CC3 JWBVQJZXSQDXKU-UHFFFAOYSA-N 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229940075439 smac mimetic Drugs 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- ODJLBQGVINUMMR-HZXDTFASSA-N strophanthidin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C=O)CC[C@@]32C)=CC(=O)OC1 ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 description 1
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000363 trapidil Drugs 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- VUMZOPMHFVDIMF-UHFFFAOYSA-N usambarensine Natural products C12=CC=CC=C2NC2=C1C=CN=C2CC1CC2C(NC=3C4=CC=CC=3)=C4CCN2CC1=CC VUMZOPMHFVDIMF-UHFFFAOYSA-N 0.000 description 1
- 229950007952 vapiprost Drugs 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320725—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with radially expandable cutting or abrading elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1018—Balloon inflating or inflation-control devices
- A61M25/10184—Means for controlling or monitoring inflation or deflation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
- A61M2025/1031—Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1059—Balloon catheters with special features or adapted for special applications having different inflatable sections mainly depending on the response to the inflation pressure, e.g. due to different material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1084—Balloon catheters with special features or adapted for special applications having features for increasing the shape stability, the reproducibility or for limiting expansion, e.g. containments, wrapped around fibres, yarns or strands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
- Y10T29/49888—Subsequently coating
Definitions
- the present disclosure relates generally to balloon assemblies having controllable topographies and systems and methods relating to the same.
- Balloons intended for use within a mammalian body are employed in a variety of medical procedures, including dilation of narrowed blood vessels, placement of stents and other implantable devices, temporary or permanent occlusion of blood vessels, drug delivery, thrombectomy, embolectomy, atherectomy, angioplasty, other endovascular procedures, and other procedures within a lumen of a mammalian body such as a human body.
- body can comprise a mammalian body such as a human body or other animal body.
- a balloon (often coupled with a catheter) is advanced to the desired location in the vascular system or other lumen of the body.
- the balloon is then pressure-expanded in accordance with a medical procedure. Thereafter, the pressure is removed from the balloon, allowing the balloon to contract and permit removal of the catheter and, in many cases, the balloon.
- Procedures such as these are generally considered minimally invasive, and are often performed in a manner which minimizes disruption to the patient's body.
- balloons are often inserted from a location remote from the region to be treated.
- the balloon catheter is typically inserted into the femoral artery in the groin region of the patient, and then advanced through vessels into the coronary region of the patient.
- These balloons typically include some type of radiopaque marker to allow the physician performing the procedure to monitor the progress of the catheter through the body.
- Non-compliant balloons are generally made of relatively strong but generally inelastic material (e.g., nylon, polyester, etc.), which must be folded to obtain a compact, small diameter cross section for delivery. These relatively stiff balloons do not easily conform to the surrounding vessel and thus can be used to compact hard deposits in vessels. Due to the need for strength and stiffness, these devices are rated to employ high inflation pressures, usually up to about 4 to about 60 atmospheres. As depicted in FIG. 1 , non-compliant balloons (line C) have a maximum diameter, and as inflation fluid is introduced, such balloons will not normally distend appreciably beyond a maximum diameter. Once a non-compliant balloon is inflated to its maximum diameter, the exertion of additional pressure can cause rupture of the balloon, creating a hazardous condition.
- high inflation pressures usually up to about 4 to about 60 atmospheres.
- compliant balloons generally comprise soft, elastic material (e.g., natural rubber latex).
- line A compliant balloons (line A) will generally expand continuously in diameter and will not appreciably increase in internal pressure as inflation fluid is introduced.
- compliant balloons are generally rated by volume (e.g., 0.3 cc) rather than by nominal diameter.
- compliant balloons generally conform to the shape of the vessel.
- compliant balloons have the advantage that they need not be folded about a delivery catheter (reducing profile) and tend to readily recompact to their initial size and dimensions following inflation and subsequent deflation.
- These balloons can be employed to displace soft deposits, such as a thrombus, where a soft and tacky material such as latex provides an effective extraction means, and also can be used as an occlusion balloon, operating at low pressures.
- semi-compliant balloons In between the spectrum of compliant balloons and non-compliant balloons fall semi-compliant balloons. As depicted in FIG. 1 , semi-compliant balloons (line B) will both increase in pressure and increase in diameter as inflation fluid is introduced. However, semi-compliant balloons operate at pressures in between the two types of balloons and will continue to distend as inflation fluid is introduced.
- variable topography may provide increased surface area over a similar conventional balloon, and thus interaction with the body may be improved.
- a variable topography balloon may also be configured to deploy sharp objects in a localized, difficult to reach part of the body, providing an improvement in therapy.
- variable topography balloons may provide improved drug delivery systems.
- a device comprising a balloon comprising a size limiting layer and a template disposed around or within the balloon.
- the template comprises at least one aperture and a portion that is more resistant to deformation in a radial direction than the balloon or the size limiting layer, either because template comprises a less compliant material or has an upper distension limit that is less than the size limiting layer's upper distension limit.
- the balloon and size limiting layer are configured to distend beyond the template about the aperture at a given volume/pressure.
- the balloon and size limiting layer will distend about an aperture to a second inflated state comprising a varied topography.
- the template and/or balloon can optionally comprise an expanded polytetrafluoroethylene (ePTFE).
- ePTFE expanded polytetrafluoroethylene
- the balloon and/or template can comprise a tape wrapped membrane. Other embodiments comprise methods of making and using the same.
- a balloon assembly comprising a balloon having a controlled topography, wherein the balloon assembly has a smooth or substantially wrinkle free surface at a first inflated state and a varied topography surface at a second inflated state.
- the balloon assembly comprises an inner balloon and an outer template
- the inner diameter of the template at a first inflated state is substantially equal to the outer diameter of the balloon at a first inflated state.
- an outer balloon is disposed around an inner template, the converse is true; namely, the outer diameter of the template at a first inflated state is substantially equal to the inner diameter of the balloon in the first inflated state.
- the balloon and/or template can comprise a tape wrapped membrane. Other embodiments comprise methods of making and using the same.
- a balloon assembly can comprise an underlying compliant balloon and an overlying less compliant template having at least one aperture. Located within the aperture can be a therapeutic agent, preferably in a solid or viscous form. Upon inflation, the underlying compliant balloon will protrude through the aperture and convey the therapeutic agent external to the template. In this manner, a therapeutic agent can be delivered to a surrounding tissue such as the intima of a vessel.
- Other embodiments include methods of making and using the same.
- a balloon can be covered and/or wrapped with a textured network that provides a topographical feature.
- a textured network can comprise beads, filaments, fibers, rings, knits, weaves, and/or braids, which can be wrapped or otherwise disposed over or within a balloon.
- the textured network creates raised surface patterns that can provide therapeutic effect.
- Other embodiments include methods of making and using the same.
- FIG. 1 compares pressure to height of complaint balloons (Line A), semi-compliant balloons (Line B), and non-compliant balloons (Line C);
- FIG. 2A illustrates a schematic varied topography balloon assembly embodiment from a cross-sectional perspective
- FIGS. 2B ( 1 ) to 2 B( 3 ) illustrates a varied topography balloon assembly embodiment of the present disclosure in a deflated state; a first inflated state; and a second inflated state;
- FIG. 2B ( 4 ) illustrates a close up, cross-sectional view about an aperture of a varied topography balloon assembly embodiment illustrated in FIG. 2B ( 3 );
- FIGS. 3A ( 1 ) to 3 A( 3 ) schematically illustrate the process under which various embodiments distend to a second inflated state thereby forming a varied topography balloon assembly;
- FIGS. 3B ( 1 ) to 3 B( 3 ) schematically illustrate the process under which various embodiments distend to a second inflated state thereby forming a varied topography balloon assembly
- FIGS. 4A to 4D illustrate wrapping a film tape to form a size limiting membrane layer
- FIG. 5A schematically illustrates a balloon assembly embodiment comprising a tapered balloon and/or size limiting layer
- FIG. 5B schematically illustrates a balloon assembly embodiment comprising a tapered template
- FIGS. 6A and 6B illustrate a cross-sectional view of a varied topography balloon assembly embodiment wherein a plurality of apertures are located on a first section of the template and no apertures are located on a second section of tem plate;
- FIG. 7 A schematically illustrates a varied topography balloon assembly embodiment of the present disclosure comprising two templates
- FIG. 7B illustrates a close up, cross-sectional view about an aperture of a varied topography balloon assembly embodiment illustrated in FIG. 7A ;
- FIG. 8 illustrates a varied topography balloon assembly comprising a therapeutic agent, in accordance with various embodiments
- FIG. 9 illustrates a varied topography balloon assembly embodiment wherein the balloon comprises a wall with regions of reduced compliance than other more distensible regions;
- FIG. 10A illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprise rigid elements
- FIG. 10B illustrates a cross-sectional view of a balloon assembly embodiment depicted in FIG. 10A with the rigid elements outwardly rotated;
- FIG. 10C illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprises rigid elements having a piercing or sharp tip that is attached to template at its proximal base;
- FIG. 10D illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprises rigid elements of FIG. 10C outwardly rotated;
- FIG. 10E illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprises rigid elements having a lumen therethrough which is in fluid communication with the balloon;
- FIG. 11 illustrates an inflated balloon assembly comprising a wire tem plate
- FIG. 12 illustrates a balloon assembly in accordance with various embodiments within the vasculature
- FIGS. 13A to 13C illustrate a textured balloon assembly in accordance with various embodiments
- FIG. 13D illustrates a cross sectional view a textured balloon assembly on a mandrel, in accordance with various embodiments
- FIG. 14A illustrates a deflated balloon assembly with a scored template pattern from an exterior perspective, in accordance with various embodiments
- FIG. 14B illustrates an inflated balloon assembly with a deployed scored template pattern from an exterior perspective, in accordance with various embodiments
- FIG. 14C ( 1 ) illustrates a close-up, perspective view of a deflated balloon assembly with an arced element across the aperture of a template, in accordance with various embodiments
- FIG. 14C ( 2 ) illustrates a close-up, perspective view of an inflated balloon assembly with a deployed arced element across the aperture of a template, in accordance with various embodiments;
- FIG. 14C ( 3 ) illustrates a close-up, side view of the inflated balloon assembly of FIG. 14C ( 2 ), in accordance with various embodiments;
- FIG. 14D ( 1 ) to 14 D( 4 ) illustrate the various patterns of template comprising an arced element across the aperture
- FIG. 14E ( 1 ) illustrates a close-up, perspective view of a deflated balloon assembly with an arced element across the aperture of a template, in accordance with various embodiments
- FIG. 14E ( 2 ) illustrates a close-up, perspective view of the inflated balloon assembly of FIG. 14E ( 1 ), in accordance with various embodiments;
- FIG. 15 illustrates a method of making, in accordance with various embodiments
- FIG. 16 illustrates a method of use, in accordance with various embodiments
- FIG. 17 illustrates a balloon assembly embodiment wherein a template is located on an intermediate section of a balloon
- FIG. 18 illustrates a balloon assembly embodiment wherein the balloon and size limiting layer is perfusable
- FIGS. 19A-B illustrates a varied topography balloon assembly embodiment wherein the balloon comprises a wall with regions of reduced compliance than other more distensible regions;
- FIGS. 20A-20B illustrates a varied topography balloon assembly with a stent device mounted thereon, the stent device having deployable anchors which are actuated by protruding apertures;
- FIG. 21 illustrates a varied topography balloon assembly wherein an aperture or a plurality of apertures are located on a circumferential section.
- balloon assembly means a balloon coupled with one or more other components, such as a template (described herein), size limiting layer (descried herein), catheter, distal cap (“olive”), cover, or other apparatus.
- size limiting means that a material or component has an upper distension or deformation limit beyond which a material or component will not appreciably expand, distend, and/or deform.
- a size-limited balloon can be inflated to a maximum diameter, and once this diameter is reached, further increases in pressure will not cause an appreciable increase in its diameter.
- a non-compliant balloon (line C) is a size-limited balloon, and traditional compliant (line A) and semi-compliant (line B) balloons are not size-limited balloons.
- a “compliant balloon,” as used herein, refers to both compliant and semi-compliant balloons or balloons that are not size limited, but will continue to expand, distend, and/or deform as the internal pressure increases until the point of failure, e.g., the balloon wall ruptures.
- the described “compliant” balloons are referred to as such because the described balloons generally conform to the shape of their surroundings (e.g., a surrounding anatomy or vessel) like traditional “compliant” balloons, e.g., portions of the described “compliant” balloons are able to outwardly extend from the template to form protrusions.
- to inflate can mean to fill or cause expansion by introducing a flowable substance (e.g., an influx of fluid), such as a liquid (e.g., saline), a gel, or a gas.
- a flowable substance e.g., an influx of fluid
- a liquid e.g., saline
- a gel e.g., a gel
- a gas e.g., a gas
- inflated means a balloon at an internal pressure or volume above the internal pressure or volume at which the balloon begins to expand from a deflated state.
- first inflated state refers to an inflated balloon at a first pressure or first volume which will result in a balloon with a generally smooth or uniform surface, except perhaps with respect to slight recesses at the site of the aperture(s).
- second inflated state refers to an inflated balloon at a second pressure or second volume greater than the first pressure or first volume which will result in a balloon with a varied topography.
- “varied topography” refers to a balloon assembly surface that has textured, bumpy, ribbed, or other three-dimensional surfaces.
- elongate element is generally any element configured for relative axial movement with an endoluminal device delivery element (e.g., a catheter-based endoluminal device delivery element such as a balloon catheter) and includes any longitudinally extending structure with or without a lumen therethrough.
- elongate elements include but are not limited to tubes with lumens (e.g., catheters), solid rods, hollow or solid wires (e.g., guidewires), hollow or solid stylets, metal tubes (e.g., hypotubes), polymer tubes, pull cords or tethers, fibers, filaments, electrical conductors, radiopaque elements, radioactive elements and radiographic elements.
- Elongate elements can be any material and can have any cross-sectional shape including, but not limited to, profiles that are elliptical, non-elliptical, or random.
- balloon assemblies used inside the body generally interact with the body through contact with an exterior surface of the balloon assembly.
- the surface topography of a balloon assembly can affect the physical interaction between the balloon assembly and the body or a device inside the body.
- the ability to control a balloon's topography, or three dimensional surface characteristics, allows balloon assemblies to interact with the body in new or improved modes.
- Various advantages can be realized using controllably variable topography balloon assemblies.
- balloon assemblies such as those that can be used with a catheter, can be inserted into a lumen of the body.
- the balloon assembly can interact with the body in a variety of ways which can be facilitated by designing topographies which yield improved results.
- a balloon having a varied topography can improve engagement with a vessel wall and/or improve atherosclerotic plaque or thrombus removal ability, such from a vessel wall or the wall of an endoprosthesis.
- FIGS. 2B ( 1 ) to 2 B( 3 ) illustrate a varied topography balloon 200 in a deflated state ( FIG. 2B ( 1 )), a first inflated state having a generally uniform or smooth surface ( FIG. 2B ( 2 )), and a second inflated state having a varied topography ( FIG. 2B ( 3 )).
- FIG. 2B ( 4 ) illustrates a close-up, cross-sectional view of a protrusion 212 of a varied topography balloon 200 .
- Balloon assembly 200 comprises balloon 210 and template 220 .
- Balloon 210 can be disposed along template 220 , either underlying or overlying the template 220 .
- the balloon 210 may comprise a working length and at least one tapered section (i.e., a shoulder).
- the template 220 may extend along at least a portion of the working length of the balloon 210 .
- the template 220 may also extend along at least a portion of at least one shoulder of the balloon 210 .
- Assembly 200 can further comprise a catheter 202 to which balloon 210 and template 220 are attached.
- Catheter 202 is shown in fluid communication with balloon 210 , such that fluid can be introduced through catheter 202 into balloon 210 .
- Catheter 202 can be coupled to any suitable medical device, such as a syringe, an indeflator, pump or any other apparatus for conducting fluid through catheter 202 and into balloon 210 .
- Template 220 can be an overlying or underlying structure comprising at least one aperture 221 .
- Template 220 constrains a portion of balloon 210 during inflation.
- balloon 210 is inflated to a second inflated state, and the restraining action of template 220 causes balloon 210 to distend at apertures 221 in template 220 as described in more detail below.
- FIGS. 3A ( 1 ) to 3 A( 3 ) and 3 B( 1 ) to 3 B( 3 ) in which is illustrated a longitudinal cross section of a balloon assembly 300 .
- balloon 310 underlies template 320 which features apertures 321 .
- FIGS. 3B ( 1 ) to 3 B( 3 ) balloon 310 overlies template 320 , and template 320 adheres to balloon during inflation.
- balloon 310 and template 320 are shown aligned with axis “A”.
- Axis “A” can comprise the longitudinal axis of a catheter.
- a first inflated state is shown in FIGS. 3A ( 2 ) and. 3 B( 2 ).
- balloon 310 has an outer radius shown as “R 1 ” under template 320
- template 320 has an inner radius of “R 2 ”.
- balloon 310 has an inner radius shown as “R 1 ” over template 320
- template 320 has an outer radius “R 2 ”.
- radius “R 1 ” is substantially equal to radius “R 2 ”.
- the height, “H 1 ” of balloon material or protrusions above template 320 has a value of zero or close to zero.
- balloon 310 comprises a substantially smooth or wrinkle free surface.
- aperture 321 has a width shown as “W 1 ” in the figures.
- FIGS. 3A ( 3 ) and 3 B( 3 ) depict balloon assembly 300 in a second inflated state.
- radius “R 2 ” increases relative to radius “R 1 ” about aperture 321 . This is because balloon 310 , upon distention, begins to distend about or protrude from or above apertures 321 .
- Radius “R 1 ” remains essentially at the same dimension as in the first inflated state shown FIGS. 3A ( 2 ) and 3 B( 2 ).
- width of aperture 321 (“W 2 ”) remains close to or even equal to width of aperture 221 (“W 1 ”) in the previous inflated state shown in FIGS. 3A ( 2 ) and 3 B( 2 ).
- W 2 can be greater than W 1 ; i.e., aperture 320 can increase in size as balloon assembly 300 is inflated. It will be understood that radius “R 2 ” can be a maxima, in particular if a size limiting layer or a size limited balloon is used as described below.
- balloon 210 can comprise any suitable compliant balloon.
- a compliant balloon can comprise a polymeric material.
- Exemplary materials for a compliant balloon include elastomers such as polyurethane and silicone, natural rubber or latex products, synthetic rubber such as nitrile butadiene, or other synthetic or naturally occurring polymeric materials.
- balloon 210 may not be fully compliant, but is more compliant than template 220 and sufficiently flexible to inflate to a diameter larger than the restraining template 220 diameter at a given pressure, and thereby produces protrusions 212 (as described below).
- a semi-compliant or non-compliant balloon can be used.
- balloon 210 can be conditioned. Conditioning can comprise stretching, pre-inflating, blow molding, heating, or other process to render the balloon 210 more amenable to use.
- balloon assembly 200 can comprise balloon 210 , template 220 , and a size limiting layer 215 .
- balloon 210 can comprise a composite material, wherein a layer of the composite is size limiting layer 215 and/or template 220 .
- Size limiting layer 215 can be disposed about balloon 210 , either between balloon 210 and template 220 or around template 220 . Similar to template 220 , size limiting layer 215 is configured to control the degree of distension of a compliant balloon 210 during inflation. However, size limiting layer 215 is configured to permit a degree of distension which is greater than the degree that template 220 is configured to permit.
- size limiting layer 215 can possess sufficient flexibility and an upper distension limit which is larger in diameter than the restraining template 220 diameter at a given pressure, allowing size limiting layer 215 to distend about or protrude through aperture 221 .
- size limiting layer 215 can be configured to have a substantially smooth or wrinkle free surface at the first inflated state. Stated differently, size liming layer is at least slightly strained at the first inflated state.
- Size limiting layer 215 can be a sheath, sleeve, layer or other component otherwise configured to at least partially enclose all or a portion of balloon 210 . Size limiting layer 215 can act to constrain balloon 210 in a substantially uniform manner once balloon 210 distends to a certain diameter or dimension. Size limiting layer 215 can be configured to operate at pressures of up to 2 atm, up to 5 atm, up to 10 atm, up to 15 atm, up to 20 atm, up to 30 atm, up to 35 atm, up to 45 atm, up to 55 atm, up to 60 atm, or up to any value between about 2 atm and about 60 atm.
- size limiting layer 215 can comprise any flexible, preferably thin material which is inelastic in at least one orientation or has a suitable upper deformation limit in at least one orientation. To withstand higher inflation pressures, size limiting layer 215 can be made of a high strength material. Size limiting layer 215 can be constructed using any material described herein for constructing template 220 . Size limiting layer 215 can be an extruded or molded tubular form which is at some point inelastic in a circumferential direction. Alternatively, size limiting layer 215 can comprise a tape wrapped form wherein the tape is, at some point, inelastic or has an upper distension limit in the tapes lengthwise direction.
- a thin film can be slit into relatively narrow widths to form a tape.
- the tape is helically wrapped onto the surface of a mandrel 12 in two opposing directions 20 and 22 , thereby forming a tube of at least two layers 14 and 16 .
- Both layers 14 and 16 can be wrapped with the same pitch angle measured with respect to the longitudinal axis 18 but measured in opposite directions. If, for example, the film layers 14 and 16 are applied at pitch angles of 70° measured from opposite directions with respect to the mandrel's longitudinal axis 18 , then included angle A between both 70° pitch angles is 40°.
- More than two layers of helically wrapped film may be applied. Alternate layers of film can be wrapped from opposing directions and an even number of film layers can be used whereby an equal number of layers are applied in each direction.
- Suitable adhesives may be used to join film wraps together.
- Such adhesives include fluorinated ethylene propylene (FEP).
- FEP fluorinated ethylene propylene
- the helically wrapped mandrel 12 can be thermally treated at suitable time and temperature to cause adjacent layers 14 and 16 to heat-bond together.
- the size limiting layer 415 is removed from mandrel 12 and can be placed over the balloon, tensioned longitudinally as needed and affixed in place over the balloon.
- size limiting layer 415 can undergo an increase in diameter which results in included angle A being substantially reduced as shown by FIG. 4D .
- Size limiting layer 415 thus reaches its pre-determined upper distension limit as included angle A approaches zero. This pre-determined limit is greater than the distension limit of template in order to yield a balloon having a varied topography at a second inflated state but one which does not appreciably distend beyond the second inflated state.
- size limiting layer 215 can optionally be adhered to or laminated with balloon 210 . If adhered, balloon 210 can aid in recompaction of size limiting layer 215 upon deflation of balloon assembly 200 , in particular if balloon 210 is made of an elastomeric materiel. Alternatively, a layer of elastomer, applied to a surface of size limiting layer 215 will cause the size limiting layer 215 to retract substantially to its pre-inflation size as shown by FIG. 4C following deflation.
- the film utilized to construct size limiting layer 215 as described above can comprise any flexible, preferably thin material that is substantially inelastic or has an upper distension limit in at least one orientation and has sufficient strength to yield a balloon 210 that can operate at pressures of up to 2 atm, up to 5 atm, up to 10 atm, up to 15 atm, up to 20 atm, up to 30 atm, up to 35 atm, up to 45 atm, up to 55 atm, or up to 60 atm.
- a film can comprise ePTFE.
- Other suitable film materials can include other fluoropolymers or non-compliant polymers.
- size limiting layer 215 can be constructed or conditioned to constrain balloon 210 upon inflation to a generally cylindrical inflation profile.
- size limiting layer 515 can be configured to alter the general profile of balloon 510 , e.g., constrain to create a tapered profile, elliptical profile, or a dumbbell profile.
- size limiting layer 215 can act to prevent release of undesired debris from the disrupted balloon assembly 200 .
- size limiting layer 215 and balloon 210 are combined into a single component.
- balloon 210 can comprise a compliant, size limiting material.
- balloon 210 behaves like a compliant or semi-compliant balloon up to a desired diameter. Once the desired diameter is reached, balloon 210 behaves like a non-compliant balloon, allowing the pressure to increase without resulting in an appreciable increase in a balloon dimension.
- template 220 comprises any size-limited form that acts to constrain balloon 210 along the points of contact.
- template 220 can comprise a form less compliant than balloon 210 and/or size limiting layer 215 so that balloon 210 is constrained along the points of contact.
- template 220 is constructed of any material that cannot be appreciably deformed beyond a first inflated state during inflation of balloon 210 .
- Template 220 can be configured as a sleeve, layer, or sheath positioned over balloon 210 .
- template 220 can comprise a generally cylindrical, ellipsoidal, spherical, or similar form that is disposed substantially coaxial to balloon 210 .
- template 220 can be an inner layer that constrains a portion of balloon 210 by being adhered to balloon 200 at selected portions not comprising an aperture 221 .
- template 520 at a first inflated state, can have a diameter that is larger or smaller at different locations along the balloon 510 , for instance to form a taper.
- balloon 510 can inflate in the shape of a cylinder
- template 520 can have a non-cylindrical shape, and this non-cylindrical shape can be the general profile of balloon assembly 500 .
- Such a generally tapered profile can be used to better conform to cardiovascular vessel diameters which change over length, for example.
- the lesion or thrombus “scraping” effect of the assembly 500 can be intensified proximally to distally or vice versa due to the varying profile dimensions.
- template 220 does not substantially deform beyond a first inflated state or deforms to a lesser extent than balloon 210 and size limiting layer 215 in response to inflation of balloon 210 .
- balloon 210 and size limiting layer 215 distends beyond template 220 about aperture 221 creating a protrusion 212 at a second inflated state.
- inflated balloon assembly 200 can have a varied topography in that the surface of balloon assembly 200 has a plurality of peaks and valleys.
- template 220 can comprise a size-limited material or configuration.
- template 220 can be substantially inelastic in at least one direction or orientation, preferable a direction transverse to the longitudinal axis of balloon assembly 200 and, in various embodiments, template 220 can also comprise a material that has high tensile strength in at least one direction.
- the template can comprise a material that has a high strength in both directions so as to prevent the perimeters of apertures 221 from deforming upon expansion of balloon 210 .
- template 220 can comprise a material that is less compliant than balloon 210 and/or template; thus, at a given pressure, balloon 210 will have a greater degree of distension than template 220 .
- template 220 can comprise a high strength, yet flexible material such as ePTFE.
- High strength provides resistance to deformation in at least one direction such that template 220 can resist expansion of underlying balloon portions beyond the application of a particular force caused by balloon inflation pressures.
- template 220 can be made from a thin, high strength film or tape to forming a template.
- template 220 can be constructed from a type of ePTFE as described in U.S. Pat. No. 7,306,729, issued Dec. 11, 2007 and entitled, “Porous PTFE Materials And Articles Produced Therefrom,” whose contents are herein incorporated by reference.
- two to sixty layers of ePTFE as described in U.S. Pat. No. 7,306,729 can comprise template 220 . Layers can be circumferentially (i.e., wrapped at about 90° to the longitudinal axis) or helically wrapped (as described previously).
- template 220 can be manufactured in a continuous process and then cut to the desired length before being disposed on balloons.
- template 220 can be adhered or laminated to balloon 210 and/or size limiting layer 215 .
- Template 220 can comprise other materials, such as other fluoropolymers, including polytetrafluoroethylenes with different microstructures from that described in U.S. Pat. No. 7,306,729, so long as they provide sufficient strength and relative lack of compliancy, to produce the desired balloon topography and operate at the previously described pressure thresholds.
- fluoropolymers including polytetrafluoroethylenes with different microstructures from that described in U.S. Pat. No. 7,306,729, so long as they provide sufficient strength and relative lack of compliancy, to produce the desired balloon topography and operate at the previously described pressure thresholds.
- template 220 can also be size-limited but compliant. In such embodiments, template 220 can be formed in a similar manner as size-limited layer and compliant balloon 210 . However, in order to create a varied topography, the upper distension limit of template 220 must be less than the upper distension limit of the balloon 210 or the degree of compliancy is less than that for balloon 210 .
- Template 220 can comprise at least one aperture 221 and, in various embodiments, template 220 can comprise an aperture pattern and/or a plurality of apertures. Apertures 221 can be present in template 220 prior to inflation or be formed or increase in size upon inflation.
- Aperture 221 can comprise an opening or weakened site in the template material.
- an opening can be a hole, cut, or any other discontinuous section of the template material.
- a hole could be formed by puncturing template 220 .
- aperture 221 can comprise an area of template 220 where a portion of the material has been removed or otherwise weakened such that the weakened portion at least partially deforms or detaches in response to inflation of balloon 210 and permits distension beyond the first inflated state.
- Apertures 221 can be formed by any suitable means, including cutting, stamping, laser cutting, perforating, and/or punching/puncturing and/or the like.
- template 220 can comprise a net like structure.
- template can comprise apertures that vary in size. Increasing the size the apertures can allow for a wider (or “coarser”) protrusion. By combining varying aperture sizes with a tapered template profile, as shown in FIG. 5B , the “scraping” effect of the assembly can be intensified proximally to distally or vice versa due to the different protrusion heights.
- template 220 can be configured such that apertures 221 are formed or increase in size upon inflation.
- a template 220 comprising a tape wrapped, woven, or braided membrane around balloon 210 can be constructed, e.g. wrapped, woven, or braided, such that apertures 221 are formed by leaving a space between tape edges and/or apertures 221 form or increase in size between tape edges upon inflation of balloon 210 .
- the angle of the tape material can change relative to the longitudinal axis of the balloon upon inflation and/or the tape material can narrow in width as the balloon assembly is expanded, thus creating apertures 221 .
- balloon assembly 600 can comprise a template 620 having a first pattern of apertures 621 on first section 650 of balloon 610 and a second pattern of aperture or zero apertures on a second section 651 .
- the longitudinal and/or circumferential variation can be random or follow a pre-defined pattern.
- Such balloon assemblies can be used for performing interventional procedures in combination.
- such a balloon configured with zero apertures on one half the length of the balloon assembly and apertures on the remainder of the assembly can be used to perform both thrombectomy (with the apertured portion of the assembly) then Percutaneous Transluminal Angioplasty (PTA) (with the non-apertured portion), all without the exchange of devices.
- thrombectomy with the apertured portion of the assembly
- PTA Percutaneous Transluminal Angioplasty
- the balloon assembly can be selectively alternated between the various inflated states, e.g., between a first inflated state and a second inflations state.
- a specific inflated state can be determined by measuring the volume injected into balloon assembly and/or pressure levels within balloon assembly. By selectively introducing or withdrawing a fluid by a predetermined amount, balloon assembly can transition from one inflated state to another.
- the balloon assembly can be configured to pulsate between the various inflations states.
- balloon assembly can optionally comprise a protective cover.
- a protective cover can be a sleeve or sheath that covers at least a portion of template. The protective cover can be delivered with the balloon assembly into the body and be retracted to expose balloon assembly 200 while within the body.
- an aperture pattern can comprise many small apertures to obtain a “fine texture” pattern or can comprise fewer larger openings to obtain a more “coarse texture” pattern.
- any possible aperture pattern, or combinations of aperture patterns is contemplated herein.
- a first portion of a template can comprise a square grid like aperture pattern and a second portion of a template can comprise a diamond shaped pattern.
- a balloon expanding through a template can define ridges and troughs which, for example, run parallel to the longitudinal axis of the balloon. In one embodiment, these provide for blood perfusion between balloon and vessel wall during a treatment when the balloon is expanded.
- protrusions 212 can form at a first inflated state as depicted in FIG. 2C , and then upon inflation to a second inflated state, having a pressure greater than the first, template 220 can distend and the surface of balloon 210 is smooth, as depicted in FIG. 2B .
- template 220 can be partially or selectively distensible. For example. a 4 mm template that is distensible up to 8 mm can overlay a balloon and/or a size limiting layer. Balloon 210 is inflated to 2 atm and the template acquires its first distension profile so that protrusions form. Upon further inflation up to 4atm, the template can distend to its second distension profile or its maximum size.
- the maximum size of template 220 can correspond to the maximum size of balloon 210 and/or size limiting layer 215 .
- template 220 can be frangible and made to break or stretch at a selected inflation pressure to then reduce the height, at least partially, of some or all of protrusions 212 to allow for increased contact between the balloon surface and the target tissue(s) at a higher pressure.
- Such embodiments can be used to perform both thrombectomy (at the first inflated state) then Percutaneous Transluminal Angioplasty (PTA) (at the second inflated state), all without the exchange of devices.
- PTA Percutaneous Transluminal Angioplasty
- balloon assembly 700 comprises balloon 710 and at least two templates 720 and 725 .
- Template 720 can be disposed coaxially or substantially coaxially over balloon 710
- secondary template 725 can be disposed coaxially or substantially coaxially over template 720 .
- both template 720 and secondary template 725 act to constrain balloon 710 and have aperture patterns to allow balloon 710 to expand through apertures 721 in each template.
- template 720 and secondary template 725 can act to shape the topography of inflated balloon assembly 700 .
- Template 720 can create a “coarse” varied topography, and secondary template 725 is selectively positioned to constrain a portion of protrusion 712 and create a “fine” aperture pattern. Protrusion 712 is thus further constrained by secondary template 725 to form at least two protrusions or protrusions of different size or shape and create a finer or varied aperture pattern.
- each template can have different upper distension limits such that the varied topography can vary by varying the distension of balloon 710 .
- balloon assembly 700 can have three or more inflated states. It is contemplated that any number of templates can be layered in a balloon assembly to vary and refine topography.
- balloon assembly 700 can optionally comprise a size limiting layer as described herein.
- FIG. 9 and FIG. 18 illustrate a varied topography balloon assembly embodiment wherein the balloon comprises a wall with regions of reduced compliance than other more distensible regions;
- balloon 1810 can comprise a wall having portions 1817 of reduced or less compliance than other, more distensible portions 1818 of wall.
- the other portions 1818 being essentially the “apertures” that expand outwardly relative to the portions of reduced or less compliance.
- the more distensible portions 1818 can comprise an upper distension limit.
- the portions 1817 of reduced compliance can be formed through laser densification or by imbibing with a polymer that reduces the compliance in the imbibed region.
- the regions 1817 of reduced compliance have substantially the same thickness as the more distensible regions 1818 .
- balloon 1810 can be formed via tape wrapping or extrusion, and can comprise ePTFE or any other material wherein the compliancy can be varied at discrete sites.
- the balloon can comprise a plurality of protrusions in the form of knob-like features.
- the distensiblity of the sites need not vary along the balloon material.
- the protrusion is pre-formed into the balloon.
- a balloon form can be placed onto a mandrel or constructed on a mandrel which has an aperture or recessed site thereon corresponding to the site of a knob-like feature.
- a heated element can be used to push the knob-like feature into the aperture or recess and set the feature into the balloon wall.
- a lower melt thermoplastic material can be imbibed into the balloon wall at the site of the recess and aperture with the application of pressure and heat, and allowed to cure while pressure is still applied and the wall is recessed.
- a vacuum can be applied to the apertures (or pressure applied to the balloon) such that a recessed site is formed on the balloon surface. The balloon can then be cured while in this configuration.
- balloon assemblies 1900 as described herein can be perfusable.
- balloon 1910 , size limiting layer 1915 , and optionally, template 1920 can comprise a porous material.
- balloon 1910 , size limiting layer 1915 , and optionally, template 1920 can comprise a variably perf usable material.
- the porosity of the material or the internal pressure is low enough to not perfuse or minimally perfuse.
- localized forces can cause the microstructure of the material protruding through apertures 1921 to become more porous, allowing the therapeutic agent to be released from balloon 1910 .
- the porosity of the microstructure is not altered but rather the water entry pressure of the balloon material is such that the balloon does not perfuse until a certain threshold pressure.
- balloon 1919 can be configured not to perfuse until the second inflated state is obtained.
- balloon 1910 can be configured to perfuse along only a portion, e.g., the regions of balloon 1910 that upon inflation, protrude through apertures 1921 .
- a balloon assembly can further comprise a therapeutic agent disposed on, inside of, temporarily filling, or otherwise be integrated with the template.
- a balloon assembly can comprise a therapeutic agent disposed on an inner or outer surface of the balloon or tem plate, or inside balloon.
- a therapeutic agent can be coated on a portion of the elongate member underlying the balloon.
- Therapeutic agent formula can comprise a liquid or solid form. Liquid from can be of a desired viscosity suitable for the treatment desired.
- balloon assembly 800 comprises balloon 810 disposed within template 820 , and therapeutic agent 808 is disposed between balloon 810 and template 820 .
- therapeutic agent 808 can be conveyed through an aperture 821 of template 820 and be released at a localized portion of the body.
- aperture 821 can form upon inflation thus containing therapeutic agent 808 until balloon assembly 800 is inflated.
- therapeutic agent can be disposed within aperture.
- therapeutic agent can be conveyed beyond aperture by protrusion and be directed to a surrounding tissue and/or a localized portion of the body.
- the therapeutic agent formula can be in a solid or viscous form to maintain location within aperture.
- therapeutic agent, positioned within aperture can be protected by a sheath until placed at a treatment site whereupon the sheath can be retracted.
- aperture can be configured to limit the release of therapeutic agent until inflation is underway.
- apertures can comprise a conical or other tapered shape, wherein the aperture defines a smaller area on the outer face than on the inner face.
- Aperture can be configured to enlarge upon inflation to facilitate release of therapeutic agent.
- balloon assembly can comprise a releasable cover to limit or prevent the release of therapeutic agent.
- any therapeutic agent that aids in any procedure, e.g., diagnostic or therapeutic procedures, or that aids in providing a therapeutic and/or curative effect is contemplated and suitable for use with balloon assemblies disclosed herein.
- therapeutic agents that become safer, effective, or achieve another benefit from localized delivery are useful with balloons disclosed herein.
- suitable therapeutic agents include anti-proliferative, anti-inflammatory, fibrolytic, thrombolytic, anti-phlogistic, anti-hyperplastic, anti-neoplastic, anti-mitotic, cytostatic, cytotoxic, anti-angiogenic, anti-restenotic, microtubule inhibiting, anti-migration or anti-thrombotic therapeutic agents.
- suitable therapeutic agents can include: abciximab, acemetacin, acetylvismione B, aclarubicin, ademetionine, adriamycin, aescin, afromoson, akagerine, aldesleukin, amidorone, aminoglutethemide, amsacrine, anakinra, anastrozole, anemonin, anopterine, antimycotics, antithrombotics, thrombolytics such as tissue plasminogen activator (tPA), apocymarin, argatroban, aristolactam-All, aristolochic acid, arsenic and arsenic-containing oxides, salts, chelates and organic compounds, ascomycin, asparaginase, aspirin, atorvastatin, auranofin, azathioprine, azithromycin, baccatine, bafilomycin, basiliximab, bendamustine, benzocaine,
- a template 1020 can optionally comprise at least one rigid element 1026 which can be coupled to or be integral with template 1020 near edge of aperture 1021 and extend into aperture 1021 .
- Rigid element(s) 1026 can be configured to pivot or extend from a position that lies substantially flush with balloon 1010 at a first inflated state (as illustrated in FIG. 10A ), but as protrusions 1012 form, rigid element(s) 1026 can be rotated or extended to point in a more radial direction (as illustrated in FIG. 10B ).
- Rigid elements 1026 can be configured to be rough and/or sharp.
- each rigid element 1026 is flush with balloon 1010 at a first inflated state and then, pivoted outward at second inflated state, the amount of “abrasion” provided by rigid element 1026 to a surrounding tissue(s) such as the luminal wall of a cardiovascular vessel can be varied during inflation.
- Rigid elements 1026 can be constructed by attaching the base of the element 1026 to template 1020 or balloon 1010 at the point underlying template 1020 and passing through template 1020 .
- rigid element 1026 can comprise a lumen, e.g. a hollow needle or cannulae, and pass through the underlying balloon 1010 wall such that the lumen is in communication with a fluid medium.
- rigid elements 1026 can be configured for delivery of a material (such as a therapeutic agent) from within the balloon assembly to the surrounding area, e.g. the vessel walls.
- rigid element 1026 can be preloaded with an agent that is delivered or elutes, e.g., stored within a lumen, at least partially coated thereon, or at least partially imbibed therein.
- rigid element 1026 can be made from a bioabsorbable material that is loaded with therapeutic agent and designed to break off in the vessel and left to elute.
- a lumen of rigid element 1026 can be in communication with a fluid reservoir that is either the inflation media or located around the balloon and compressed by inflation of balloon 1010 leading to elution of the therapeutic agent through the lumen.
- a template can also comprise wires or blades.
- abrasive balloon assembly 1100 is shown having template 1120 comprising wires 1123 overlying balloon 1110 . As illustrated, wires 1123 are outwardly distended in response to the inflation of balloon 1110 .
- the balloon assembly embodiments described herein can optionally comprise electrical components (e.g., circuitry applied to the balloon surface via methods known in the art). Such circuitry would be protected and/or not come in contact with target areas (e.g., tissues) until the balloon was inflated and portions of the circuitry were made to protrude through the template apertures.
- target areas e.g., tissues
- Such constructs can have application in selective ablation of vessel or cavity walls, for example.
- the template could be patterned to match the desired ablation (or other treatment) pattern.
- ultrasound transducers or diagnostic sensors can be disposed on or near the protrusions.
- templates depending on their shape, size and general configuration can also be made to provide protection to the underlying balloon, e.g., provide puncture resistance.
- FIG. 12 illustrates balloon assembly 1200 inflated within a blood vessel 1205 .
- Catheter 1202 is shown coupled to balloon 1210 .
- Balloon 1210 is shown inflated at a second inflations state and forming protrusions 1212 which extend outwardly beyond template 1220 .
- Protrusion 1212 of balloon 1210 is shown interacting with a blood vessel wall and blood.
- balloon assembly 1200 can serve to occlude fluid (e.g., blood) flow within a lumen or cavity.
- balloon protrusions 1212 and/or template 1220 can be constructed so as to encourage tissue in-growth into balloon 1210 and can anchor and/or prevent migration of the balloon 1210 . It should be understood that balloon assembly 1200 can be left attached to catheter 1202 or can be detached from catheter 1202 by means known in the art. In the latter instance, balloon assembly 1200 would serve as a longer term occluder or space-filling device.
- balloon assembly 1700 can comprise template 1720 disposed along an intermediate section, whereby a proximal 1708 and distal 1709 region of balloon 1710 is unconstrained.
- Template 1720 comprises apertures 1721 as described previously.
- Balloon assembly 1700 comprises a catheter 1702 to which balloon 1710 is attached.
- balloon 1710 Upon inflation, balloon 1710 inflates and expands in size preferentially in the regions located to each side of the intermediate section of balloon 1710 covered and constrained by template 1720 .
- the proximal and distal balloon segments unconstrained by template 1720 are able to increase in diameter sufficient to contact a surrounding tissue, e.g., the luminal wall of a cardiovascular vessel, while the intermediate, constrained section remains at a smaller diameter.
- the expanded portions of balloon 1710 in contact with the vessel walls serve to occlude blood flow from the vessel area occupied by the center of the balloon covered by the template.
- the intermediate section of balloon 1710 constrained by template 1720 can be designed to subsequently release a therapeutic agent into the vessel area isolated from blood flow.
- Balloon 1710 and/or template 1720 is configured to perfuse.
- balloon 1710 and/or template 1720 can comprise a porous material.
- balloon 1710 and/or template 1720 can comprise a variably perf usable material.
- the porosity of the material prior to protrusion, is such or the internal pressure is low enough to not perfuse or minimally perfuse.
- the microstructure of the material protruding through apertures 1721 i.e., protrusions 1712
- the porosity of the microstructure is not altered but rather the microstructure is resistant to perfusion (e.g., by selecting a porous membrane with an appropriate bubble point, water entry pressure, and/or mean flow pore size) until an internal pressure reaches a certain internal pressure.
- balloon 1710 can be configured to perfuse along only a portion, e.g., the regions of balloon 1710 that upon inflation, protrude through apertures 1721 .
- the balloon material comprises a fluoropolymer such as ePTFE.
- perfusing balloons as described herein can be at least partially coated with polyvinyl alcohol (PVA) to render them more hydrophilic. This could result in the lowering of the perfusion pressure at select sites or across the entire surface.
- PVA polyvinyl alcohol
- perfusing balloons as described herein can further comprise an outer layer or coating that is oleophobic or render it to have a low surface energy.
- an outer layer or coating that is oleophobic or render it to have a low surface energy.
- the reaction product of perfluoroalkyl alkyl alcohol compounds with selected diisocyanates can be applied to the outermost membrane, whether it be the weeping control layer, the reinforcing layer, or the sealing layer, in order to lower the surface energy of the microstructure while preserving the microporous structure.
- Other examples of oleophobic coatings are described in the following, which are hereby incorporated by reference in their entireties: U.S. Pat. No. 5,342,434 to Wu; U.S. Pat. No. 5,460,872 to Wu and Kaler; WO 2006/127946 to Gore Enterprise Holding; and Canadian Patent No. 2609327 to Freese.
- a balloon assembly placed for long term implantation and detached from a catheter can be constructed so as to feature one or more lumens (e.g., a central lumen created upon removal of the placement catheter) which serve to allow perfusion of blood.
- the balloon assembly can serve as an inflatable endoprostheses.
- this type of balloon assembly can be fitted with a filter to capture emboli.
- balloon assemblies in accordance with the present disclosure can have pre-configured varied topographies or textured topographies.
- a particular topography for example, a textured surface
- a balloon assembly can be modified such that a desired topography is not substantially altered by balloon inflation.
- a balloon need not substantially protrude into an aperture to provide a varied topography as previously described.
- a balloon can provide support for a textured network such that the textured network provides a raised surface of the balloon assembly.
- a balloon can be covered and/or wrapped with a textured network that provides a topographical feature.
- a textured network can comprise beads, filaments, fibrils, rings, knits, weaves, and/or braids, which can be wrapped or otherwise disposed over or within a balloon.
- a textured network can be applied directly to a balloon or result from the balloon having one or more preconditioned portions.
- the textured network can be used to alter the topography of the balloon.
- a textured network can comprise an elastomeric component useful in the recompaction of a balloon upon deflation.
- a textured network can be configured in any pattern or combination of patterns, such as a lattice having various geometric shapes and/or patterns, helix, or consecutive rings.
- textured network 1314 does not act to constrain balloon 1310 but rather distends therewith or has an inner diameter that is equal to the nominal outer diameter of the balloon.
- Textured network 1314 can be formed in a variety of ways. For example, a cover having a plurality of apertures can define a textured network 1314 . Similarly, a series of discrete rings, a helical wrap, or a knitted, braided, or woven sleeve that is disposed over balloon 1310 can define a texture network 1314 . FIG. 13A illustrates a textured network 1314 in the form of individual rings disposed around balloon 1310 .
- balloon 1310 can be covered with a knitted, woven, and/or braided sleeve, such as a knitted tubular form to define textured network 1314 .
- a knitted, woven, and/or braided sleeve such as a knitted tubular form to define textured network 1314 .
- Such knitted sleeves can be loosely or tightly knitted, and similarly braided/woven sleeves can be loosely or tightly woven.
- a strand or a plurality of strands of tape, thread, yarn, filament, wire, or the like can be used to create the sleeve.
- a variety of factors of the knitted sleeve can be controlled to control the properties of textured network 1314 , e.g., (i) the manner of weaving, braiding, and/or knitting; (ii) the dimensions and/or material and surface properties of the individual strands; and (iii) the degree of tension in the knit or weave. Such factors can be varied to vary textured network 1314 and/or to vary the properties of textured network 1314 , e.g., the elasticity of network 1314 .
- reinforcement strands can be woven, braided, or otherwise integrated into the textured network 1314 to give the balloon 1310 an upper distension limit. Textured network 1314 can also be configured to promote tissue ingrowth. Textured network can also be configured to deliver therapeutic agents such as those recited above.
- Reinforcement strands can be comprised of any suitable biocompatible material that can be formed into a flexible strand.
- Strands can be a metallic, polymeric, or composite material.
- Strands can be elastic or inelastic.
- a strand can comprise an ePTFE tape that is formed into a knitted sleeve.
- the knitted sleeve can be wrapped with ePTFE film such that the ePTFE film is at least partially within the knitted ePTFE.
- Textured network 1314 can be formed from wires, thermoplastic filaments or rings. As shown in FIG. 13A , textured network 1314 can comprise a thermoplastic polymer, e.g., fluoro ethylene propylene (FEP). Forms of ePTFE such as urethane imbibed ePTFE can be used as well.
- a thermoplastic polymer e.g., fluoro ethylene propylene (FEP).
- FEP fluoro ethylene propylene
- a sleeve or tube can be thermally bonded to an underlying or overlying film material in order to bond or integrate textured network 1314 to balloon 1310 .
- an outer film can be wrapped over textured network 1314 .
- the assembly can be subjected to thermal treatment at about 380° C. for 15 minutes to facilitate bonding. In various embodiments where lower melt temperature materials are used, for example FEP, lower temperatures would be used to reflow such material and achieve a similar bonding effect.
- the distal end can be crimped and wrapped with a sealing film.
- the proximal end can be adhered to a catheter using adhesive.
- a cross section of textured balloon assembly 1300 having an outer film disposed over texture network 1314 is shown.
- Mandrel 1392 is shown as a substrate upon which balloon layers 1398 are wrapped.
- Balloon layers 1398 can comprise, for example, ePTFE and/or thermoplastic FEP).
- Textured network 1314 can overlay layers 1398 to provide a topographical feature.
- Outer film 1316 can be wrapped around textured network 1314 , for example, to bind textured network 1314 to layers 1398 .
- balloon 1310 can be subjected to thermal treatment to facilitate bonding and mandrel 1392 can then be removed.
- a pre-configured textured balloon assembly 1300 can comprise any suitable balloon 1310 , whether it is compliant, semi-compliant, or non-compliant.
- Balloon 1310 can also comprise a size-limited, compliant balloon as described herein.
- balloon 1310 should be a non-compliant or size-limited, compliant balloon.
- the textured network can form a coherent irregular network. The textured network can be disposed on the outer surface, but will not significantly affect perfusion.
- the textured network can be constructed such that the bubble point, Frazier Number, and/or Gurley Number of the porous membrane are substantially the same or minimally altered.
- balloon 1310 can have a porous membrane and configured to perfuse a fluid and can comprise a textured network on its outer surface.
- the network can be formed from thermoplastic elements.
- the coherent irregular network that may be attached to the underlying balloon 1310 or made into a free standing article as defined herein is a coherent irregular network of thermoplastic particles attached together.
- the term coherent as used in defining the coherent irregular network means that the article comprises elements effectively connected together such that the article can be free standing, and therefore does not include discrete particles that may be attached to a substrate, such as fluoroplastic adhesive coated onto an expanded fluoropolymer substrate.
- the term irregular as used in defining the coherent irregular network means that the structure of the coherent irregular network comprises connecting portions that do not have a consistent diameter or cross-section area across along the length of the connecting portions between intersections or attachments with other connecting portions, particles or elements, and therefore does not included spun-bonded, woven, or felted products that consists of fibers having a consistent cross sectional area.
- the term network as used in defining the coherent irregular network means that individual elements of the coherent irregular network are effectively attached together to provide a contiguous structure.
- the coherent irregular network is further defined as comprising porosity between the attached elements throughout the thickness such that the coherent irregular network is porous and permeable.
- the coherent irregular network is still further defined as having open areas.
- thermoplastic particles could be used to create the coherent irregular network, including particles having a high molecular weight, or low melt flow index (MFI). Particles with MFI values between 0.2 and 30 g/10 min when tested according to the MFI method described herein may be more desirable. However particles with MFI values greater than 0.1 or less than 50 g/10 min may also be used.
- fluoroplastic particles including but not limited to FEP, EFEP, PFA, THV, PVDF, CTFE, and the like, and mixtures thereof are desired in some applications.
- the coherent irregular network is attached to balloon 1310 , e.g., the porous membrane of balloon 1310 , and has a surface roughness defined by a Sp value of at least 35 ⁇ m.
- the size, type, and blend of the particles can be selected to get a desired degree of surface roughness.
- using two or more different types of particles can aid in attaching the coherent irregular network to the expanded fluoropolymer layer, attaching the permeable layer to a support layer, or provide a desired permeability, porosity, surface area, abrasion resistance, surface roughness, free standing film strength, or electrical conductivity or the like.
- the coherent irregular network disposed on at least a portion of the outer surface of balloon 1310 can comprise attached thermoplastic elements that have been fused together creating a network having connecting portions, porosity, and open areas.
- Open areas as used herein are defined as areas of porosity in the coherent irregular network that extend completely through the thickness of the material.
- the coherent irregular network does not completely occlude the surface of the underlying porous membrane, and the areas where the porous membrane can be identified through the coherent irregular network are open areas.
- the “size” of an open area as used herein is defined as being the distance of the longest straight line that can be drawn across the open area. Upon inflation of the balloon, the size of the open area can increase in size as the elements of the textured network become separated. This increase in size can further increase the “grittiness” of the balloon.
- the coherent irregular network further comprises non-melt processible particles.
- the nonmelt processible particles may be inorganic particle, such as silica, carbon, and the like, or a non-melt processible polymer such as polyimide, PPS, PTFE, or the like.
- the thermoplastic particles or elements are attached to create a coherent irregular network, and the non-melt processible particles are attached therein or thereon.
- a balloon assembly can comprise a balloon having a porous membrane having an outer surface and configured to perfuse a fluid, a template having at least one aperture about which a protrusion can distend, and a textured network disposed on at least a portion of the outer surface of the balloon and comprising a plurality of voids.
- the textured network can be a coherent irregular network of thermoplastic elements.
- the portion of the outer surface of the porous membrane can comprise an Sp value of at least 35 ⁇ m.
- balloon 1310 can comprise an ePTFE wrapped balloon.
- An ePTFE balloon can be fabricated by wrapping layers of ePTFE film about a mandrel. Wrapping can be a helical or longitudinal wrap.
- the ePTFE balloon can be subjected to thermal treatment at about 380° C. for 15 minutes to facilitate bonding and one end crimped. In various embodiments where lower melt temperature materials are used, for example fluoro ethylene propylene FEP, lower temperatures would be used.
- Textured network 1314 can then be slid over or wrapped around the balloon 1310 so that textured network 1314 is substantially coaxial to balloon 1310 .
- Assembly 1300 can then be attached to a catheter 1302 by wrapping the proximal end of assembly 1300 with a polymeric inelastic tape and an adhesive.
- a balloon assembly comprising a pre-configured texture balloon as described combined with a template having at least one aperture.
- a ribbed balloon can form a protrusion about an aperture.
- a size limiting layer can also be present to limit distension of balloon if desired.
- portions of a template or balloon cover can be scored, etched, or otherwise partially cut or weakened.
- a scored portion of a template can rupture or otherwise break. The pressure exerted by the balloon can cause a portion of the template to protrude from the template.
- the protruding portion can be configured to be sharp by selectively shaping the scored portion.
- a triangle shape can be formed and scored at one apex. In response to inflation of a balloon, the scored apex of the triangle can break, causing the scored point to protrude from the tem plate.
- the point (or other resulting shape) can be directionally oriented relative to the tissue.
- the raised points can be oriented pointing toward the distal end of a catheter such that upon insertion in a vessel a rubbing or scraping along the vessel walls occurs.
- Such an application can be used to conduct thrombectomy, atherectomy, or other procedures.
- the points can be oriented in multiple directions.
- the points, serving as anchors could be oriented to retain the device in place, i.e., against the direction of blood flow or motion of the surrounding tissue(s). Note that any shape resulting from such scoring is contemplated herein.
- balloon assembly can comprise balloon and a template overlying at least a portion thereof which comprises a surface that is disrupted upon inflation.
- a balloon assembly 1400 comprises balloon 1410 and an overlying template 1420 having a scored portion 1422 .
- scored portion 1422 will partially separate from template surface and will form an outwardly extending protrusion.
- the ruptured portion of template 1420 that is created by the rupture of score 1422 is aperture 1421 in which balloon 1410 can be at least partially exposed.
- score 1422 can be formed as a through cut in the template material which would not have to rupture to achieve the desired effect.
- scoring and later rupturing of scores can enable the insertion of sharp objects into the body in a substantially unsharpened state and then provide for the deployment of the sharp object at a particular time.
- scoring and later rupturing can aid in the delivery of therapeutic agents.
- a therapeutic agent can be disposed between a balloon and a template.
- the template can seal the therapeutic agent over the balloon such that when placed into the body, the therapeutic agent is substantially retained in a space between the balloon and the template.
- the therapeutic agent Upon rupture of a scored portion of the template, the therapeutic agent can be released into a localized portion of the body.
- a balloon assembly can comprise a balloon 1410 and a template 1420 overlying at least a portion thereof, wherein template 1420 comprises at least one aperture 1421 and wherein an arced element 1423 spans across aperture 1421 .
- balloon 1410 is inflated and is configured to form a protrusion 1412 through aperture 1421 at a second inflated state.
- arced element 1423 is dimensioned so that it does not restrain (or only slightly or partially restrains) protrusion 1412 and thus is situated atop protrusion 1412 at the second inflated state.
- Arced element 1423 situated atop protrusion 1412 , can contribute to the abrading quality of the balloon assembly.
- Arced element 1423 can comprise an inner arc edge having an arc length, wherein the arc length of the inner arc edge is similar to the arc length of the protrusion that protrudes through the aperture so that the inner edge lay atop protrusion 1412 .
- the arced element 1423 in the first inflated state, can lay flat on the surface of balloon 1410 or flush with template 1420 , and upon inflation to second inflated state, balloon 1410 forms a protrusion 1412 and arced element 1423 reorients itself to reduce strain and situates atop protrusion 1412 .
- arced element 1423 can comprise a filament, wire, film, tape, thread, or the like.
- arced element 1423 can be integral with template 1420 , i.e., cut into the template pattern or be attached thereto.
- FIGS. 14E ( 1 ) to 14 E( 4 ) illustrate various arced element 1423 patterns.
- arced element 1423 can have an inner arc edge and an outer arc edge with different lengths.
- both edges of arced element 1423 lay flat on balloon 1410 in a first inflated state, and upon inflation the inner edge is in substantial contact with protrusion 1412 , wherein the outer edge is not in continuous contact with the protrusion and at least a portion of the outer edge is separated a distance radially outward of protrusion 1412 .
- arced element 1423 can be part of a template pattern, wherein arced element 1423 that spans aperture 1421 .
- arced element 1423 can comprise a wire or filament coupled to the template.
- the wire or filament can be an undulating form that spans a plurality of apertures 1421 .
- both above mentioned embodiments may be combined to create an arced element which both comprises wrinkles, ruffles and also comprises wire(s) or filament(s).
- step 1502 comprises coupling a template with a balloon and a size limiting layer.
- a balloon can be disposed substantially coaxially with a template and a size limiting layer.
- sintering can be performed on the balloon assembly.
- the balloon can be brought to a temperature above the melting point of the material that comprises the balloon and/or template. Sintering in this manner can produce bonding of ePTFE layers.
- Step 1504 can comprise disposing a balloon on a catheter.
- Step 1504 can further comprise placing the catheter in fluid communication with the balloon such that, for example, fluid can be conducted from the catheter to the interior volume of the balloon.
- Method 1600 for using a balloon assembly can be used.
- Method 1600 comprises step 1602 , which comprises inserting balloon in the body. Any portion of the body or a lumen of the body can be used in step 1602 .
- a lumen can comprise human blood vessels, urethra, esophagus, intervertebral spaces, and the like.
- Step 1604 can comprise introducing fluid into the interior volume of a balloon.
- Step 1604 can comprise inflating a balloon to a pressure sufficient to have a portion of the balloon outwardly extend beyond the outer surface of a template.
- Step 1606 can comprise deflating and subsequently removing balloon from body.
- the balloon assembly with a template can comprise a plurality of apertures located along a length of the assembly (and optionally about a circumference) and can be used for locating a side branch vessel.
- a fluid having an agent which is externally detectable such as a radiopaque dye.
- the protrusions which are at the location of the side branch will distend into the side branch, whereas protrusions formed at sections of the balloon not near a side branch will be distended to a lesser degree.
- the side branch is visible by way of the protrusions therein.
- a balloon assembly can be configured to have an abrasive topography.
- the surface of the balloon is roughened or provided with a desired textured network, for example, as described above.
- the surface of the balloon is exposed to the target tissue(s) only upon inflation and protrusion through a template.
- the balloon assembly can be configured so that a template has rough and/or sharp edges that do not interact with the outside environment upon entry into the body but, in response to inflation of the compliant balloon, the rough and/or sharp edges are deployed, forming an abrasive topography.
- a varied topography balloon or a pre-configured textured balloon assembly can be constructed using multiple layers of material, such as ePTFE, nylon and/or elastomers on either or both the balloon or the template.
- various longitudinal segments of the balloon and/or template can be constructed of different materials featuring different compliance characteristics. Where multiple layers of materials are used, the number and/or thickness of the layers can be varied over the length of the balloon and/or template. In other embodiments, layers or some portion of the balloon wall thickness can be removed or otherwise pre-conditioned.
- Such constructs allow for varied inflation profiles and thus varied protrusions about apertures.
- the balloon cones can be made to be more compliant than the body of the balloon.
- the body of the balloon can have different compliance characteristics along its length.
- Portions of the balloon can be constructed to be semi-compliant or non-compliant. Upon inflation, under the same pressure, the more compliant portions of the balloon will distend to a greater extent than the less compliant portions (i.e., form a height gradient).
- balloon assemblies as described herein can comprise a distal cap to secure the distal terminus of a balloon to catheter.
- a distal cap can be referred to as an olive.
- An olive can abut against the distal end of a balloon or catheter.
- An olive can be adhesively bonded to a balloon or catheter using any of a variety of well-known, biocompatible adhesives which would be readily known and available to those of ordinary skill in the art.
- olive could be screw threaded, heat bonded, spin welded, or fixed to a balloon or catheter by a variety of other known techniques which would be equivalent for purposes of this disclosure.
- a catheter or other apparatus can be disposed on the distal terminus of a balloon.
- balloons assemblies disclosed herein can comprise size-limited, compliant balloons that perfuse in response to an increase in internal pressure.
- balloon assemblies disclosed herein are steerable when in both inflated and/or deflated states.
- the balloon assemblies described herein can be made to be conformable to vessel anatomy in which they are used.
- the balloon assemblies of the present disclosure can be made to be length-adjustable.
- multiple of the balloon assemblies of the present disclosure can be disposed along the length of a single balloon catheter.
- balloon assemblies can further comprise an elastomeric cover or inner elastomeric lining to aid in compaction of the balloon.
- balloon assemblies disclosed herein can be used with a pressure retaining valve.
- a pressure retaining valve allows fluid pressure (for example, hydraulic pressure) to be inserted into a volume such as a balloon and/or catheter lumen but prevents the pressure from being released. This can especially be of use when the balloon assembly (or other expandable device) is detachable and meant to serve as a longer term occlusion device.
- devices disclosed herein are useful in any medical applications or treatments such as, for example, tissue ablation, angioplasty, cancer therapies, thrombectomy, embolectomy, angioplasty/stenting; angioplasty/stenting in the kidneys; angioplasty/stenting in blood carrying passageways; angioplasty/stenting in the legs; angioplasties of graft-artery anastomotic strictures; stenting used to aid attachment of endoprostheses such as gastrointestinal liners, cancer of the adrenal cortex; cancer of the endometrium; cancer of the larynx (voice box); cancer of the pancreas; cancer of the parathyroid; cancer of the thyroid gland; cancer of tissues of the lip or mouth (e.g.; tongue; gums; lining of cheeks; bottom of mouth; hard & soft palate; retromolar trigone); cancers; cancers of the blood; cancers of the nasal cavity; candidiasis;
- balloon assemblies of the present disclosure can be used in conjunction with drug eluting or drug delivery balloons.
- the drug eluting balloon underlays one or more templates and upon inflation not only delivers a therapeutic agent to the adjacent target tissues, but does so via the protrusions extending from template apertures. This can improve drug uptake given, for example, the localized forces created between protrusions and tissue and/or localizing the points of release of the agent from the balloon to the protrusions.
- a varied topography or textured balloon of the present disclosure can be constructed so as to provide enhanced stent retention, stent deployment, and stent release.
- the protrusions formed by the tem plate(s) can be of any shape, size, surface texture and/or material to adhere to or prevent slippage of the balloon and inner walls of such prostheses.
- protrusions can be designed so as to fit or mesh with stent features, e.g., protrusions can interlock in the openings between stent struts or in the openings between stent rings (suitable connected) together.
- protrusions correspondingly located at a proximal and/or distal end of the stent can also facilitate stent retention. This makes their tracking and placement easier and more accurate.
- varied topographies can also reduce adhesion or “stiction” between the balloon and endoprosthesis by creating protrusion patterns at a second inflated state, which can result in minimal, localized contact between the two rather than the entire balloon surface (as is common with conventional balloons).
- the location of the protrusions can be engineered so as to engage only portions of an endoprostheses. Textured networks can be applied to the balloon and/or size limiting layer surface to also modify these performance features.
- protrusions 2012 are used to deploy anchors 2051 for holding the endoprosthesis 2050 in place at the desired treatment site.
- Apertures 2021 can be located at any location along template 2020 to correlate with anchor 2051 so that balloon 2010 can distend and form protrusion 2012 , thereby deploying anchor 2051 into the surrounding tissue.
- a balloon assembly 2100 can comprise balloon 2110 and template 2120 as described herein wherein at least two apertures 2121 form a generally circumferential protrusion 2012 profile along a section of balloon 2110 . This section can be located at a proximal and/or distal end of assembly.
- these balloon constructs offer several clinical advantages. Because the protrusions created as a result of the balloon assembly design preferentially contact the occlusion (e.g., plaque), there are distributed stress concentrations created over the surface of the occlusion. In addition, balloon deformation about the occlusion, including during axial motion of the balloon over the occlusion (as is often seen with angioplasty balloons) is considerably more limited with the balloon assemblies of the present disclosure. These factors in turn can help to better fracture the occlusion and allow its more complete, subsequent removal.
- occlusion e.g., plaque
- the balloon assemblies of the present disclosure can be inflated far above typical nominal inflation pressures for compliant or semi-compliant balloons. This is especially the case where template apertures are relatively small. Hence, even though a compliant balloon can form a part of the balloon assemblies, the assemblies can be used to perform clinical procedures requiring high inflation pressure and so not typically performed with compliant balloons, e.g., angioplasty.
- the protrusions resulting from designs made in accordance with the present disclosure can be used in the visualization of anatomical structures.
- the balloon can be filled with a visualization (e.g., contrast) agent.
- a visualization agent e.g., contrast
- the protrusions will be distinctly visualized (e.g., via fluoroscopy).
- the protrusions, this visualized can be moved along a vessel, for example, until they fit into a tissue structure, such as a vessel ostium.
- a clinician can easily locate anatomical features which conform in shape, to some degree, to the shape of the protrusion(s).
- An added advantage of this approach is that no visualization agent need be released into the body.
- balloons can be constructed so as to expand protrusions to pre-determined heights, both final expanded heights and heights during expansion.
- This “progressive protrusion” can be clinically useful. This can be done by engineering the design of the balloons to correlate with inflation pressures and/or inflation fluid volumes. This provides clinicians with variable control during use of these devices.
- a topographically-variable balloon used can provide increased surface area to prevent acute migration of the balloon and/or encourage tissue ingrowth and/or thrombogenesis. This can be beneficial in balloon assemblies used as occluders.
- balloon assemblies in accordance with present disclosure can be used to “scrub” or otherwise displace or remove thrombus or plaque in the vasculature.
- a coarse or textured topography can be helpful in enhancing engagement of the balloon assembly with the thrombus or plaque and/or helpful in occluding a blood vessel.
- balloon assemblies in accordance with the present disclosure can be used in conjunction with a reverse blood flow system like those used in carotid artery stenting. In such reverse blood flow systems, balloon assemblies in accordance with present disclosure can be used to occlude the external carotid artery and/or the common carotid artery. Balloon assemblies in accordance with present disclosure can provide enhanced occlusion characteristics relative to conventional balloon assemblies.
- balloon assemblies in accordance with present disclosure can be used as a balloon anchored introducer in a stenting procedure.
- a balloon assembly can be positioned in the body distal to the desired stent site.
- the balloon assembly can then be inflated to anchor the balloon assembly and thus provide support for a guidewire or other apparatus that can deliver and deploy a stent to the desired stent site.
- Balloon assemblies in accordance with present disclosure can provide enhanced anchoring characteristics relative to conventional balloon assemblies.
- An ePTFE film was obtained of the general type as disclosed in U.S. Pat. No. 7,306,729.
- a discontinuous layer of the thermoplastic FEP fluoro ethylene propylene
- the tape was wrapped around a 6 mm mandrel so that the film's machine direction was oriented about the circumference of the mandrel.
- a length of tape was wrapped that resulted in approximately 18 layers of film.
- the tape-wrapped tube was thermally treated in an oven at 320° C. for 12 minutes. The film tube was removed from the oven and then removed from the mandrel and cut to 80 mm in length.
- the 6 mm tube was placed over a suitable mandrel and square apertures measuring 2 mm by 2 mm were cut through the tube using a CO2 laser, leaving 1 mm of film material between apertures.
- Six rows of apertures were cut about the circumference of the tube, parallel to the tube's longitudinal axis.
- the pattern was cut over a 60 mm length centered in the 80 mm tube. This tube is referred to as a “template” with “apertures.”
- Example 2 Method of Making a Balloon Assembly Comprising a Size Limiting Layer Overlaying a Compliant Balloon, Both of which are Circumscribed by a Template with Apertures
- An ePTFE film was obtained of the general type as disclosed in U.S. Pat. No. 5,476,589, entitled, “Porous PTFE Film And A Manufacturing Method Therefore,” which issued Dec. 19, 1995.
- the film was cut into a tape of 25 mm width and helically wrapped about a 9 mm stainless steel mandrel at an 11.4 mm pitch. The wraps were repeated on a bias in opposite directions to produce an approximately 4-layer film tube.
- This tube was then thermally treated in an oven at 380° C. for 9 minutes and then removed from the oven.
- the tube was removed from the mandrel, placed over a 7 mm mandrel and axially stretched to decrease its diameter to 7 mm.
- a sacrificial ePTFE tape was helically wrapped over the film tube on the 7 mm mandrel.
- the tube assembly was then axially compressed to 85% of its original length.
- the tube assembly was then subjected to thermal treatment at 380° C. for 1 minute and then removed from the oven.
- the sacrificial ePTFE layer was removed and discarded.
- the 7 mm tube construct was cut to an 80 mm length. This tube can be referred to as a “size limiting layer”.
- a compliant polyurethane balloon catheter was obtained with a balloon having a diameter of 10 mm and length of 60 mm (“COAX,” Bavarian Medizin Technologies (BMT), Germany).
- the size limiting layer was slid over the balloon assembly (with the balloon in its collapsed state).
- the ends of the size limiting layer were secured to the catheter using LOCTITE adhesive 4981 (Henkel Corporation, Düsseldorf, 40589 Germany) applied to a 6 mm wide ePTFE tape as it was wrapped 5 times about the size limiting layer tube ends.
- the balloon was then inflated to an approximate 5 mm diameter.
- the template layer as described in Example 2, was slid over the size-limiting layer and the compliant balloon (with the balloon at its 5 mm diameter).
- the ends of the template layer were secured to the catheter using LOCTITE adhesive 4981 applied to a 6 mm wide ePTFE tape as it was wrapped 5 times about the tube ends.
- the balloon was then inflated to an approximate 6 mm diameter.
- the balloon assembly was then inflated to 4 atmospheres and protrusions of the underlying compliant balloon were noted extending from the apertures.
- Example 3 Method of Making a Balloon Assembly Comprising a Size Limiting Layer Overlaying a Compliant Balloon, Both of which are Circumscribed by a Template with Apertures Having a First Distension Profile and a Second Distension Profile
- an inflatable, compliant balloon element constructed to be 8 mm ⁇ 40 mm with a working length of 40 mm, two shoulders of length of 4 mm, and two seals of 7 mm, giving it an overall length of 62 mm.
- a frangible template can be constructed as described in Example 3, instead using an ePTFE film as described in U.S. Pat. No. 5,814,405 Branca et al., which is hereby incorporated by reference in its entirety.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Manufacturing & Machinery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
Various embodiments provide a device comprising a balloon assembly including a balloon, a film template, and a rigid element. The film template may have a fixed upper distension limit and may include at least one aperture. The rigid element may lay substantially flush with an outer surface of the balloon at a first inflated state of the balloon. The first upper distension limit of the balloon may be greater than the fixed upper distension limit of the film template and the balloon may outwardly protrude through the at least one aperture at a second inflated state. The rigid element may be extended in a radial direction away from the outer surface of the balloon as the balloon outwardly protrudes through the at least one aperture relative to the outer surface of the film template.
Description
- This application is a continuation application of U.S. application Ser. No. 15/645,176, filed Jul. 10, 2017, now U.S. Pat. No. 10,881,426, issued Jan. 5, 2021, which is a continuation application of U.S. application Ser. No. 13/645,414 filed on Oct. 4, 2012, now U.S. Pat. No. 9,730,726, issued Aug. 15, 2017, which claims priority to U.S. Provisional Application No. 61/545,039, filed Oct. 7, 2011, wherein the above-listed applications are hereby incorporated by reference in their entireties.
- The present disclosure relates generally to balloon assemblies having controllable topographies and systems and methods relating to the same.
- Balloons intended for use within a mammalian body, such as a human, are employed in a variety of medical procedures, including dilation of narrowed blood vessels, placement of stents and other implantable devices, temporary or permanent occlusion of blood vessels, drug delivery, thrombectomy, embolectomy, atherectomy, angioplasty, other endovascular procedures, and other procedures within a lumen of a mammalian body such as a human body. In this regard, as used herein, the term “body” can comprise a mammalian body such as a human body or other animal body.
- In a typical application, a balloon (often coupled with a catheter) is advanced to the desired location in the vascular system or other lumen of the body. The balloon is then pressure-expanded in accordance with a medical procedure. Thereafter, the pressure is removed from the balloon, allowing the balloon to contract and permit removal of the catheter and, in many cases, the balloon.
- Procedures such as these are generally considered minimally invasive, and are often performed in a manner which minimizes disruption to the patient's body. As a result, balloons are often inserted from a location remote from the region to be treated. For example, during angioplasty procedures involving coronary vessels, the balloon catheter is typically inserted into the femoral artery in the groin region of the patient, and then advanced through vessels into the coronary region of the patient. These balloons typically include some type of radiopaque marker to allow the physician performing the procedure to monitor the progress of the catheter through the body.
- Non-compliant balloons are generally made of relatively strong but generally inelastic material (e.g., nylon, polyester, etc.), which must be folded to obtain a compact, small diameter cross section for delivery. These relatively stiff balloons do not easily conform to the surrounding vessel and thus can be used to compact hard deposits in vessels. Due to the need for strength and stiffness, these devices are rated to employ high inflation pressures, usually up to about 4 to about 60 atmospheres. As depicted in
FIG. 1 , non-compliant balloons (line C) have a maximum diameter, and as inflation fluid is introduced, such balloons will not normally distend appreciably beyond a maximum diameter. Once a non-compliant balloon is inflated to its maximum diameter, the exertion of additional pressure can cause rupture of the balloon, creating a hazardous condition. - By contrast, compliant balloons generally comprise soft, elastic material (e.g., natural rubber latex). As depicted in
FIG. 1 , compliant balloons (line A) will generally expand continuously in diameter and will not appreciably increase in internal pressure as inflation fluid is introduced. As a result, compliant balloons are generally rated by volume (e.g., 0.3 cc) rather than by nominal diameter. Also, compliant balloons generally conform to the shape of the vessel. Although comparatively weak compared to non-compliant balloons, compliant balloons have the advantage that they need not be folded about a delivery catheter (reducing profile) and tend to readily recompact to their initial size and dimensions following inflation and subsequent deflation. These balloons can be employed to displace soft deposits, such as a thrombus, where a soft and tacky material such as latex provides an effective extraction means, and also can be used as an occlusion balloon, operating at low pressures. - In between the spectrum of compliant balloons and non-compliant balloons fall semi-compliant balloons. As depicted in
FIG. 1 , semi-compliant balloons (line B) will both increase in pressure and increase in diameter as inflation fluid is introduced. However, semi-compliant balloons operate at pressures in between the two types of balloons and will continue to distend as inflation fluid is introduced. - Both compliant and non-compliant balloons tend to have a uniform surface topography. In other words, conventional balloons tend to have smooth surfaces. Balloons with more varied topographies may facilitate a variety of medical procedures and therapies not possible using conventional balloons. For instance, a variable topography may provide increased surface area over a similar conventional balloon, and thus interaction with the body may be improved. A variable topography balloon may also be configured to deploy sharp objects in a localized, difficult to reach part of the body, providing an improvement in therapy. In addition, variable topography balloons may provide improved drug delivery systems. Moreover, it would be beneficial for a balloon to have a controllable topography.
- The present disclosure provides systems and methods for balloon assemblies having varied topographies and pre-configured surface textures. In various embodiments, a device is provided comprising a balloon comprising a size limiting layer and a template disposed around or within the balloon. The template comprises at least one aperture and a portion that is more resistant to deformation in a radial direction than the balloon or the size limiting layer, either because template comprises a less compliant material or has an upper distension limit that is less than the size limiting layer's upper distension limit. As such, the balloon and size limiting layer are configured to distend beyond the template about the aperture at a given volume/pressure. The balloon and size limiting layer will distend about an aperture to a second inflated state comprising a varied topography. The size limiting layer prevents further appreciable distension beyond the second inflated state. In various embodiments, the template and/or balloon can optionally comprise an expanded polytetrafluoroethylene (ePTFE). The balloon and/or template can comprise a tape wrapped membrane. Other embodiments comprise methods of making and using the same.
- In various embodiments, a balloon assembly is provided comprising a balloon having a controlled topography, wherein the balloon assembly has a smooth or substantially wrinkle free surface at a first inflated state and a varied topography surface at a second inflated state. In an embodiment wherein the balloon assembly comprises an inner balloon and an outer template, the inner diameter of the template at a first inflated state is substantially equal to the outer diameter of the balloon at a first inflated state. In an embodiment wherein an outer balloon is disposed around an inner template, the converse is true; namely, the outer diameter of the template at a first inflated state is substantially equal to the inner diameter of the balloon in the first inflated state. The balloon and/or template can comprise a tape wrapped membrane. Other embodiments comprise methods of making and using the same.
- In other embodiments, a balloon assembly can comprise an underlying compliant balloon and an overlying less compliant template having at least one aperture. Located within the aperture can be a therapeutic agent, preferably in a solid or viscous form. Upon inflation, the underlying compliant balloon will protrude through the aperture and convey the therapeutic agent external to the template. In this manner, a therapeutic agent can be delivered to a surrounding tissue such as the intima of a vessel. Other embodiments include methods of making and using the same.
- Another aspect of the present disclosure comprises textured balloon assemblies. In various embodiments, a balloon can be covered and/or wrapped with a textured network that provides a topographical feature. For example, a textured network can comprise beads, filaments, fibers, rings, knits, weaves, and/or braids, which can be wrapped or otherwise disposed over or within a balloon. The textured network creates raised surface patterns that can provide therapeutic effect. Other embodiments include methods of making and using the same.
- The accompanying drawings are included to provide a further understanding of the present disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure, and together with the description serve to explain the principles of the disclosure.
-
FIG. 1 compares pressure to height of complaint balloons (Line A), semi-compliant balloons (Line B), and non-compliant balloons (Line C); -
FIG. 2A illustrates a schematic varied topography balloon assembly embodiment from a cross-sectional perspective; -
FIGS. 2B (1) to 2B(3) illustrates a varied topography balloon assembly embodiment of the present disclosure in a deflated state; a first inflated state; and a second inflated state; -
FIG. 2B (4) illustrates a close up, cross-sectional view about an aperture of a varied topography balloon assembly embodiment illustrated inFIG. 2B (3); -
FIGS. 3A (1) to 3A(3) schematically illustrate the process under which various embodiments distend to a second inflated state thereby forming a varied topography balloon assembly; -
FIGS. 3B (1) to 3B(3) schematically illustrate the process under which various embodiments distend to a second inflated state thereby forming a varied topography balloon assembly; -
FIGS. 4A to 4D illustrate wrapping a film tape to form a size limiting membrane layer; -
FIG. 5A schematically illustrates a balloon assembly embodiment comprising a tapered balloon and/or size limiting layer; -
FIG. 5B schematically illustrates a balloon assembly embodiment comprising a tapered template; -
FIGS. 6A and 6B illustrate a cross-sectional view of a varied topography balloon assembly embodiment wherein a plurality of apertures are located on a first section of the template and no apertures are located on a second section of tem plate; -
FIG. 7 A schematically illustrates a varied topography balloon assembly embodiment of the present disclosure comprising two templates; -
FIG. 7B illustrates a close up, cross-sectional view about an aperture of a varied topography balloon assembly embodiment illustrated inFIG. 7A ; -
FIG. 8 illustrates a varied topography balloon assembly comprising a therapeutic agent, in accordance with various embodiments; -
FIG. 9 illustrates a varied topography balloon assembly embodiment wherein the balloon comprises a wall with regions of reduced compliance than other more distensible regions; -
FIG. 10A illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprise rigid elements; -
FIG. 10B illustrates a cross-sectional view of a balloon assembly embodiment depicted inFIG. 10A with the rigid elements outwardly rotated; -
FIG. 10C illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprises rigid elements having a piercing or sharp tip that is attached to template at its proximal base; -
FIG. 10D illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprises rigid elements ofFIG. 10C outwardly rotated; -
FIG. 10E illustrates a cross-sectional view of a balloon assembly embodiment wherein the overlying template comprises rigid elements having a lumen therethrough which is in fluid communication with the balloon; -
FIG. 11 illustrates an inflated balloon assembly comprising a wire tem plate; -
FIG. 12 illustrates a balloon assembly in accordance with various embodiments within the vasculature; -
FIGS. 13A to 13C illustrate a textured balloon assembly in accordance with various embodiments; -
FIG. 13D illustrates a cross sectional view a textured balloon assembly on a mandrel, in accordance with various embodiments; -
FIG. 14A illustrates a deflated balloon assembly with a scored template pattern from an exterior perspective, in accordance with various embodiments; -
FIG. 14B illustrates an inflated balloon assembly with a deployed scored template pattern from an exterior perspective, in accordance with various embodiments; -
FIG. 14C (1) illustrates a close-up, perspective view of a deflated balloon assembly with an arced element across the aperture of a template, in accordance with various embodiments; -
FIG. 14C (2) illustrates a close-up, perspective view of an inflated balloon assembly with a deployed arced element across the aperture of a template, in accordance with various embodiments; -
FIG. 14C (3) illustrates a close-up, side view of the inflated balloon assembly ofFIG. 14C (2), in accordance with various embodiments; -
FIG. 14D (1) to 14D(4) illustrate the various patterns of template comprising an arced element across the aperture; -
FIG. 14E (1) illustrates a close-up, perspective view of a deflated balloon assembly with an arced element across the aperture of a template, in accordance with various embodiments; -
FIG. 14E (2) illustrates a close-up, perspective view of the inflated balloon assembly ofFIG. 14E (1), in accordance with various embodiments; -
FIG. 15 illustrates a method of making, in accordance with various embodiments; -
FIG. 16 illustrates a method of use, in accordance with various embodiments; -
FIG. 17 illustrates a balloon assembly embodiment wherein a template is located on an intermediate section of a balloon; -
FIG. 18 illustrates a balloon assembly embodiment wherein the balloon and size limiting layer is perfusable; -
FIGS. 19A-B illustrates a varied topography balloon assembly embodiment wherein the balloon comprises a wall with regions of reduced compliance than other more distensible regions; -
FIGS. 20A-20B illustrates a varied topography balloon assembly with a stent device mounted thereon, the stent device having deployable anchors which are actuated by protruding apertures; and -
FIG. 21 illustrates a varied topography balloon assembly wherein an aperture or a plurality of apertures are located on a circumferential section. - Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatuses configured to perform the intended functions. Stated differently, other methods and apparatuses can be incorporated herein to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not all drawn to scale, but can be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting. Finally, although the present disclosure can be described in connection with various principles and beliefs, the present disclosure should not be bound by theory.
- As used herein, “balloon assembly” means a balloon coupled with one or more other components, such as a template (described herein), size limiting layer (descried herein), catheter, distal cap (“olive”), cover, or other apparatus.
- As used herein, the term “size limiting” means that a material or component has an upper distension or deformation limit beyond which a material or component will not appreciably expand, distend, and/or deform. For example, a size-limited balloon can be inflated to a maximum diameter, and once this diameter is reached, further increases in pressure will not cause an appreciable increase in its diameter. As reflected in
FIG. 1 , a non-compliant balloon (line C) is a size-limited balloon, and traditional compliant (line A) and semi-compliant (line B) balloons are not size-limited balloons. Accordingly, a “compliant balloon,” as used herein, refers to both compliant and semi-compliant balloons or balloons that are not size limited, but will continue to expand, distend, and/or deform as the internal pressure increases until the point of failure, e.g., the balloon wall ruptures. In accordance with certain embodiments of the present disclosure, the described “compliant” balloons are referred to as such because the described balloons generally conform to the shape of their surroundings (e.g., a surrounding anatomy or vessel) like traditional “compliant” balloons, e.g., portions of the described “compliant” balloons are able to outwardly extend from the template to form protrusions. - As used herein, the term “to inflate” can mean to fill or cause expansion by introducing a flowable substance (e.g., an influx of fluid), such as a liquid (e.g., saline), a gel, or a gas.
- As used herein, the term “inflated” means a balloon at an internal pressure or volume above the internal pressure or volume at which the balloon begins to expand from a deflated state. As used herein, a “first inflated state” refers to an inflated balloon at a first pressure or first volume which will result in a balloon with a generally smooth or uniform surface, except perhaps with respect to slight recesses at the site of the aperture(s). As used herein, a “second inflated state” refers to an inflated balloon at a second pressure or second volume greater than the first pressure or first volume which will result in a balloon with a varied topography. As used herein, “varied topography” refers to a balloon assembly surface that has textured, bumpy, ribbed, or other three-dimensional surfaces.
- As used herein, the term “elongate element” is generally any element configured for relative axial movement with an endoluminal device delivery element (e.g., a catheter-based endoluminal device delivery element such as a balloon catheter) and includes any longitudinally extending structure with or without a lumen therethrough. Thus, elongate elements include but are not limited to tubes with lumens (e.g., catheters), solid rods, hollow or solid wires (e.g., guidewires), hollow or solid stylets, metal tubes (e.g., hypotubes), polymer tubes, pull cords or tethers, fibers, filaments, electrical conductors, radiopaque elements, radioactive elements and radiographic elements. Elongate elements can be any material and can have any cross-sectional shape including, but not limited to, profiles that are elliptical, non-elliptical, or random.
- As described herein, balloon assemblies used inside the body generally interact with the body through contact with an exterior surface of the balloon assembly. Thus, the surface topography of a balloon assembly can affect the physical interaction between the balloon assembly and the body or a device inside the body. The ability to control a balloon's topography, or three dimensional surface characteristics, allows balloon assemblies to interact with the body in new or improved modes. Various advantages can be realized using controllably variable topography balloon assemblies. For example, balloon assemblies, such as those that can be used with a catheter, can be inserted into a lumen of the body. The balloon assembly can interact with the body in a variety of ways which can be facilitated by designing topographies which yield improved results. In this regard, for example, a balloon having a varied topography can improve engagement with a vessel wall and/or improve atherosclerotic plaque or thrombus removal ability, such from a vessel wall or the wall of an endoprosthesis.
- By selectively constraining the expansion of a balloon at selected sites, the balloon assembly topography can be varied. For example, with reference to
FIG. 2A , a schematic of aballoon assembly 200 is shown.FIGS. 2B (1) to 2B(3) illustrate avaried topography balloon 200 in a deflated state (FIG. 2B (1)), a first inflated state having a generally uniform or smooth surface (FIG. 2B (2)), and a second inflated state having a varied topography (FIG. 2B (3)).FIG. 2B (4) illustrates a close-up, cross-sectional view of aprotrusion 212 of avaried topography balloon 200. -
Balloon assembly 200 comprisesballoon 210 andtemplate 220.Balloon 210 can be disposed alongtemplate 220, either underlying or overlying thetemplate 220. Theballoon 210 may comprise a working length and at least one tapered section (i.e., a shoulder). Thetemplate 220 may extend along at least a portion of the working length of theballoon 210. Thetemplate 220 may also extend along at least a portion of at least one shoulder of theballoon 210.Assembly 200 can further comprise acatheter 202 to whichballoon 210 andtemplate 220 are attached.Catheter 202 is shown in fluid communication withballoon 210, such that fluid can be introduced throughcatheter 202 intoballoon 210.Catheter 202 can be coupled to any suitable medical device, such as a syringe, an indeflator, pump or any other apparatus for conducting fluid throughcatheter 202 and intoballoon 210. -
Template 220 can be an overlying or underlying structure comprising at least oneaperture 221.Template 220 constrains a portion ofballoon 210 during inflation. In this regard,balloon 210 is inflated to a second inflated state, and the restraining action oftemplate 220 causesballoon 210 to distend atapertures 221 intemplate 220 as described in more detail below. - The operation of the balloon assemblies of the present disclosure is shown schematically for various embodiments in
FIGS. 3A (1) to 3A(3) and 3B(1) to 3B(3) in which is illustrated a longitudinal cross section of aballoon assembly 300. InFIGS. 3A (1) to 3A(3),balloon 310 underliestemplate 320 which featuresapertures 321. InFIGS. 3B (1) to 3B(3),balloon 310 overliestemplate 320, andtemplate 320 adheres to balloon during inflation. In these illustrations,balloon 310 andtemplate 320 are shown aligned with axis “A”. Axis “A” can comprise the longitudinal axis of a catheter. - A first inflated state is shown in
FIGS. 3A (2) and. 3B(2). With reference toFIG. 3A (2),balloon 310 has an outer radius shown as “R1” undertemplate 320, andtemplate 320 has an inner radius of “R2”. With reference toFIG. 3B (2),balloon 310 has an inner radius shown as “R1” overtemplate 320, andtemplate 320 has an outer radius “R2”. In the first inflated state, radius “R1” is substantially equal to radius “R2”. No protrusions are observed in a first inflated state. Stated differently, the height, “H1” of balloon material or protrusions abovetemplate 320 has a value of zero or close to zero. At the first inflated state,balloon 310 comprises a substantially smooth or wrinkle free surface. Also in the first inflated state,aperture 321 has a width shown as “W1” in the figures. -
FIGS. 3A (3) and 3B(3) depictballoon assembly 300 in a second inflated state. As balloon 110 is inflated beyond a first inflated state, radius “R2” increases relative to radius “R1” aboutaperture 321. This is becauseballoon 310, upon distention, begins to distend about or protrude from or aboveapertures 321. Radius “R1” remains essentially at the same dimension as in the first inflated state shownFIGS. 3A (2) and 3B(2). In some embodiments, width of aperture 321 (“W2”) remains close to or even equal to width of aperture 221 (“W1”) in the previous inflated state shown inFIGS. 3A (2) and 3B(2). In other embodiments, W2 can be greater than W1; i.e.,aperture 320 can increase in size asballoon assembly 300 is inflated. It will be understood that radius “R2” can be a maxima, in particular if a size limiting layer or a size limited balloon is used as described below. - Referring again to
FIGS. 2A and 2B (1) to 2B(4), in various embodiments,balloon 210 can comprise any suitable compliant balloon. As described above, a compliant balloon can comprise a polymeric material. Exemplary materials for a compliant balloon include elastomers such as polyurethane and silicone, natural rubber or latex products, synthetic rubber such as nitrile butadiene, or other synthetic or naturally occurring polymeric materials. In various embodiments,balloon 210 may not be fully compliant, but is more compliant thantemplate 220 and sufficiently flexible to inflate to a diameter larger than the restrainingtemplate 220 diameter at a given pressure, and thereby produces protrusions 212 (as described below). Thus, a semi-compliant or non-compliant balloon can be used. In various embodiments,balloon 210 can be conditioned. Conditioning can comprise stretching, pre-inflating, blow molding, heating, or other process to render theballoon 210 more amenable to use. - In various embodiments,
balloon assembly 200 can compriseballoon 210,template 220, and asize limiting layer 215. Similarly,balloon 210 can comprise a composite material, wherein a layer of the composite issize limiting layer 215 and/ortemplate 220. Size limitinglayer 215 can be disposed aboutballoon 210, either betweenballoon 210 andtemplate 220 or aroundtemplate 220. Similar totemplate 220,size limiting layer 215 is configured to control the degree of distension of acompliant balloon 210 during inflation. However,size limiting layer 215 is configured to permit a degree of distension which is greater than the degree thattemplate 220 is configured to permit. In this regard,size limiting layer 215 can possess sufficient flexibility and an upper distension limit which is larger in diameter than the restrainingtemplate 220 diameter at a given pressure, allowingsize limiting layer 215 to distend about or protrude throughaperture 221. In addition,size limiting layer 215 can be configured to have a substantially smooth or wrinkle free surface at the first inflated state. Stated differently, size liming layer is at least slightly strained at the first inflated state. - Size limiting
layer 215 can be a sheath, sleeve, layer or other component otherwise configured to at least partially enclose all or a portion ofballoon 210. Size limitinglayer 215 can act to constrainballoon 210 in a substantially uniform manner onceballoon 210 distends to a certain diameter or dimension. Size limitinglayer 215 can be configured to operate at pressures of up to 2 atm, up to 5 atm, up to 10 atm, up to 15 atm, up to 20 atm, up to 30 atm, up to 35 atm, up to 45 atm, up to 55 atm, up to 60 atm, or up to any value between about 2 atm and about 60 atm. - In various embodiments,
size limiting layer 215 can comprise any flexible, preferably thin material which is inelastic in at least one orientation or has a suitable upper deformation limit in at least one orientation. To withstand higher inflation pressures,size limiting layer 215 can be made of a high strength material. Size limitinglayer 215 can be constructed using any material described herein for constructingtemplate 220. Size limitinglayer 215 can be an extruded or molded tubular form which is at some point inelastic in a circumferential direction. Alternatively,size limiting layer 215 can comprise a tape wrapped form wherein the tape is, at some point, inelastic or has an upper distension limit in the tapes lengthwise direction. - To form tape-wrapped
size limiting layer 215, with reference toFIG. 4A to 4D , a thin film can be slit into relatively narrow widths to form a tape. The tape is helically wrapped onto the surface of amandrel 12 in two opposingdirections layers longitudinal axis 18 but measured in opposite directions. If, for example, the film layers 14 and 16 are applied at pitch angles of 70° measured from opposite directions with respect to the mandrel'slongitudinal axis 18, then included angle A between both 70° pitch angles is 40°. - More than two layers of helically wrapped film may be applied. Alternate layers of film can be wrapped from opposing directions and an even number of film layers can be used whereby an equal number of layers are applied in each direction.
- Suitable adhesives may be used to join film wraps together. Such adhesives include fluorinated ethylene propylene (FEP). Alternatively, following completion of film wrapping, the helically wrapped
mandrel 12 can be thermally treated at suitable time and temperature to causeadjacent layers size limiting layer 415 is removed frommandrel 12 and can be placed over the balloon, tensioned longitudinally as needed and affixed in place over the balloon. - During inflation of balloon,
size limiting layer 415 can undergo an increase in diameter which results in included angle A being substantially reduced as shown byFIG. 4D . Size limitinglayer 415 thus reaches its pre-determined upper distension limit as included angle A approaches zero. This pre-determined limit is greater than the distension limit of template in order to yield a balloon having a varied topography at a second inflated state but one which does not appreciably distend beyond the second inflated state. - Again with reference to
FIGS. 2A and 2B (1) to 2B(4),size limiting layer 215 can optionally be adhered to or laminated withballoon 210. If adhered,balloon 210 can aid in recompaction ofsize limiting layer 215 upon deflation ofballoon assembly 200, in particular ifballoon 210 is made of an elastomeric materiel. Alternatively, a layer of elastomer, applied to a surface ofsize limiting layer 215 will cause thesize limiting layer 215 to retract substantially to its pre-inflation size as shown byFIG. 4C following deflation. - The film utilized to construct
size limiting layer 215 as described above can comprise any flexible, preferably thin material that is substantially inelastic or has an upper distension limit in at least one orientation and has sufficient strength to yield aballoon 210 that can operate at pressures of up to 2 atm, up to 5 atm, up to 10 atm, up to 15 atm, up to 20 atm, up to 30 atm, up to 35 atm, up to 45 atm, up to 55 atm, or up to 60 atm. For example, a film can comprise ePTFE. Other suitable film materials can include other fluoropolymers or non-compliant polymers. - In various embodiments,
size limiting layer 215 can be constructed or conditioned to constrainballoon 210 upon inflation to a generally cylindrical inflation profile. Optionally, with momentary reference toFIG. 5A , size limiting layer 515 can be configured to alter the general profile ofballoon 510, e.g., constrain to create a tapered profile, elliptical profile, or a dumbbell profile. In addition, in the event of a failure of balloon 210 (e.g., a rupture),size limiting layer 215 can act to prevent release of undesired debris from the disruptedballoon assembly 200. - In other embodiments,
size limiting layer 215 andballoon 210 are combined into a single component. Stated differently,balloon 210 can comprise a compliant, size limiting material. In such embodiments,balloon 210 behaves like a compliant or semi-compliant balloon up to a desired diameter. Once the desired diameter is reached,balloon 210 behaves like a non-compliant balloon, allowing the pressure to increase without resulting in an appreciable increase in a balloon dimension. - In various embodiments,
template 220 comprises any size-limited form that acts to constrainballoon 210 along the points of contact. Alternatively,template 220 can comprise a form less compliant thanballoon 210 and/orsize limiting layer 215 so thatballoon 210 is constrained along the points of contact. As such,template 220 is constructed of any material that cannot be appreciably deformed beyond a first inflated state during inflation ofballoon 210.Template 220 can be configured as a sleeve, layer, or sheath positioned overballoon 210. For example,template 220 can comprise a generally cylindrical, ellipsoidal, spherical, or similar form that is disposed substantially coaxial to balloon 210. Alternatively,template 220 can be an inner layer that constrains a portion ofballoon 210 by being adhered to balloon 200 at selected portions not comprising anaperture 221. - In addition, while
aperture 221 oftemplate 220 can be spatially configured to create a varied topography, the constraining portion oftemplate 220 can also impact the general profile ofballoon 210. For example, as illustrated inFIG. 5B ,template 520, at a first inflated state, can have a diameter that is larger or smaller at different locations along theballoon 510, for instance to form a taper. Thus, whileballoon 510 can inflate in the shape of a cylinder,template 520 can have a non-cylindrical shape, and this non-cylindrical shape can be the general profile ofballoon assembly 500. Such a generally tapered profile can be used to better conform to cardiovascular vessel diameters which change over length, for example. In addition, the lesion or thrombus “scraping” effect of theassembly 500 can be intensified proximally to distally or vice versa due to the varying profile dimensions. - Returning to
FIGS. 2A and 2B (1) to 2B(4),template 220 does not substantially deform beyond a first inflated state or deforms to a lesser extent thanballoon 210 andsize limiting layer 215 in response to inflation ofballoon 210. As depicted inFIGS. 2B (3) and 2B(4),balloon 210 andsize limiting layer 215 distends beyondtemplate 220 aboutaperture 221 creating aprotrusion 212 at a second inflated state. As shown, at the second inflated state,inflated balloon assembly 200 can have a varied topography in that the surface ofballoon assembly 200 has a plurality of peaks and valleys. - In various embodiments,
template 220 can comprise a size-limited material or configuration. For example,template 220 can be substantially inelastic in at least one direction or orientation, preferable a direction transverse to the longitudinal axis ofballoon assembly 200 and, in various embodiments,template 220 can also comprise a material that has high tensile strength in at least one direction. In an alternate embodiment, the template can comprise a material that has a high strength in both directions so as to prevent the perimeters ofapertures 221 from deforming upon expansion ofballoon 210. In various embodiments,template 220 can comprise a material that is less compliant thanballoon 210 and/or template; thus, at a given pressure,balloon 210 will have a greater degree of distension thantemplate 220. - In an embodiment,
template 220 can comprise a high strength, yet flexible material such as ePTFE. High strength provides resistance to deformation in at least one direction such thattemplate 220 can resist expansion of underlying balloon portions beyond the application of a particular force caused by balloon inflation pressures. - In various embodiments,
template 220 can be made from a thin, high strength film or tape to forming a template. For example,template 220 can be constructed from a type of ePTFE as described in U.S. Pat. No. 7,306,729, issued Dec. 11, 2007 and entitled, “Porous PTFE Materials And Articles Produced Therefrom,” whose contents are herein incorporated by reference. In various embodiments, two to sixty layers of ePTFE as described in U.S. Pat. No. 7,306,729 can comprisetemplate 220. Layers can be circumferentially (i.e., wrapped at about 90° to the longitudinal axis) or helically wrapped (as described previously). In various embodiments,template 220 can be manufactured in a continuous process and then cut to the desired length before being disposed on balloons. Optionally,template 220 can be adhered or laminated to balloon 210 and/orsize limiting layer 215. -
Template 220 can comprise other materials, such as other fluoropolymers, including polytetrafluoroethylenes with different microstructures from that described in U.S. Pat. No. 7,306,729, so long as they provide sufficient strength and relative lack of compliancy, to produce the desired balloon topography and operate at the previously described pressure thresholds. - In various embodiments,
template 220 can also be size-limited but compliant. In such embodiments,template 220 can be formed in a similar manner as size-limited layer andcompliant balloon 210. However, in order to create a varied topography, the upper distension limit oftemplate 220 must be less than the upper distension limit of theballoon 210 or the degree of compliancy is less than that forballoon 210. -
Template 220 can comprise at least oneaperture 221 and, in various embodiments,template 220 can comprise an aperture pattern and/or a plurality of apertures.Apertures 221 can be present intemplate 220 prior to inflation or be formed or increase in size upon inflation. -
Aperture 221 can comprise an opening or weakened site in the template material. In this regard, an opening can be a hole, cut, or any other discontinuous section of the template material. For example, a hole could be formed by puncturingtemplate 220. Alternatively,aperture 221 can comprise an area oftemplate 220 where a portion of the material has been removed or otherwise weakened such that the weakened portion at least partially deforms or detaches in response to inflation ofballoon 210 and permits distension beyond the first inflated state.Apertures 221 can be formed by any suitable means, including cutting, stamping, laser cutting, perforating, and/or punching/puncturing and/or the like. In various embodiments,template 220 can comprise a net like structure. - Optionally, template can comprise apertures that vary in size. Increasing the size the apertures can allow for a wider (or “coarser”) protrusion. By combining varying aperture sizes with a tapered template profile, as shown in
FIG. 5B , the “scraping” effect of the assembly can be intensified proximally to distally or vice versa due to the different protrusion heights. - With reference again to
FIGS. 2A and 2B (1) to 2B(4),template 220 can be configured such thatapertures 221 are formed or increase in size upon inflation. For example, atemplate 220 comprising a tape wrapped, woven, or braided membrane aroundballoon 210 can be constructed, e.g. wrapped, woven, or braided, such thatapertures 221 are formed by leaving a space between tape edges and/orapertures 221 form or increase in size between tape edges upon inflation ofballoon 210. In an embodiment, the angle of the tape material can change relative to the longitudinal axis of the balloon upon inflation and/or the tape material can narrow in width as the balloon assembly is expanded, thus creatingapertures 221. - In addition, the varied topography can vary longitudinally along the length of the balloon and/or can vary circumferentially about the perimeter of the balloon. For example, with reference to
FIG. 6 (A-B),balloon assembly 600 can comprise atemplate 620 having a first pattern ofapertures 621 onfirst section 650 ofballoon 610 and a second pattern of aperture or zero apertures on asecond section 651. Similarly, the longitudinal and/or circumferential variation can be random or follow a pre-defined pattern. Such balloon assemblies can be used for performing interventional procedures in combination. For example, such a balloon configured with zero apertures on one half the length of the balloon assembly and apertures on the remainder of the assembly can be used to perform both thrombectomy (with the apertured portion of the assembly) then Percutaneous Transluminal Angioplasty (PTA) (with the non-apertured portion), all without the exchange of devices. - The balloon assembly can be selectively alternated between the various inflated states, e.g., between a first inflated state and a second inflations state. A specific inflated state can be determined by measuring the volume injected into balloon assembly and/or pressure levels within balloon assembly. By selectively introducing or withdrawing a fluid by a predetermined amount, balloon assembly can transition from one inflated state to another. In an embodiment, the balloon assembly can be configured to pulsate between the various inflations states.
- In various embodiments, balloon assembly can optionally comprise a protective cover. A protective cover can be a sleeve or sheath that covers at least a portion of template. The protective cover can be delivered with the balloon assembly into the body and be retracted to expose
balloon assembly 200 while within the body. - With the described components, one can adapt the compliance of the balloon, a template, an aperture pattern, inflation pressures and extensibility of a size limiting layer to control the topography of a balloon assembly. For example, an aperture pattern can comprise many small apertures to obtain a “fine texture” pattern or can comprise fewer larger openings to obtain a more “coarse texture” pattern. As one can appreciate, any possible aperture pattern, or combinations of aperture patterns, is contemplated herein. For example, a first portion of a template can comprise a square grid like aperture pattern and a second portion of a template can comprise a diamond shaped pattern.
- In other embodiments, a balloon expanding through a template can define ridges and troughs which, for example, run parallel to the longitudinal axis of the balloon. In one embodiment, these provide for blood perfusion between balloon and vessel wall during a treatment when the balloon is expanded.
- In other embodiments,
protrusions 212 can form at a first inflated state as depicted inFIG. 2C , and then upon inflation to a second inflated state, having a pressure greater than the first,template 220 can distend and the surface ofballoon 210 is smooth, as depicted inFIG. 2B . In an embodiment,template 220 can be partially or selectively distensible. For example. a 4 mm template that is distensible up to 8 mm can overlay a balloon and/or a size limiting layer.Balloon 210 is inflated to 2 atm and the template acquires its first distension profile so that protrusions form. Upon further inflation up to 4atm, the template can distend to its second distension profile or its maximum size. The maximum size oftemplate 220 can correspond to the maximum size ofballoon 210 and/orsize limiting layer 215. In other embodiments,template 220 can be frangible and made to break or stretch at a selected inflation pressure to then reduce the height, at least partially, of some or all ofprotrusions 212 to allow for increased contact between the balloon surface and the target tissue(s) at a higher pressure. Such embodiments can be used to perform both thrombectomy (at the first inflated state) then Percutaneous Transluminal Angioplasty (PTA) (at the second inflated state), all without the exchange of devices. - In various additional embodiments, multiple templates can be used with one compliant balloon to further control and further vary topography. With reference to
FIGS. 7A and 7B ,balloon assembly 700 comprisesballoon 710 and at least twotemplates Template 720 can be disposed coaxially or substantially coaxially overballoon 710, andsecondary template 725 can be disposed coaxially or substantially coaxially overtemplate 720. Upon inflation ofballoon 710 to the second inflated state, as depicted inFIG. 7A , bothtemplate 720 andsecondary template 725 act to constrainballoon 710 and have aperture patterns to allowballoon 710 to expand throughapertures 721 in each template. In an embodiment,template 720 andsecondary template 725 can act to shape the topography ofinflated balloon assembly 700.Template 720 can create a “coarse” varied topography, andsecondary template 725 is selectively positioned to constrain a portion ofprotrusion 712 and create a “fine” aperture pattern.Protrusion 712 is thus further constrained bysecondary template 725 to form at least two protrusions or protrusions of different size or shape and create a finer or varied aperture pattern. - Optionally, each template can have different upper distension limits such that the varied topography can vary by varying the distension of
balloon 710. In such embodiments,balloon assembly 700 can have three or more inflated states. It is contemplated that any number of templates can be layered in a balloon assembly to vary and refine topography. In addition,balloon assembly 700 can optionally comprise a size limiting layer as described herein. -
FIG. 9 andFIG. 18 illustrate a varied topography balloon assembly embodiment wherein the balloon comprises a wall with regions of reduced compliance than other more distensible regions; - With reference to
FIG. 18 ,balloon 1810 can comprise awall having portions 1817 of reduced or less compliance than other, moredistensible portions 1818 of wall. Theother portions 1818 being essentially the “apertures” that expand outwardly relative to the portions of reduced or less compliance. The moredistensible portions 1818 can comprise an upper distension limit. Theportions 1817 of reduced compliance can be formed through laser densification or by imbibing with a polymer that reduces the compliance in the imbibed region. In an embodiment, theregions 1817 of reduced compliance have substantially the same thickness as the moredistensible regions 1818. Similar, with other embodiments described herein,balloon 1810 can be formed via tape wrapping or extrusion, and can comprise ePTFE or any other material wherein the compliancy can be varied at discrete sites. - Similarly, in an embodiment, the balloon can comprise a plurality of protrusions in the form of knob-like features. Unlike the previously described embodiment, the distensiblity of the sites need not vary along the balloon material. Here, the protrusion is pre-formed into the balloon. To form a knob-like feature on the balloon, a balloon form can be placed onto a mandrel or constructed on a mandrel which has an aperture or recessed site thereon corresponding to the site of a knob-like feature. In an embodiment, a heated element can be used to push the knob-like feature into the aperture or recess and set the feature into the balloon wall. Similarly, a lower melt thermoplastic material can be imbibed into the balloon wall at the site of the recess and aperture with the application of pressure and heat, and allowed to cure while pressure is still applied and the wall is recessed. In another embodiment, a vacuum can be applied to the apertures (or pressure applied to the balloon) such that a recessed site is formed on the balloon surface. The balloon can then be cured while in this configuration.
- In further embodiments, with reference to
FIG. 19 ,balloon assemblies 1900 as described herein can be perfusable. For example,balloon 1910,size limiting layer 1915, and optionally,template 1920 can comprise a porous material. In addition,balloon 1910,size limiting layer 1915, and optionally,template 1920 can comprise a variably perf usable material. In various embodiments, prior to protrusion, the porosity of the material or the internal pressure is low enough to not perfuse or minimally perfuse. For example, upon expansion ofballoon 1910 and its protrusion throughapertures 1921, localized forces can cause the microstructure of the material protruding throughapertures 1921 to become more porous, allowing the therapeutic agent to be released fromballoon 1910. In other embodiments, the porosity of the microstructure is not altered but rather the water entry pressure of the balloon material is such that the balloon does not perfuse until a certain threshold pressure. As such, balloon 1919 can be configured not to perfuse until the second inflated state is obtained. In addition,balloon 1910 can be configured to perfuse along only a portion, e.g., the regions ofballoon 1910 that upon inflation, protrude throughapertures 1921. - In various embodiments, a balloon assembly can further comprise a therapeutic agent disposed on, inside of, temporarily filling, or otherwise be integrated with the template. Similarly, a balloon assembly can comprise a therapeutic agent disposed on an inner or outer surface of the balloon or tem plate, or inside balloon. In an embodiment, a therapeutic agent can be coated on a portion of the elongate member underlying the balloon. Therapeutic agent formula can comprise a liquid or solid form. Liquid from can be of a desired viscosity suitable for the treatment desired.
- With reference to
FIG. 8 , balloon assembly 800 comprisesballoon 810 disposed within template 820, andtherapeutic agent 808 is disposed betweenballoon 810 and template 820. Upon inflation ofballoon 810,therapeutic agent 808 can be conveyed through anaperture 821 of template 820 and be released at a localized portion of the body. In an embodiment,aperture 821 can form upon inflation thus containingtherapeutic agent 808 until balloon assembly 800 is inflated. - Similarly, therapeutic agent can be disposed within aperture. Upon inflation of balloon, therapeutic agent can be conveyed beyond aperture by protrusion and be directed to a surrounding tissue and/or a localized portion of the body. In various embodiments, the therapeutic agent formula can be in a solid or viscous form to maintain location within aperture. Alternatively, therapeutic agent, positioned within aperture can be protected by a sheath until placed at a treatment site whereupon the sheath can be retracted.
- In addition, aperture can be configured to limit the release of therapeutic agent until inflation is underway. For example, apertures can comprise a conical or other tapered shape, wherein the aperture defines a smaller area on the outer face than on the inner face. Aperture can be configured to enlarge upon inflation to facilitate release of therapeutic agent. In addition, balloon assembly can comprise a releasable cover to limit or prevent the release of therapeutic agent.
- Any therapeutic agent that aids in any procedure, e.g., diagnostic or therapeutic procedures, or that aids in providing a therapeutic and/or curative effect is contemplated and suitable for use with balloon assemblies disclosed herein. In particular, therapeutic agents that become safer, effective, or achieve another benefit from localized delivery are useful with balloons disclosed herein. Among others, suitable therapeutic agents include anti-proliferative, anti-inflammatory, fibrolytic, thrombolytic, anti-phlogistic, anti-hyperplastic, anti-neoplastic, anti-mitotic, cytostatic, cytotoxic, anti-angiogenic, anti-restenotic, microtubule inhibiting, anti-migration or anti-thrombotic therapeutic agents.
- For example, suitable therapeutic agents can include: abciximab, acemetacin, acetylvismione B, aclarubicin, ademetionine, adriamycin, aescin, afromoson, akagerine, aldesleukin, amidorone, aminoglutethemide, amsacrine, anakinra, anastrozole, anemonin, anopterine, antimycotics, antithrombotics, thrombolytics such as tissue plasminogen activator (tPA), apocymarin, argatroban, aristolactam-All, aristolochic acid, arsenic and arsenic-containing oxides, salts, chelates and organic compounds, ascomycin, asparaginase, aspirin, atorvastatin, auranofin, azathioprine, azithromycin, baccatine, bafilomycin, basiliximab, bendamustine, benzocaine, berberine, betulin, betulinic acid, bilobol, biolimus, bisparthenolidine, bleomycin, bombrestatin, boswellic acids and their derivatives, bruceanoles A, B and C, bryophyllin A, busulfan, antithrombin, bivalirudin, cadherins, camptothecin, capecitabine, o-carbamoylphenoxyacetic acid, carboplatin, carmustine, celecoxib, cepharanthin, cerivastatin, CETP inhibitors, chlorambucil, chloroquine phosphate, cictoxin, ciprofloxacin, cisplatin, cladribine, clarithromycin, colchicine, concanamycin, coumadin, C-Type natriuretic peptide (CNP), cudxaisoflavone A, curcumin, cyclophosphamide, cyclosporine A, cytarabine, dacarbazine, daclizumab, dactinomycin, dapson, daunorubicin, diclofenac, 1,11-dimethoxycanthin-6-one, docetaxel, doxorubicin, dunaimycin, epirubicin, epothilone A and B, erythromycine, estramustine, etoposide, everolimus, filgrastim, fluroblastin, fluvastatin, fludarabine, fludarabin-5′-dihydrogenphosphate, fluorouracil, folimycin, fosfestrol, gem citabine, ghalakinoside, ginkgol, ginkgolic acid, glycoside 1 a, 4-hydroxyoxycyclophosphamide, idarubicin, ifosfamide, josamycin, lapachol, lomustine, lovastatin, melphalan, midecamycin, mitoxantrone, nimustine, pitavastatin, pravastatin, procarbazin, mitomycin, methotrexate, mercaptopurine, thioguanine, oxaliplatin, bismuth and bismuth compounds or chelates, irinotecan, topotecan, hydroxycarbamide, miltefosine, pentostatine, pegaspargase, exemestane, letrozole, formestane, SMC proliferation inhibitor-2co, mitoxantrone, mycophenolate mofetil, c-myc antisense, b-myc antisense, [3-1apachone, podophyllotoxin, podophyllic acid-2-ethylhydrazide, molgramostim (rhuGM-CSF), peginterferon ct-2b, lanograstim (r-HuG-CSF), macrogol, selectin (cytokin antagonist), cytokin inhibitors, COX-2 inhibitor, NFkB, angiopeptin, monoclonal antibodies which inhibit muscle cell proliferation, bFGF antagonists, probucol, prostaglandins, 1-hydloxyl 1-methoxycanthin-6-one, scopolectin, NO donors, pentaerythiltol tetranitrate, syndxloimines, S-nitrosodeilvatives, tamoxifen, staurosporine, [3-oestradiol, ct-oestradiol, oestriol, oestrone, ethinyloestradiol, medroxyprogesterone, oestradiol cypionates, oestradiol benzoates, tranilast, kamebakaurin and other terpenoids, which are used in the treatment of cancer, verapamil, tyrosine kinase inhibitors (tyrphostins), paclitaxel, paclitaxel derivatives, 6-c-hydroxy paclitaxel, 2′-succinylpaclitaxel, 2′-succinylpaclitaxeltilethanolamine, 2′-glutarylpaclitaxel, 2′-glutarylpaclitaxeltilethanolamine, T-O-ester of paclitaxel with N-(dimethylaminoethyl) glutamide, T-O-ester of paclitaxel with N-(dimethylaminoethyl)glutamidhydrochloride, taxotere, carbon suboxides (MCS), macrocyclic oligomers of carbon suboxide, mofebutazone, lonazolac, lidocaine, ketoprofen, mefenamic acid, piroxicam, meloxicam, penicillamine, hydroxychloroquine, sodium aurothiomalate, oxaceprol, [3-sitosteiln, myrtecaine, polidocanol, nonivamide, levomenthol, ellipticine, D-24851 (Calbiochem), colcemid, cytochalasinA-E, indanocine, nocadazole, S 100 protein, bacitracin, vitronectin receptor antagonists, azelastine, guanidyl cyclase stimulator tissue inhibitor of metal proteinasel and 2, free nucleic acids, nucleic acids incorporated into virus transmitters, DNA and RNA fragments, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, antisense oligonucleotides, VEGF inhibitors, IGF-1, active substances from the group of antibiotics such as cefadroxil, cefazolin, cefaclor, cefotixin, tobramycin, gentamycin, penicillins such as dicloxacillin, oxacillin, sulfonamides, metronidazole, enoxoparin, desulphated and N-reacetylated hepailn, tissue plasminogen activator, GpIIb/IIIa platelet membrane receptor, factor Xa inhibitor antibodies, hepailn, hirudin, r-hirudin, PPACK, protamine, prourokinase, streptokinase, warfarin, urokinase, vasodilators such as dipyramidol, trapidil, nitroprussides, PDGF antagonists such as triazolopyilmidine and seramine, ACE inhibitors such as captopril, cilazapill, lisinopill, enalapril, losartan, thioprotease inhibitors, prostacyclin, vapiprost, interferon a, [3 and y, histamine antagonists, serotonin blockers, apoptosis inhibitors, apoptosis regulators such as p65, NF-kB or Bcl-x L antisense oligonucleotides, halofuginone, nifedipine, tocopherol tranilast, molsidomine, tea polyphenols, epicatechin gallate, epigallocatechin gallate, leflunomide, etanercept, sulfasalazine, etoposide, dicloxacillin, tetracycline, triamcinolone, mutamycin, procainimide, retinoic acid, quinidine, disopyramide, flecainide, propafenone, sotolol, naturally and synthetically obtained steroids such as inotodiol, maquiroside A, ghalakinoside, mansonine, strebloside, hydlocortisone, betamethasone, dexamethasone, non-steroidal substances (NSAIDS) such as fenoporfen, ibuprofen, indomethacin, naproxen, phenylbutazone and other antiviral agents such as acyclovir, ganciclovir and zidovudin, clotilmazole, flucytosine, griseofulvin, ketoconazole, miconazole, nystatin, terbinafine, antiprozoal agents such as chloroquine, mefloquine, quinine, furthermore natural terpenoids such as hippocaesculin, barringtogenol C21-angelate, 14-dehydloagrostistachin, agroskeiln, agrostistachin, 17-hydroxyagrostistachin, ovatodiolids, 4,7-oxycycloanisomelic acid, baccharinoids B1, B2, B3 and B7, tubeimoside, bruceantinoside C, yadanziosides N, and P, isodeoxyelephantopin, tomenphantopin A and B, coronailn A, B, C and D, ursolic acid, hyptatic acidA, iso-iildogermanal, cantenfoliol, effusantin A, excisaninA and B, longikauiln B, sculponeatin C, kamebaunin, leukamenin A and B, 13,18-dehydro-6-alpha-senecioyloxychapariln, taxamaiiln A and B, regenilol, triptolide, cymarin, hydroxyanopterin, protoanemonin, cheliburin chloride, sinococuline A and B, dihydronitidine, nitidine chloride, 12-beta-hydroxypregnadien-3,20-dion, helenalin, indicine, indicine-N-oxide, lasiocarpine, inotodiol, podophyllotoxin, justicidin A and B, larreatin, malloterin, mallotochromanol, isobutyrylmallotochromanol, maquiroside A, marchantin A, cantansin, lycoridicin, margetine, pancratistatin, liilodenine, bisparthenolidine, oxoushinsunine, periplocoside A, ursolic acid, deoxypsorospermin, psycorubin, ilcin A, sanguinailne, manu wheat acid, methylsorbifolin, sphatheliachromen, stizophyllin, mansonine, strebloside, dihydrousambaraensine, hydroxyusambailne, strychnopentamine, strychnophylline, usambarine, usambarensine, liriodenine, oxoushinsunine, daphnoretin, lariciresinol, methoxylailciresinol, sclerosant agents, syringaresinol, sirolimus (rapamycin), rapamycin combined with arsenic or with compounds of arsenic or with complexes containing arsenic, somatostatin, tacrolimus, roxithromycin, troleandomycin, simvastatin, rosuvastatin, vinblastine, vincilstine, vindesine, thalidomide, teniposide, vinorelbine, trofosfamide, treosulfan, tremozolomide, thlotepa, tretinoin, spiramycin, umbelliferone, desacetylvismioneA, vismioneA and B, zeoiln, fasudil.
- In various embodiments, with reference to
FIGS. 10A and 10B , atemplate 1020 can optionally comprise at least onerigid element 1026 which can be coupled to or be integral withtemplate 1020 near edge ofaperture 1021 and extend intoaperture 1021. Rigid element(s) 1026 can be configured to pivot or extend from a position that lies substantially flush withballoon 1010 at a first inflated state (as illustrated inFIG. 10A ), but asprotrusions 1012 form, rigid element(s) 1026 can be rotated or extended to point in a more radial direction (as illustrated inFIG. 10B ).Rigid elements 1026 can be configured to be rough and/or sharp. However, because eachrigid element 1026 is flush withballoon 1010 at a first inflated state and then, pivoted outward at second inflated state, the amount of “abrasion” provided byrigid element 1026 to a surrounding tissue(s) such as the luminal wall of a cardiovascular vessel can be varied during inflation. -
Rigid elements 1026 can be constructed by attaching the base of theelement 1026 totemplate 1020 orballoon 1010 at the pointunderlying template 1020 and passing throughtemplate 1020. In some embodiments,rigid element 1026 can comprise a lumen, e.g. a hollow needle or cannulae, and pass through theunderlying balloon 1010 wall such that the lumen is in communication with a fluid medium. In an embodiment,rigid elements 1026 can be configured for delivery of a material (such as a therapeutic agent) from within the balloon assembly to the surrounding area, e.g. the vessel walls. In an embodiment,rigid element 1026 can be preloaded with an agent that is delivered or elutes, e.g., stored within a lumen, at least partially coated thereon, or at least partially imbibed therein. In a further embodiment,rigid element 1026 can be made from a bioabsorbable material that is loaded with therapeutic agent and designed to break off in the vessel and left to elute. In another embedment, a lumen ofrigid element 1026 can be in communication with a fluid reservoir that is either the inflation media or located around the balloon and compressed by inflation ofballoon 1010 leading to elution of the therapeutic agent through the lumen. - Similarly, in various embodiments, a template can also comprise wires or blades. With momentary reference to
FIG. 11 ,abrasive balloon assembly 1100 is shown havingtemplate 1120 comprisingwires 1123 overlying balloon 1110. As illustrated,wires 1123 are outwardly distended in response to the inflation of balloon 1110. - In various embodiments, the balloon assembly embodiments described herein can optionally comprise electrical components (e.g., circuitry applied to the balloon surface via methods known in the art). Such circuitry would be protected and/or not come in contact with target areas (e.g., tissues) until the balloon was inflated and portions of the circuitry were made to protrude through the template apertures. Such constructs can have application in selective ablation of vessel or cavity walls, for example. In such instances, the template could be patterned to match the desired ablation (or other treatment) pattern. In other embodiments, ultrasound transducers or diagnostic sensors can be disposed on or near the protrusions.
- It should also be noted that templates, depending on their shape, size and general configuration can also be made to provide protection to the underlying balloon, e.g., provide puncture resistance.
- In various embodiments, balloon assemblies disclosed herein can be used in the vasculature. For example,
FIG. 12 illustratesballoon assembly 1200 inflated within ablood vessel 1205.Catheter 1202 is shown coupled toballoon 1210.Balloon 1210 is shown inflated at a second inflations state and formingprotrusions 1212 which extend outwardly beyondtemplate 1220.Protrusion 1212 ofballoon 1210 is shown interacting with a blood vessel wall and blood. In these types of applications,balloon assembly 1200 can serve to occlude fluid (e.g., blood) flow within a lumen or cavity. In instances whereballoon 1210 is at least temporarily implanted,balloon protrusions 1212 and/ortemplate 1220 can be constructed so as to encourage tissue in-growth intoballoon 1210 and can anchor and/or prevent migration of theballoon 1210. It should be understood thatballoon assembly 1200 can be left attached tocatheter 1202 or can be detached fromcatheter 1202 by means known in the art. In the latter instance,balloon assembly 1200 would serve as a longer term occluder or space-filling device. - In one embodiment, with reference to
FIG. 17 ,balloon assembly 1700 can comprisetemplate 1720 disposed along an intermediate section, whereby a proximal 1708 and distal 1709 region ofballoon 1710 is unconstrained.Template 1720 comprisesapertures 1721 as described previously.Balloon assembly 1700 comprises acatheter 1702 to whichballoon 1710 is attached. - Upon inflation,
balloon 1710 inflates and expands in size preferentially in the regions located to each side of the intermediate section ofballoon 1710 covered and constrained bytemplate 1720. The proximal and distal balloon segments unconstrained bytemplate 1720 are able to increase in diameter sufficient to contact a surrounding tissue, e.g., the luminal wall of a cardiovascular vessel, while the intermediate, constrained section remains at a smaller diameter. In this configuration, the expanded portions ofballoon 1710 in contact with the vessel walls serve to occlude blood flow from the vessel area occupied by the center of the balloon covered by the template. - In a further embodiment, the intermediate section of
balloon 1710 constrained bytemplate 1720 can be designed to subsequently release a therapeutic agent into the vessel area isolated from blood flow.Balloon 1710 and/ortemplate 1720 is configured to perfuse. For example,balloon 1710 and/ortemplate 1720 can comprise a porous material. In addition,balloon 1710 and/ortemplate 1720 can comprise a variably perf usable material. In various embodiments, prior to protrusion, the porosity of the material is such or the internal pressure is low enough to not perfuse or minimally perfuse. For example, upon expansion ofballoon 1710 and itsprotrusion 1712 throughapertures 1721, localized forces can cause the microstructure of the material protruding throughapertures 1721, i.e.,protrusions 1712, to become more porous, allowing the therapeutic agent to be released fromballoon 1710. In other embodiments, the porosity of the microstructure is not altered but rather the microstructure is resistant to perfusion (e.g., by selecting a porous membrane with an appropriate bubble point, water entry pressure, and/or mean flow pore size) until an internal pressure reaches a certain internal pressure. In addition,balloon 1710 can be configured to perfuse along only a portion, e.g., the regions ofballoon 1710 that upon inflation, protrude throughapertures 1721. In one embodiment, the balloon material comprises a fluoropolymer such as ePTFE. - In various embodiments, perfusing balloons as described herein can be at least partially coated with polyvinyl alcohol (PVA) to render them more hydrophilic. This could result in the lowering of the perfusion pressure at select sites or across the entire surface.
- Similarly, in various embodiments, perfusing balloons as described herein can further comprise an outer layer or coating that is oleophobic or render it to have a low surface energy. For example, as described in U.S. Pat. No. 5,586,279 by Wu, which is hereby incorporated by reference, the reaction product of perfluoroalkyl alkyl alcohol compounds with selected diisocyanates can be applied to the outermost membrane, whether it be the weeping control layer, the reinforcing layer, or the sealing layer, in order to lower the surface energy of the microstructure while preserving the microporous structure. Other examples of oleophobic coatings are described in the following, which are hereby incorporated by reference in their entireties: U.S. Pat. No. 5,342,434 to Wu; U.S. Pat. No. 5,460,872 to Wu and Kaler; WO 2006/127946 to Gore Enterprise Holding; and Canadian Patent No. 2609327 to Freese.
- In other embodiments, a balloon assembly placed for long term implantation and detached from a catheter can be constructed so as to feature one or more lumens (e.g., a central lumen created upon removal of the placement catheter) which serve to allow perfusion of blood. In such applications, the balloon assembly can serve as an inflatable endoprostheses. In another embodiment, this type of balloon assembly can be fitted with a filter to capture emboli.
- In various embodiments, balloon assemblies in accordance with the present disclosure can have pre-configured varied topographies or textured topographies. Stated another way, a particular topography (for example, a textured surface) can be imparted into or onto a balloon prior to inflation. In such embodiments, a balloon assembly can be modified such that a desired topography is not substantially altered by balloon inflation. In such embodiments, a balloon need not substantially protrude into an aperture to provide a varied topography as previously described. Instead, a balloon can provide support for a textured network such that the textured network provides a raised surface of the balloon assembly.
- In various embodiments, a balloon can be covered and/or wrapped with a textured network that provides a topographical feature. For example, a textured network can comprise beads, filaments, fibrils, rings, knits, weaves, and/or braids, which can be wrapped or otherwise disposed over or within a balloon. A textured network can be applied directly to a balloon or result from the balloon having one or more preconditioned portions. The textured network can be used to alter the topography of the balloon. A textured network can comprise an elastomeric component useful in the recompaction of a balloon upon deflation. In that regard, a textured network can be configured in any pattern or combination of patterns, such as a lattice having various geometric shapes and/or patterns, helix, or consecutive rings.
- With reference to
FIG. 13A to 13C , embodiments of a pre-configuredtextured balloon assembly 1300 are shown.Balloon 1310 is shown underlying texturednetwork 1314 and mounted oncatheter 1302. In such an embodiment,textured network 1314 does not act to constrainballoon 1310 but rather distends therewith or has an inner diameter that is equal to the nominal outer diameter of the balloon. -
Textured network 1314 can be formed in a variety of ways. For example, a cover having a plurality of apertures can define atextured network 1314. Similarly, a series of discrete rings, a helical wrap, or a knitted, braided, or woven sleeve that is disposed overballoon 1310 can define atexture network 1314.FIG. 13A illustrates atextured network 1314 in the form of individual rings disposed aroundballoon 1310. - In other embodiments,
balloon 1310 can be covered with a knitted, woven, and/or braided sleeve, such as a knitted tubular form to definetextured network 1314. Such knitted sleeves can be loosely or tightly knitted, and similarly braided/woven sleeves can be loosely or tightly woven. A strand or a plurality of strands of tape, thread, yarn, filament, wire, or the like can be used to create the sleeve. - A variety of factors of the knitted sleeve can be controlled to control the properties of
textured network 1314, e.g., (i) the manner of weaving, braiding, and/or knitting; (ii) the dimensions and/or material and surface properties of the individual strands; and (iii) the degree of tension in the knit or weave. Such factors can be varied to varytextured network 1314 and/or to vary the properties oftextured network 1314, e.g., the elasticity ofnetwork 1314. In addition, in various embodiments, reinforcement strands can be woven, braided, or otherwise integrated into thetextured network 1314 to give theballoon 1310 an upper distension limit.Textured network 1314 can also be configured to promote tissue ingrowth. Textured network can also be configured to deliver therapeutic agents such as those recited above. - Reinforcement strands can be comprised of any suitable biocompatible material that can be formed into a flexible strand. Strands can be a metallic, polymeric, or composite material. Strands can be elastic or inelastic. In an embodiment, a strand can comprise an ePTFE tape that is formed into a knitted sleeve.
- The knitted sleeve can be wrapped with ePTFE film such that the ePTFE film is at least partially within the knitted ePTFE.
-
Textured network 1314 can be formed from wires, thermoplastic filaments or rings. As shown inFIG. 13A ,textured network 1314 can comprise a thermoplastic polymer, e.g., fluoro ethylene propylene (FEP). Forms of ePTFE such as urethane imbibed ePTFE can be used as well. - Optionally, a sleeve or tube can be thermally bonded to an underlying or overlying film material in order to bond or integrate
textured network 1314 toballoon 1310. For example, an outer film can be wrapped overtextured network 1314. The assembly can be subjected to thermal treatment at about 380° C. for 15 minutes to facilitate bonding. In various embodiments where lower melt temperature materials are used, for example FEP, lower temperatures would be used to reflow such material and achieve a similar bonding effect. The distal end can be crimped and wrapped with a sealing film. The proximal end can be adhered to a catheter using adhesive. - With reference to
FIG. 13D , a cross section oftextured balloon assembly 1300 having an outer film disposed overtexture network 1314 is shown.Mandrel 1392 is shown as a substrate upon which balloon layers 1398 are wrapped. Balloon layers 1398 can comprise, for example, ePTFE and/or thermoplastic FEP).Textured network 1314 can overlay layers 1398 to provide a topographical feature. Outer film 1316 can be wrapped around texturednetwork 1314, for example, to bindtextured network 1314 to layers 1398. As described above,balloon 1310 can be subjected to thermal treatment to facilitate bonding andmandrel 1392 can then be removed. - With reference again to
FIGS. 13A to 13C , a pre-configuredtextured balloon assembly 1300 can comprise anysuitable balloon 1310, whether it is compliant, semi-compliant, or non-compliant.Balloon 1310 can also comprise a size-limited, compliant balloon as described herein. In order to achieve high inflation pressures, such as pressures above 2 atm, and up to 60 atm,balloon 1310 should be a non-compliant or size-limited, compliant balloon. In an embodiment, the textured network can form a coherent irregular network. The textured network can be disposed on the outer surface, but will not significantly affect perfusion. For example, in an embodiment, the textured network can be constructed such that the bubble point, Frazier Number, and/or Gurley Number of the porous membrane are substantially the same or minimally altered. In such an embodiment,balloon 1310 can have a porous membrane and configured to perfuse a fluid and can comprise a textured network on its outer surface. The network can be formed from thermoplastic elements. U.S. Patent Publication No. 2012/064273 by Bacino entitled “Porous Article” is hereby incorporated by reference in its entirety for purposes of describing a coherent irregular network and various techniques for applying the network to the balloon's outer surface. Some of the details of the Bacino publication are described below. - In an embodiment, the coherent irregular network that may be attached to the
underlying balloon 1310 or made into a free standing article as defined herein is a coherent irregular network of thermoplastic particles attached together. The term coherent as used in defining the coherent irregular network means that the article comprises elements effectively connected together such that the article can be free standing, and therefore does not include discrete particles that may be attached to a substrate, such as fluoroplastic adhesive coated onto an expanded fluoropolymer substrate. The term irregular as used in defining the coherent irregular network means that the structure of the coherent irregular network comprises connecting portions that do not have a consistent diameter or cross-section area across along the length of the connecting portions between intersections or attachments with other connecting portions, particles or elements, and therefore does not included spun-bonded, woven, or felted products that consists of fibers having a consistent cross sectional area. The term network as used in defining the coherent irregular network means that individual elements of the coherent irregular network are effectively attached together to provide a contiguous structure. The coherent irregular network is further defined as comprising porosity between the attached elements throughout the thickness such that the coherent irregular network is porous and permeable. The coherent irregular network is still further defined as having open areas. - A wide range of thermoplastic particles could be used to create the coherent irregular network, including particles having a high molecular weight, or low melt flow index (MFI). Particles with MFI values between 0.2 and 30 g/10 min when tested according to the MFI method described herein may be more desirable. However particles with MFI values greater than 0.1 or less than 50 g/10 min may also be used. In addition, fluoroplastic particles including but not limited to FEP, EFEP, PFA, THV, PVDF, CTFE, and the like, and mixtures thereof are desired in some applications.
- In an embodiment, the coherent irregular network is attached to
balloon 1310, e.g., the porous membrane ofballoon 1310, and has a surface roughness defined by a Sp value of at least 35 μm. The size, type, and blend of the particles can be selected to get a desired degree of surface roughness. In addition, using two or more different types of particles can aid in attaching the coherent irregular network to the expanded fluoropolymer layer, attaching the permeable layer to a support layer, or provide a desired permeability, porosity, surface area, abrasion resistance, surface roughness, free standing film strength, or electrical conductivity or the like. - The coherent irregular network disposed on at least a portion of the outer surface of
balloon 1310 can comprise attached thermoplastic elements that have been fused together creating a network having connecting portions, porosity, and open areas. Open areas as used herein are defined as areas of porosity in the coherent irregular network that extend completely through the thickness of the material. The coherent irregular network does not completely occlude the surface of the underlying porous membrane, and the areas where the porous membrane can be identified through the coherent irregular network are open areas. The “size” of an open area as used herein is defined as being the distance of the longest straight line that can be drawn across the open area. Upon inflation of the balloon, the size of the open area can increase in size as the elements of the textured network become separated. This increase in size can further increase the “grittiness” of the balloon. - In one embodiment, the coherent irregular network further comprises non-melt processible particles. The nonmelt processible particles may be inorganic particle, such as silica, carbon, and the like, or a non-melt processible polymer such as polyimide, PPS, PTFE, or the like. In these embodiments, the thermoplastic particles or elements are attached to create a coherent irregular network, and the non-melt processible particles are attached therein or thereon.
- In accordance with the above description, in an embodiment, a balloon assembly can comprise a balloon having a porous membrane having an outer surface and configured to perfuse a fluid, a template having at least one aperture about which a protrusion can distend, and a textured network disposed on at least a portion of the outer surface of the balloon and comprising a plurality of voids. The textured network can be a coherent irregular network of thermoplastic elements. In addition, the portion of the outer surface of the porous membrane can comprise an Sp value of at least 35 μm.
- In an embodiment,
balloon 1310 can comprise an ePTFE wrapped balloon. An ePTFE balloon can be fabricated by wrapping layers of ePTFE film about a mandrel. Wrapping can be a helical or longitudinal wrap. The ePTFE balloon can be subjected to thermal treatment at about 380° C. for 15 minutes to facilitate bonding and one end crimped. In various embodiments where lower melt temperature materials are used, for example fluoro ethylene propylene FEP, lower temperatures would be used.Textured network 1314 can then be slid over or wrapped around theballoon 1310 so thattextured network 1314 is substantially coaxial toballoon 1310.Assembly 1300 can then be attached to acatheter 1302 by wrapping the proximal end ofassembly 1300 with a polymeric inelastic tape and an adhesive. - It should be noted that the present disclosure contemplates a balloon assembly comprising a pre-configured texture balloon as described combined with a template having at least one aperture. For example, a ribbed balloon can form a protrusion about an aperture. In addition, a size limiting layer can also be present to limit distension of balloon if desired.
- In various embodiments, portions of a template or balloon cover can be scored, etched, or otherwise partially cut or weakened. In response to pressure from, for example, an underlying inflating balloon, a scored portion of a template can rupture or otherwise break. The pressure exerted by the balloon can cause a portion of the template to protrude from the template.
- In various embodiments, the protruding portion can be configured to be sharp by selectively shaping the scored portion. For example, a triangle shape can be formed and scored at one apex. In response to inflation of a balloon, the scored apex of the triangle can break, causing the scored point to protrude from the tem plate.
- The point (or other resulting shape) can be directionally oriented relative to the tissue. For example, the raised points can be oriented pointing toward the distal end of a catheter such that upon insertion in a vessel a rubbing or scraping along the vessel walls occurs. Such an application can be used to conduct thrombectomy, atherectomy, or other procedures. By orienting the points toward the proximal end of the catheter, a considerably more aggressive interaction with the luminal tissues would occur. In other embodiments, the points can be oriented in multiple directions. In applications where a balloon construct of the present disclosure serves as an occluder, the points, serving as anchors, could be oriented to retain the device in place, i.e., against the direction of blood flow or motion of the surrounding tissue(s). Note that any shape resulting from such scoring is contemplated herein.
- Accordingly, in an embodiment, balloon assembly can comprise balloon and a template overlying at least a portion thereof which comprises a surface that is disrupted upon inflation. For example, with reference to
FIGS. 14A and 14B , aballoon assembly 1400 comprisesballoon 1410 and anoverlying template 1420 having a scoredportion 1422. Upon inflation, as illustrated inFIG. 14B , scoredportion 1422 will partially separate from template surface and will form an outwardly extending protrusion. - In an embodiment, the ruptured portion of
template 1420 that is created by the rupture ofscore 1422 isaperture 1421 in whichballoon 1410 can be at least partially exposed. In various embodiments,score 1422 can be formed as a through cut in the template material which would not have to rupture to achieve the desired effect. - As illustrated, scoring and later rupturing of scores can enable the insertion of sharp objects into the body in a substantially unsharpened state and then provide for the deployment of the sharp object at a particular time. In addition, scoring and later rupturing can aid in the delivery of therapeutic agents. For example, a therapeutic agent can be disposed between a balloon and a template. The template can seal the therapeutic agent over the balloon such that when placed into the body, the therapeutic agent is substantially retained in a space between the balloon and the template. Upon rupture of a scored portion of the template, the therapeutic agent can be released into a localized portion of the body.
- Similarly, in another embodiment, with reference to
FIGS. 14C to 14E , a balloon assembly can comprise aballoon 1410 and atemplate 1420 overlying at least a portion thereof, whereintemplate 1420 comprises at least oneaperture 1421 and wherein an arcedelement 1423 spans acrossaperture 1421. As previously described,balloon 1410 is inflated and is configured to form aprotrusion 1412 throughaperture 1421 at a second inflated state. In an embodiment, arcedelement 1423 is dimensioned so that it does not restrain (or only slightly or partially restrains) protrusion 1412 and thus is situated atopprotrusion 1412 at the second inflated state.Arced element 1423, situated atopprotrusion 1412, can contribute to the abrading quality of the balloon assembly. -
Arced element 1423 can comprise an inner arc edge having an arc length, wherein the arc length of the inner arc edge is similar to the arc length of the protrusion that protrudes through the aperture so that the inner edge lay atopprotrusion 1412. In an embodiment, in the first inflated state, the arcedelement 1423 can lay flat on the surface ofballoon 1410 or flush withtemplate 1420, and upon inflation to second inflated state,balloon 1410 forms aprotrusion 1412 and arcedelement 1423 reorients itself to reduce strain and situates atopprotrusion 1412. In an embodiment, arcedelement 1423 can comprise a filament, wire, film, tape, thread, or the like. In addition, arcedelement 1423 can be integral withtemplate 1420, i.e., cut into the template pattern or be attached thereto.FIGS. 14E (1) to 14E(4) illustrate various arcedelement 1423 patterns. - In an embodiment, with reference to
FIGS. 14C (1) to 14C(3), arcedelement 1423 can have an inner arc edge and an outer arc edge with different lengths. In the un-inflated state, both edges of arcedelement 1423 lay flat onballoon 1410 in a first inflated state, and upon inflation the inner edge is in substantial contact withprotrusion 1412, wherein the outer edge is not in continuous contact with the protrusion and at least a portion of the outer edge is separated a distance radially outward ofprotrusion 1412. Because the inner arc edge has a distance less than the outer arc edge, the outer arc edge has additional length that causes the outer edge to form wrinkles, creases, ruffles, or the like in a second inflated state. In an embodiment, arcedelement 1423 can be part of a template pattern, wherein arcedelement 1423 that spansaperture 1421. In other embodiments, with reference toFIGS. 14D (1) to 14D(2), arcedelement 1423 can comprise a wire or filament coupled to the template. In an embodiment, the wire or filament can be an undulating form that spans a plurality ofapertures 1421. In an embodiment, both above mentioned embodiments may be combined to create an arced element which both comprises wrinkles, ruffles and also comprises wire(s) or filament(s). - Various embodiments of the herein disclosed balloon assemblies can be constructed in any suitable manner. For example, as shown in
FIG. 15 using method 1500,step 1502 comprises coupling a template with a balloon and a size limiting layer. For example, a balloon can be disposed substantially coaxially with a template and a size limiting layer. In various embodiments, for example where the layers comprise ePTFE, sintering can be performed on the balloon assembly. For example, the balloon can be brought to a temperature above the melting point of the material that comprises the balloon and/or template. Sintering in this manner can produce bonding of ePTFE layers.Step 1504 can comprise disposing a balloon on a catheter.Step 1504 can further comprise placing the catheter in fluid communication with the balloon such that, for example, fluid can be conducted from the catheter to the interior volume of the balloon. - In various embodiments, method 1600, as shown in
FIG. 16 , for using a balloon assembly can be used. Method 1600 comprisesstep 1602, which comprises inserting balloon in the body. Any portion of the body or a lumen of the body can be used instep 1602. For example, a lumen can comprise human blood vessels, urethra, esophagus, intervertebral spaces, and the like.Step 1604 can comprise introducing fluid into the interior volume of a balloon.Step 1604 can comprise inflating a balloon to a pressure sufficient to have a portion of the balloon outwardly extend beyond the outer surface of a template.Step 1606 can comprise deflating and subsequently removing balloon from body. - In various embodiment, the balloon assembly with a template can comprise a plurality of apertures located along a length of the assembly (and optionally about a circumference) and can be used for locating a side branch vessel. Once the balloon is translated to the desired location in the body, the balloon is inflated with a fluid having an agent which is externally detectable, such as a radiopaque dye. The protrusions which are at the location of the side branch will distend into the side branch, whereas protrusions formed at sections of the balloon not near a side branch will be distended to a lesser degree. Thus, the side branch is visible by way of the protrusions therein.
- In various embodiments, a balloon assembly can be configured to have an abrasive topography. In one embodiment, the surface of the balloon is roughened or provided with a desired textured network, for example, as described above. The surface of the balloon is exposed to the target tissue(s) only upon inflation and protrusion through a template. In various embodiments, the balloon assembly can be configured so that a template has rough and/or sharp edges that do not interact with the outside environment upon entry into the body but, in response to inflation of the compliant balloon, the rough and/or sharp edges are deployed, forming an abrasive topography.
- In various embodiments, a varied topography balloon or a pre-configured textured balloon assembly can be constructed using multiple layers of material, such as ePTFE, nylon and/or elastomers on either or both the balloon or the template. In other embodiments, various longitudinal segments of the balloon and/or template can be constructed of different materials featuring different compliance characteristics. Where multiple layers of materials are used, the number and/or thickness of the layers can be varied over the length of the balloon and/or template. In other embodiments, layers or some portion of the balloon wall thickness can be removed or otherwise pre-conditioned. Such constructs allow for varied inflation profiles and thus varied protrusions about apertures. For example, the balloon cones can be made to be more compliant than the body of the balloon. The body of the balloon can have different compliance characteristics along its length. Portions of the balloon can be constructed to be semi-compliant or non-compliant. Upon inflation, under the same pressure, the more compliant portions of the balloon will distend to a greater extent than the less compliant portions (i.e., form a height gradient).
- Optionally, balloon assemblies as described herein can comprise a distal cap to secure the distal terminus of a balloon to catheter. A distal cap can be referred to as an olive. An olive can abut against the distal end of a balloon or catheter. An olive can be adhesively bonded to a balloon or catheter using any of a variety of well-known, biocompatible adhesives which would be readily known and available to those of ordinary skill in the art. Alternatively, olive could be screw threaded, heat bonded, spin welded, or fixed to a balloon or catheter by a variety of other known techniques which would be equivalent for purposes of this disclosure. Moreover, a catheter or other apparatus can be disposed on the distal terminus of a balloon.
- In further embodiments, balloons assemblies disclosed herein can comprise size-limited, compliant balloons that perfuse in response to an increase in internal pressure.
- In various embodiments, balloon assemblies disclosed herein are steerable when in both inflated and/or deflated states. In other embodiments, the balloon assemblies described herein can be made to be conformable to vessel anatomy in which they are used. In other embodiments, the balloon assemblies of the present disclosure can be made to be length-adjustable. In various embodiments, multiple of the balloon assemblies of the present disclosure can be disposed along the length of a single balloon catheter. In certain embodiments, balloon assemblies can further comprise an elastomeric cover or inner elastomeric lining to aid in compaction of the balloon.
- In various embodiments, balloon assemblies disclosed herein can be used with a pressure retaining valve. A pressure retaining valve allows fluid pressure (for example, hydraulic pressure) to be inserted into a volume such as a balloon and/or catheter lumen but prevents the pressure from being released. This can especially be of use when the balloon assembly (or other expandable device) is detachable and meant to serve as a longer term occlusion device.
- Without intent of limiting, devices disclosed herein (e.g., varied topography or textured balloon assemblies) are useful in any medical applications or treatments such as, for example, tissue ablation, angioplasty, cancer therapies, thrombectomy, embolectomy, angioplasty/stenting; angioplasty/stenting in the kidneys; angioplasty/stenting in blood carrying passageways; angioplasty/stenting in the legs; angioplasties of graft-artery anastomotic strictures; stenting used to aid attachment of endoprostheses such as gastrointestinal liners, cancer of the adrenal cortex; cancer of the endometrium; cancer of the larynx (voice box); cancer of the pancreas; cancer of the parathyroid; cancer of the thyroid gland; cancer of tissues of the lip or mouth (e.g.; tongue; gums; lining of cheeks; bottom of mouth; hard & soft palate; retromolar trigone); cancers; cancers of the blood; cancers of the nasal cavity; candidiasis; capsules; carcinoid syndrome; carcinoid tumors; cardiovascular disease (CVD); cardiovascular patches; carotid artery stenting (CAS); casts; catheters; cells; choriocarcinoma; chronic myeloid leukemia (CML); deep venous thrombosis (DVT); delayed release grafts; delayed release stent-grafts; delayed release stents; dialysis access applications; dialysis equipment; dialysis grafts; drug delivery devices; drug-eluting grafts; drug-eluting implants; drug-eluting sutures; drug-eluting stents; endoprosthesis stent-grafts; ostia ballooning, deployment of endoprosthesis in an ostia; endovascular aneurysm repair (EVAR); endografts; endovascular grafting; endovascular stent-grafts; endovascular therapy; esophageal stenting; eustachian tube dysfunction; iliac stents and stent-grafts; immunizations; infection (e.g. in the lungs; throat; sinuses; kidneys; bladder; abdomen; and skin); infections of female reproductive organs; infections of the urinary and lower respiratory tract; infections of throughout the body (septicemia); inflammatory bowel disease (e.g., Crohn's disease); interatrial defects; influenzas; injuries; insomnia; internal thoracic artery grafts (ITA, mammary artery); intestinal stents; intestinal stent-grafts; locating a side branch; medical devices; modified release stent-grafts; modified release stents; nephroureteral stenting; neurological devices; pancreatic stenting; pancreatic cancer; pancreas; pancreatitis; percutaneous angioplasty of Takayasu arteritis; penile implants; peripheral vascular stents and stent-grafts; positioning in urethral lumen; pulmonary conditions; radial artery grafts; rectal stents and stent-grafts; reduction or shrinkage of aneurism al (sac); regrow nerve fibers or organs; reinforce collapsing structures; renal cell cancer; renal cell carcinoma (RCC) tumors; renal impairment; renal grafts; renal stents and stent-grafts; renal transplants; renal transplants; repair of aneurysms; repair of living cells; tissues or organs; stenosis of the renal artery (e.g., at ostium); stent-grafts; stenting; stents; stents in femoral arteries; surgical procedures; sustained released grafts; sustained release stent-grafts; thoracic aneurysm repair; thrombosis; thrombotic conditions; treatment of other diseases, cells, tissue, organs, bones, referenced in Gray's Anatomy and disorders (herein incorporated in its entirety as a reference); or combinations thereof, for example.
- In various embodiments, balloon assemblies of the present disclosure can be used in conjunction with drug eluting or drug delivery balloons. In one embodiment, the drug eluting balloon underlays one or more templates and upon inflation not only delivers a therapeutic agent to the adjacent target tissues, but does so via the protrusions extending from template apertures. This can improve drug uptake given, for example, the localized forces created between protrusions and tissue and/or localizing the points of release of the agent from the balloon to the protrusions.
- When used to place, size, or “touch up” stents or stent grafts (or other endoprostheses), a varied topography or textured balloon of the present disclosure can be constructed so as to provide enhanced stent retention, stent deployment, and stent release.
- For example, the protrusions formed by the tem plate(s) can be of any shape, size, surface texture and/or material to adhere to or prevent slippage of the balloon and inner walls of such prostheses. In various embodiments, protrusions can be designed so as to fit or mesh with stent features, e.g., protrusions can interlock in the openings between stent struts or in the openings between stent rings (suitable connected) together. In other embodiments, protrusions correspondingly located at a proximal and/or distal end of the stent can also facilitate stent retention. This makes their tracking and placement easier and more accurate. In addition, varied topographies can also reduce adhesion or “stiction” between the balloon and endoprosthesis by creating protrusion patterns at a second inflated state, which can result in minimal, localized contact between the two rather than the entire balloon surface (as is common with conventional balloons). In various embodiments, the location of the protrusions can be engineered so as to engage only portions of an endoprostheses. Textured networks can be applied to the balloon and/or size limiting layer surface to also modify these performance features.
- In one embodiment, with reference to
FIG. 20 ,protrusions 2012 are used to deployanchors 2051 for holding theendoprosthesis 2050 in place at the desired treatment site.Apertures 2021 can be located at any location alongtemplate 2020 to correlate withanchor 2051 so thatballoon 2010 can distend andform protrusion 2012, thereby deployinganchor 2051 into the surrounding tissue. - Similarly, the aperture and/or protrusions pattern can be designed for purposes of ostia ballooning, flaring a stent end(s), and/or deploying a flange. In an embodiment, with reference to
FIG. 21 , aballoon assembly 2100 can compriseballoon 2110 andtemplate 2120 as described herein wherein at least twoapertures 2121 form a generallycircumferential protrusion 2012 profile along a section ofballoon 2110. This section can be located at a proximal and/or distal end of assembly. - With regard to application of these balloon constructs to angioplasty, it will be understood that they offer several clinical advantages. Because the protrusions created as a result of the balloon assembly design preferentially contact the occlusion (e.g., plaque), there are distributed stress concentrations created over the surface of the occlusion. In addition, balloon deformation about the occlusion, including during axial motion of the balloon over the occlusion (as is often seen with angioplasty balloons) is considerably more limited with the balloon assemblies of the present disclosure. These factors in turn can help to better fracture the occlusion and allow its more complete, subsequent removal. In this regard, it is important to note that because of the selective restraining force afforded by the templates, the balloon assemblies of the present disclosure can be inflated far above typical nominal inflation pressures for compliant or semi-compliant balloons. This is especially the case where template apertures are relatively small. Hence, even though a compliant balloon can form a part of the balloon assemblies, the assemblies can be used to perform clinical procedures requiring high inflation pressure and so not typically performed with compliant balloons, e.g., angioplasty.
- Additionally, in various embodiments, the protrusions resulting from designs made in accordance with the present disclosure can be used in the visualization of anatomical structures. The balloon can be filled with a visualization (e.g., contrast) agent. Upon inflation, the protrusions will be distinctly visualized (e.g., via fluoroscopy). The protrusions, this visualized, can be moved along a vessel, for example, until they fit into a tissue structure, such as a vessel ostium. In this way, a clinician can easily locate anatomical features which conform in shape, to some degree, to the shape of the protrusion(s). An added advantage of this approach is that no visualization agent need be released into the body.
- Another clinical advantage offered by the present disclosure is that balloons can be constructed so as to expand protrusions to pre-determined heights, both final expanded heights and heights during expansion. This “progressive protrusion” can be clinically useful. This can be done by engineering the design of the balloons to correlate with inflation pressures and/or inflation fluid volumes. This provides clinicians with variable control during use of these devices.
- As noted above, further clinical advantages are offered by the present disclosure in that a topographically-variable balloon used can provide increased surface area to prevent acute migration of the balloon and/or encourage tissue ingrowth and/or thrombogenesis. This can be beneficial in balloon assemblies used as occluders.
- In addition, balloon assemblies in accordance with present disclosure can be used to “scrub” or otherwise displace or remove thrombus or plaque in the vasculature. A coarse or textured topography can be helpful in enhancing engagement of the balloon assembly with the thrombus or plaque and/or helpful in occluding a blood vessel. For example, balloon assemblies in accordance with the present disclosure can be used in conjunction with a reverse blood flow system like those used in carotid artery stenting. In such reverse blood flow systems, balloon assemblies in accordance with present disclosure can be used to occlude the external carotid artery and/or the common carotid artery. Balloon assemblies in accordance with present disclosure can provide enhanced occlusion characteristics relative to conventional balloon assemblies.
- In addition, balloon assemblies in accordance with present disclosure can be used as a balloon anchored introducer in a stenting procedure. A balloon assembly can be positioned in the body distal to the desired stent site. The balloon assembly can then be inflated to anchor the balloon assembly and thus provide support for a guidewire or other apparatus that can deliver and deploy a stent to the desired stent site. Balloon assemblies in accordance with present disclosure can provide enhanced anchoring characteristics relative to conventional balloon assemblies.
- The following example details how an exemplary balloon of the present disclosure was constructed.
- An ePTFE film was obtained of the general type as disclosed in U.S. Pat. No. 7,306,729. A discontinuous layer of the thermoplastic FEP (fluoro ethylene propylene) was applied to one surface and the film was slit into a tape. The tape was wrapped around a 6 mm mandrel so that the film's machine direction was oriented about the circumference of the mandrel. A length of tape was wrapped that resulted in approximately 18 layers of film. The tape-wrapped tube was thermally treated in an oven at 320° C. for 12 minutes. The film tube was removed from the oven and then removed from the mandrel and cut to 80 mm in length.
- The 6 mm tube was placed over a suitable mandrel and square apertures measuring 2 mm by 2 mm were cut through the tube using a CO2 laser, leaving 1 mm of film material between apertures. Six rows of apertures were cut about the circumference of the tube, parallel to the tube's longitudinal axis. The pattern was cut over a 60 mm length centered in the 80 mm tube. This tube is referred to as a “template” with “apertures.”
- An ePTFE film was obtained of the general type as disclosed in U.S. Pat. No. 5,476,589, entitled, “Porous PTFE Film And A Manufacturing Method Therefore,” which issued Dec. 19, 1995. The film was cut into a tape of 25 mm width and helically wrapped about a 9 mm stainless steel mandrel at an 11.4 mm pitch. The wraps were repeated on a bias in opposite directions to produce an approximately 4-layer film tube.
- This tube was then thermally treated in an oven at 380° C. for 9 minutes and then removed from the oven. The tube was removed from the mandrel, placed over a 7 mm mandrel and axially stretched to decrease its diameter to 7 mm. A sacrificial ePTFE tape was helically wrapped over the film tube on the 7 mm mandrel.
- The tube assembly was then axially compressed to 85% of its original length. The tube assembly was then subjected to thermal treatment at 380° C. for 1 minute and then removed from the oven. The sacrificial ePTFE layer was removed and discarded. The 7 mm tube construct was cut to an 80 mm length. This tube can be referred to as a “size limiting layer”.
- A compliant polyurethane balloon catheter was obtained with a balloon having a diameter of 10 mm and length of 60 mm (“COAX,” Bavarian Medizin Technologies (BMT), Germany).
- The size limiting layer was slid over the balloon assembly (with the balloon in its collapsed state). The ends of the size limiting layer were secured to the catheter using LOCTITE adhesive 4981 (Henkel Corporation, Düsseldorf, 40589 Germany) applied to a 6 mm wide ePTFE tape as it was wrapped 5 times about the size limiting layer tube ends. The balloon was then inflated to an approximate 5 mm diameter.
- The template layer, as described in Example 2, was slid over the size-limiting layer and the compliant balloon (with the balloon at its 5 mm diameter). The ends of the template layer were secured to the catheter using LOCTITE adhesive 4981 applied to a 6 mm wide ePTFE tape as it was wrapped 5 times about the tube ends. The balloon was then inflated to an approximate 6 mm diameter.
- The balloon assembly was then inflated to 4 atmospheres and protrusions of the underlying compliant balloon were noted extending from the apertures.
- In order to form a distensible template, construct a helically wrapped 8 mm film tube using an ePTFE film as described in U.S. Pat. No. 7,306,729, issued Dec. 11, 2007. Laser cut the 8 mm film tube to form 2 mm×2 mm openings. Reduce the template diameter by stretching the template in a longitudinal direction until the inside diameter of the template reaches approximately 4 mm. Insert a 4 mm mandrel into the 4 mm drawn down template. Over wrap the template on the 4 mm mandrel with a sacrificial film. Longitudinally compress (or scrunch) the over-wrapped template to approximately 60% of the original length. Bake the compressed template at 380° C. at a time ranging from (0 sec. to 120 sec.). This step sets the load at which the template will begin to distend. The lower the baking time, the smaller the load required to distend. Once set, remove the sacrificial film and the template from the 4 mm mandrel.
- Obtain an inflatable, compliant balloon element constructed to be 8 mm×40 mm with a working length of 40 mm, two shoulders of length of 4 mm, and two seals of 7 mm, giving it an overall length of 62 mm.
- Place an 8 mm×62 mm size limiting layer (constructed in a similar manner as described in Example 2) that has also been drawn down to 4 mm on a 4 mm mandrel. Cut the template to a length of (24 mm+7 mm to form the attachment to the size limiting layer at the seal), giving it an overall length of 31 mm. Slide the cut template over the size limiting layer that is on the 4 mm mandrel so the inside end of the template aligns with the center line of the size limiting layer. Wrap approximately 5 to 20 layers of a porous, sintered, sufficiently thin and strong ePTFE film, ½″wide using 4498 LocTite glue to adhere the template at center line of the size limiting layer. Remove the size limiting layer with the template attached from the 4 mm mandrel.
- Place the 4 mm template and size limiting assembly over the compacted 8 mm balloon and secure both the proximal and distal ends (7 mm each) by wrapping approximately 10 or more layers of a porous, sintered, sufficiently thin and strong ePTFE film and 4498 LocTite adhesive around each end of the cover and catheter.
- In another embodiment, a frangible template can be constructed as described in Example 3, instead using an ePTFE film as described in U.S. Pat. No. 5,814,405 Branca et al., which is hereby incorporated by reference in its entirety.
- It will be apparent to those skilled in the art that various modifications and variations can be made in the present disclosure without departing from the spirit or scope of the disclosure. For example, while embodiments of the present disclosure have been described with reference to the inferior vena cava, embodiments are scaleable and applications in various central and peripheral vessels and lumens are contemplated herein. Additionally, the embodiments can be used in connection with not just humans, but also various organisms having mammalian anatomies. Thus, it is intended that the embodiments described herein cover the modifications and variations of this disclosure provided they come within the scope of the appended claims and their equivalents.
- Benefits, other advantages, and solutions to problems have been described herein with regard to specific embodiments. However, the benefits, advantages, solutions to problems, and any element or combination of elements that can cause any benefit, advantage, or solution to occur or become more pronounced are not to be construed as critical, required, or essential features or elements of any or all the claims of the disclosure. Many changes and modifications within the scope of the instant disclosure can be made without departing from the spirit thereof, and the disclosure includes all such modifications. Corresponding structures, materials, acts, and equivalents of all elements in the claims below are intended to include any structure, material, or acts for performing the functions in combination with other claim elements as specifically claimed. The scope of the disclosure should be determined by the appended claims and their legal equivalents, rather than by the examples given above.
Claims (12)
1. A medical balloon comprising
an inflatable balloon element;
a template having an outer surface and extending along at least a portion of the inflatable balloon element for at least a portion of its length and having an first distension profile and a second distension profile;
wherein the template includes at least one aperture,
wherein the inflatable balloon element outwardly extends about the at least one aperture relative to the outer surface of the template when inflated to the first distention profile, and
wherein the inflatable balloon element forms a relatively smooth surface about the at least one aperture relative to the outer surface of the film template when inflated to the second distention profile.
2. The medical balloon of claim 1 , wherein the template comprises a first nominal size at the first distention profile and a second nominal size at the second distension profile, wherein the the first nominal size is less than the second nominal size.
3. The medical balloon of claim 2 , wherein when the inflatable balloon element is inflated to a first pressure, the template is at a first distension pressure and when the inflatable balloon element is inflated to a second pressure, the template is at a second distension profile.
4. The medical balloon of claim 1 , wherein the inflatable balloon element is size limited.
5. The medical balloon of claim 4 , wherein the inflatable balloon element is strained during inflation.
6. The assembly of claim 1 , wherein inflatable balloon comprises a size limiting layer.
7. The assembly of claim 4 , wherein the size limiting layer comprises at least two layers of a helically wrapped polymeric tape.
8. The assembly of claim 1 , further comprising a therapeutic agent underlying the film template, wherein at least a portion of the therapeutic agent is conveyed out of at least one aperture upon the balloon extending through the aperture.
9. The assembly of claim 1 , wherein the film template comprises a rigid element.
10. The assembly of claim 9 , wherein the inflatable balloon element outwardly rotates the rigid element during inflation.
11. The assembly of claim 1 , wherein the inflatable balloon element is configured to perfuse.
12. The assembly of claim 1 , wherein the template comprises a high-strength ePTFE.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/136,570 US20210186555A1 (en) | 2011-10-07 | 2020-12-29 | Balloon assemblies having controllably variable topographies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161545039P | 2011-10-07 | 2011-10-07 | |
US13/645,414 US9730726B2 (en) | 2011-10-07 | 2012-10-04 | Balloon assemblies having controllably variable topographies |
US15/645,176 US10881426B2 (en) | 2011-10-07 | 2017-07-10 | Balloon assemblies having controllably variable topographies |
US17/136,570 US20210186555A1 (en) | 2011-10-07 | 2020-12-29 | Balloon assemblies having controllably variable topographies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/645,176 Continuation US10881426B2 (en) | 2011-10-07 | 2017-07-10 | Balloon assemblies having controllably variable topographies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210186555A1 true US20210186555A1 (en) | 2021-06-24 |
Family
ID=47089161
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/645,414 Active 2034-07-25 US9730726B2 (en) | 2011-10-07 | 2012-10-04 | Balloon assemblies having controllably variable topographies |
US15/645,176 Active 2034-03-22 US10881426B2 (en) | 2011-10-07 | 2017-07-10 | Balloon assemblies having controllably variable topographies |
US17/136,570 Abandoned US20210186555A1 (en) | 2011-10-07 | 2020-12-29 | Balloon assemblies having controllably variable topographies |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/645,414 Active 2034-07-25 US9730726B2 (en) | 2011-10-07 | 2012-10-04 | Balloon assemblies having controllably variable topographies |
US15/645,176 Active 2034-03-22 US10881426B2 (en) | 2011-10-07 | 2017-07-10 | Balloon assemblies having controllably variable topographies |
Country Status (12)
Country | Link |
---|---|
US (3) | US9730726B2 (en) |
EP (4) | EP3488892B1 (en) |
JP (4) | JP6612502B2 (en) |
KR (1) | KR20140074378A (en) |
CN (1) | CN103930158B (en) |
AU (1) | AU2012333084A1 (en) |
BR (1) | BR112014008291A2 (en) |
CA (1) | CA2850504C (en) |
ES (2) | ES2877118T3 (en) |
HK (1) | HK1200744A1 (en) |
RU (1) | RU2014118473A (en) |
WO (1) | WO2013066566A1 (en) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8435283B2 (en) * | 2007-06-13 | 2013-05-07 | Boston Scientific Scimed, Inc. | Anti-migration features and geometry for a shape memory polymer stent |
US8926688B2 (en) | 2008-01-11 | 2015-01-06 | W. L. Gore & Assoc. Inc. | Stent having adjacent elements connected by flexible webs |
EP2431067A1 (en) * | 2008-03-07 | 2012-03-21 | London Equitable Limited in its capacity as Trustee of the Think Tank Trust | A dilation catheter |
US9480826B2 (en) | 2008-03-21 | 2016-11-01 | Cagent Vascular, Llc | Intravascular device |
US11229777B2 (en) | 2008-03-21 | 2022-01-25 | Cagent Vascular, Inc. | System and method for plaque serration |
US8323243B2 (en) | 2008-03-21 | 2012-12-04 | Innovasc Llc | Device and method for opening blood vessels by pre-angioplasty serration and dilatation of atherosclerotic plaque |
US9539081B2 (en) | 2009-12-02 | 2017-01-10 | Surefire Medical, Inc. | Method of operating a microvalve protection device |
US9199066B2 (en) | 2010-03-12 | 2015-12-01 | Quattro Vascular Pte Ltd. | Device and method for compartmental vessel treatment |
EP2579943B1 (en) | 2010-06-10 | 2019-11-13 | Myriad Medical LLC | Intracavity balloon catheter |
US10589071B2 (en) | 2010-09-23 | 2020-03-17 | Best Medical International, Inc. | Multiple function balloon catheter |
US10744307B2 (en) * | 2010-09-23 | 2020-08-18 | Best Medical International, Inc. | Multi-purpose balloon catheter for intra cavity radiation delivery |
US20130116549A1 (en) * | 2010-10-18 | 2013-05-09 | Erhan H. Gunday | Anchored Working Channel |
WO2012102919A1 (en) * | 2011-01-24 | 2012-08-02 | Tufts Medical Center, Inc. | Endovascular stent |
US20120209375A1 (en) * | 2011-02-11 | 2012-08-16 | Gilbert Madrid | Stability device for use with percutaneous delivery systems |
WO2012154539A1 (en) | 2011-05-06 | 2012-11-15 | Merit Medical Systems, Inc. | Mechanically assisted inflation device handle and method of use |
ES2665307T3 (en) * | 2011-05-26 | 2018-04-25 | Adn International, Llc | Expandable device for tissue collection of an aerodigestive body light |
US9861444B2 (en) * | 2011-11-01 | 2018-01-09 | The Johns Hopkins University | Method and device for endoscopic abrasion |
CN104159541A (en) | 2012-02-01 | 2014-11-19 | 夸超脉管私人有限公司 | Device for compartmental dilatation of blood vessels |
US9216033B2 (en) * | 2012-02-08 | 2015-12-22 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
EP3542849B1 (en) | 2012-02-08 | 2020-12-09 | TriReme Medical, LLC | Constraining structure with non-linear axial struts |
US9381326B2 (en) | 2012-06-15 | 2016-07-05 | W. L. Gore & Associates, Inc. | Vascular occlusion and drug delivery devices, systems, and methods |
US9283072B2 (en) | 2012-07-25 | 2016-03-15 | W. L. Gore & Associates, Inc. | Everting transcatheter valve and methods |
US11938287B2 (en) | 2012-10-26 | 2024-03-26 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10966820B2 (en) | 2012-12-19 | 2021-04-06 | W. L. Gore & Associates, Inc. | Geometric control of bending character in prosthetic heart valve leaflets |
US9101469B2 (en) | 2012-12-19 | 2015-08-11 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with leaflet shelving |
US9144492B2 (en) | 2012-12-19 | 2015-09-29 | W. L. Gore & Associates, Inc. | Truncated leaflet for prosthetic heart valves, preformed valve |
US9968443B2 (en) | 2012-12-19 | 2018-05-15 | W. L. Gore & Associates, Inc. | Vertical coaptation zone in a planar portion of prosthetic heart valve leaflet |
US10039638B2 (en) | 2012-12-19 | 2018-08-07 | W. L. Gore & Associates, Inc. | Geometric prosthetic heart valves |
US10758667B2 (en) * | 2013-02-04 | 2020-09-01 | Michael Rontal | Balloon irrigation and cleaning system for interior walls of body cavities |
US9623213B2 (en) | 2013-03-15 | 2017-04-18 | Acclarent, Inc. | Uncinate process support for ethmoid infundibulum illumination |
US9615959B2 (en) | 2013-03-15 | 2017-04-11 | Acclarent, Inc. | Uncinate process support for ethmoid infundibulum illumination |
CA2921278C (en) * | 2013-08-16 | 2021-11-30 | Merit Medical Systems, Inc. | High-pressure inflation devices and methods of use |
US10207091B2 (en) | 2013-09-13 | 2019-02-19 | David G. Dillard | Force-directional nasal surgery dilatation device |
US9968740B2 (en) | 2014-03-25 | 2018-05-15 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
GB2525005B (en) * | 2014-04-09 | 2016-03-09 | Cook Medical Technologies Llc | Delivery system for implantable medical device |
WO2015179631A1 (en) * | 2014-05-21 | 2015-11-26 | The Regents Of The University Of Michigan | Fenestrated decoupling system for internal selective attachment to soft tissue organs |
US10463842B2 (en) | 2014-06-04 | 2019-11-05 | Cagent Vascular, Llc | Cage for medical balloon |
US9486231B2 (en) | 2014-08-08 | 2016-11-08 | Coloplast A/S | Tool with a clasp useful for implanting a penile prosthetic cylinder |
US9480566B2 (en) | 2014-08-08 | 2016-11-01 | Coloplast A/S | Tool with a groove useful for implanting a penile prosthetic cylinder |
CA2956402C (en) | 2014-08-18 | 2020-08-25 | W.L. Gore & Associates, Inc. | Frame with integral sewing cuff for prosthetic valves |
US9724197B2 (en) | 2014-09-10 | 2017-08-08 | Coloplast A/S | Tool with a suction feature useful for implanting a penile prosthetic cylinder |
WO2016040820A1 (en) * | 2014-09-12 | 2016-03-17 | Acclarent, Inc. | Uncinate process support for ethmoid infundibulum illumination |
US9827094B2 (en) | 2014-09-15 | 2017-11-28 | W. L. Gore & Associates, Inc. | Prosthetic heart valve with retention elements |
US9642707B2 (en) | 2014-09-29 | 2017-05-09 | Coloplast A/S | Tool with a pincher useful for implanting an inflatable penile cylinder |
EP3215212B1 (en) | 2014-11-03 | 2020-07-29 | Cagent Vascular, LLC | Serration balloon |
JP6803838B2 (en) * | 2014-11-17 | 2020-12-23 | トライレム・メディカル・エルエルシー | Balloon catheter system and how to use this system |
US10299948B2 (en) * | 2014-11-26 | 2019-05-28 | W. L. Gore & Associates, Inc. | Balloon expandable endoprosthesis |
EP3042687B1 (en) | 2015-01-08 | 2020-10-14 | Myriad Medical LLC | Intracavity balloon catheter |
US10117738B2 (en) | 2015-01-23 | 2018-11-06 | The Regents Of The University Of Michigan | Atraumatic tip geometry for indwelling devices |
US20160287839A1 (en) | 2015-03-31 | 2016-10-06 | Surefire Medical, Inc. | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
US20180099126A1 (en) * | 2015-04-06 | 2018-04-12 | C.R.BARD, INC., C/o Bard Peripheral Vascular, Inc. | Inflatable perfusion balloon with outer mesh and related methods |
EP3346928A4 (en) * | 2015-09-08 | 2019-04-17 | Transit Scientific, LLC | Exoskeleton devices for use with elongated medical instruments |
CN108348734B (en) | 2015-09-17 | 2021-11-09 | 开金血管公司 | Wedge-shaped cutter of medical air bag |
US10448805B2 (en) | 2015-09-28 | 2019-10-22 | Bio-Medical Engineering (HK) Limited | Endoscopic systems, devices and methods |
WO2017096350A1 (en) | 2015-12-05 | 2017-06-08 | The Regents Of The University Of Colorado, A Body Corporate | Novel endoscopic devices and methods using same |
CN107412892B (en) * | 2016-02-16 | 2021-04-16 | 上海微创医疗器械(集团)有限公司 | Catheter sheath and ventricular assist circulation device |
EP3391932B1 (en) * | 2016-03-23 | 2023-10-11 | Terumo Kabushiki Kaisha | Balloon catheter and method for producing the same |
WO2017164281A1 (en) * | 2016-03-23 | 2017-09-28 | テルモ株式会社 | Balloon catheter and production method therefor, and treatment method |
JP2019510607A (en) * | 2016-04-04 | 2019-04-18 | イノベンションズ リミテッド | Drug delivery device and method |
US10568752B2 (en) | 2016-05-25 | 2020-02-25 | W. L. Gore & Associates, Inc. | Controlled endoprosthesis balloon expansion |
CN106037920A (en) * | 2016-06-24 | 2016-10-26 | 王强 | Irregular-shape sacculus assembly used for bone cement filling |
CN105963850A (en) * | 2016-06-30 | 2016-09-28 | 首都医科大学附属北京同仁医院 | T-shaped expanding tube for tracheostenosis |
US11400263B1 (en) | 2016-09-19 | 2022-08-02 | Trisalus Life Sciences, Inc. | System and method for selective pressure-controlled therapeutic delivery |
US10780250B1 (en) | 2016-09-19 | 2020-09-22 | Surefire Medical, Inc. | System and method for selective pressure-controlled therapeutic delivery |
US20180104458A1 (en) * | 2016-10-17 | 2018-04-19 | Cook Medical Technologies Llc | Shape controlled balloon catheter |
CN110114108B (en) | 2016-11-16 | 2022-12-06 | 开金血管公司 | System and method for depositing a drug into tissue through teeth |
KR102149574B1 (en) * | 2016-11-22 | 2020-08-28 | 아사히 인텍크 가부시키가이샤 | Balloon catheter |
US10729546B2 (en) | 2017-02-02 | 2020-08-04 | Coloplast A/S | Inflatable penile prosthetic system |
US10588636B2 (en) | 2017-03-20 | 2020-03-17 | Surefire Medical, Inc. | Dynamic reconfigurable microvalve protection device |
JP6804370B2 (en) * | 2017-03-31 | 2020-12-23 | テルモ株式会社 | Medical long body |
US11690645B2 (en) | 2017-05-03 | 2023-07-04 | Medtronic Vascular, Inc. | Tissue-removing catheter |
CN110621243B (en) | 2017-05-03 | 2023-05-05 | 美敦力瓦斯科尔勒公司 | Tissue removal catheter with guidewire isolation bushing |
EP4275709A3 (en) * | 2017-05-05 | 2024-01-17 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10350395B2 (en) * | 2017-06-23 | 2019-07-16 | Cook Medical Technologies Llc | Introducer for lumen support or dilation |
US11660218B2 (en) * | 2017-07-26 | 2023-05-30 | Intact Vascular, Inc. | Delivery device and method of delivery |
CN111182856B (en) | 2017-09-12 | 2022-04-29 | W.L.戈尔及同仁股份有限公司 | Leaflet frame attachment for prosthetic valves |
CA3158845A1 (en) | 2017-09-12 | 2019-03-21 | W. L. Gore & Associates, Inc. | Substrate with rotatable struts for medical device |
CN115024861A (en) | 2017-09-27 | 2022-09-09 | W.L.戈尔及同仁股份有限公司 | Prosthetic valve with mechanically coupled leaflets |
CA3178271A1 (en) | 2017-09-27 | 2019-04-04 | W.L. Gore & Associates, Inc. | Prosthetic valve with expandable frame and associated systems and methods |
CN111447890B (en) | 2017-10-13 | 2023-01-31 | W.L.戈尔及同仁股份有限公司 | Nested prosthetic valve and delivery system |
JP7072062B2 (en) | 2017-10-31 | 2022-05-19 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | Transcatheter placement system and related methods |
AU2018362081B2 (en) | 2017-10-31 | 2021-05-06 | Edwards Lifesciences Corporation | Prosthetic heart valve |
US11154397B2 (en) | 2017-10-31 | 2021-10-26 | W. L. Gore & Associates, Inc. | Jacket for surgical heart valve |
CA3205219A1 (en) | 2017-10-31 | 2019-05-09 | Edwards Lifesciences Corporation | Medical valve and leaflet promoting tissue ingrowth |
CN111556771A (en) * | 2018-01-03 | 2020-08-18 | 巴德股份有限公司 | Balloon with integral scoring element and related methods |
US11577056B2 (en) | 2018-01-16 | 2023-02-14 | Aspero Medical, Inc. | Medical devices including textured inflatable balloons |
US11089944B2 (en) | 2018-01-16 | 2021-08-17 | The Regents Of The University Of Colorado | Medical devices including textured inflatable balloons |
US11730928B2 (en) | 2018-01-16 | 2023-08-22 | Aspero Medical, Inc. | Split overtube assembly |
US10894148B2 (en) * | 2018-01-31 | 2021-01-19 | C. R. Bard, Inc. | Balloon-manipulating devices, balloon catheter assemblies, and methods thereof |
WO2020023749A1 (en) | 2018-07-25 | 2020-01-30 | Cagent Vascular, Llc | Medical balloon catheters with enhanced pushability |
US11850398B2 (en) | 2018-08-01 | 2023-12-26 | Trisalus Life Sciences, Inc. | Systems and methods for pressure-facilitated therapeutic agent delivery |
US11541204B2 (en) * | 2018-09-26 | 2023-01-03 | W. L. Gore & Associates, Inc. | Cyclic expansion tissue treatment programs and associated systems |
CN209967376U (en) * | 2018-10-04 | 2020-01-21 | 口径疗法有限公司 | Balloon catheter system for infusing micelles at high pressure |
US11338117B2 (en) | 2018-10-08 | 2022-05-24 | Trisalus Life Sciences, Inc. | Implantable dual pathway therapeutic agent delivery port |
USD926322S1 (en) | 2018-11-07 | 2021-07-27 | W. L. Gore & Associates, Inc. | Heart valve cover |
EP3880266A1 (en) * | 2018-11-14 | 2021-09-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
EP3880096B1 (en) | 2018-11-16 | 2024-09-18 | Medtronic Vascular Inc. | Tissue-removing catheter |
US11497601B2 (en) | 2019-03-01 | 2022-11-15 | W. L. Gore & Associates, Inc. | Telescoping prosthetic valve with retention element |
CN109998748A (en) * | 2019-03-09 | 2019-07-12 | 苏州莱诺医疗器械有限公司 | A kind of lacrimal canal bracket fully absorbed and its transportation system |
CN110075413A (en) * | 2019-04-28 | 2019-08-02 | 汪秀华 | A kind of severe medicine section's Breathing Suppotion airway patency device |
US11819236B2 (en) | 2019-05-17 | 2023-11-21 | Medtronic Vascular, Inc. | Tissue-removing catheter |
WO2020236646A1 (en) * | 2019-05-17 | 2020-11-26 | The Regents Of The University Of Colorado, A Body Corporate | Split overtube assembly |
CN110074906A (en) * | 2019-06-03 | 2019-08-02 | 陈光忠 | Blood flow controlling apparatus |
CN110292701B (en) * | 2019-06-27 | 2021-11-16 | 山东瑞安泰医疗技术有限公司 | Drug eluting balloon catheter and preparation method thereof |
CN110507385B (en) * | 2019-09-04 | 2021-02-19 | 肖平喜 | Embedded expansion balloon |
DE102020111805A1 (en) * | 2019-09-09 | 2021-03-11 | Alexander Ruebben | Diameter reduction |
CN110548210B (en) * | 2019-10-09 | 2024-02-20 | 四川省肿瘤医院 | Catheter for preventing corner formed by decompression from damaging urethra |
US20210145262A1 (en) * | 2019-11-18 | 2021-05-20 | Nido Surgical Inc. | System with instrument port for epicardial ablation |
US12011184B2 (en) | 2020-02-10 | 2024-06-18 | Elixir Medical Corporation | Methods and apparatus for plaque disruption |
CN114159676A (en) * | 2020-09-09 | 2022-03-11 | 上海鸿脉医疗科技有限公司 | Balloon catheter |
KR102284709B1 (en) * | 2020-10-07 | 2021-08-02 | 문동언 | Balloon Catheter Comprising a Metal Body |
CN114305582A (en) * | 2020-10-10 | 2022-04-12 | 赛诺神畅医疗科技有限公司 | Balloon catheter for thrombus removal |
CN112793172B (en) * | 2020-12-21 | 2022-07-15 | 科塞尔医疗科技(苏州)有限公司 | Balloon forming device suitable for forming different special balloons |
WO2024039373A1 (en) * | 2022-08-18 | 2024-02-22 | Bard Peripheral Vascular, Inc. | Balloon catheter with enhanced scoring capability |
CN115554578B (en) * | 2022-12-05 | 2023-04-28 | 苏州天鸿盛捷医疗器械有限公司 | Restraint device for balloon, preparation method thereof and vasodilation instrument |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020010489A1 (en) * | 2000-07-24 | 2002-01-24 | Jeffrey Grayzel | Stiffened balloon catheter for dilatation and stenting |
US20060241680A1 (en) * | 2005-01-03 | 2006-10-26 | Eric Johnson | Coated endoluminal filter |
US20080097301A1 (en) * | 2006-08-07 | 2008-04-24 | Alpini Alfred A | Non-shortening high angle wrapped balloons |
US20100189876A1 (en) * | 2001-01-05 | 2010-07-29 | Abbott Cardiovascular Systems Inc. | Balloon Catheter for Delivering Therapeutic Agents |
US20120059401A1 (en) * | 2010-03-12 | 2012-03-08 | Quatro Vascular Pe Ltd. | Device and method for compartmental vessel treatment |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1327858A (en) | 1971-07-22 | 1973-08-22 | Euromedical Ind Ltd | Balloon catheters |
JPH0790042B2 (en) | 1985-09-20 | 1995-10-04 | レイケム・コ−ポレイション | Guiding category |
US4771776A (en) | 1987-01-06 | 1988-09-20 | Advanced Cardiovascular Systems, Inc. | Dilatation catheter with angled balloon and method |
US4950232A (en) | 1987-08-11 | 1990-08-21 | Surelab Superior Research Laboratories | Cerebrospinal fluid shunt system |
JPH074422B2 (en) | 1988-12-27 | 1995-01-25 | 寛治 井上 | Balloon catheter manufacturing method |
US4941877A (en) | 1989-01-26 | 1990-07-17 | Cordis Corporation | Balloon catheter |
US5250070A (en) | 1991-05-28 | 1993-10-05 | Parodi Juan C | Less traumatic angioplasty balloon for arterial dilatation |
CA2060133C (en) | 1992-01-30 | 2002-05-28 | Geoffrey S. Martin | Balloon catheter |
US5342434A (en) | 1992-12-14 | 1994-08-30 | W. L. Gore & Associates, Inc. | Gas permeable coated porous membranes |
US5487730A (en) | 1992-12-30 | 1996-01-30 | Medtronic, Inc. | Balloon catheter with balloon surface retention means |
GB2275119B (en) | 1993-02-03 | 1997-05-14 | Motorola Inc | A cached processor |
US5460872A (en) | 1993-03-26 | 1995-10-24 | W. L. Gore & Associates, Inc. | Process for coating microporous substrates and products therefrom |
JP3694524B2 (en) | 1993-08-23 | 2005-09-14 | ボストン サイエンティフィック コーポレイション | Improved balloon catheter |
US6689158B1 (en) | 1993-09-30 | 2004-02-10 | Endogad Research Pty Limited | Intraluminal graft |
US5545209A (en) | 1993-09-30 | 1996-08-13 | Texas Petrodet, Inc. | Controlled deployment of a medical device |
US5409458A (en) | 1993-11-10 | 1995-04-25 | Medtronic, Inc. | Grooved balloon for dilatation catheter |
US5545132A (en) | 1993-12-21 | 1996-08-13 | C. R. Bard, Inc. | Helically grooved balloon for dilatation catheter and method of using |
US5484411A (en) | 1994-01-14 | 1996-01-16 | Cordis Corporation | Spiral shaped perfusion balloon and method of use and manufacture |
US6245040B1 (en) | 1994-01-14 | 2001-06-12 | Cordis Corporation | Perfusion balloon brace and method of use |
US5470313A (en) | 1994-02-24 | 1995-11-28 | Cardiovascular Dynamics, Inc. | Variable diameter balloon dilatation catheter |
US5843116A (en) | 1996-05-02 | 1998-12-01 | Cardiovascular Dynamics, Inc. | Focalized intraluminal balloons |
EP0777567B1 (en) | 1994-09-02 | 2001-08-22 | W.L. Gore & Associates, Inc. | Porous polytetrafluoroethylene compositions |
ES2144574T3 (en) | 1994-10-20 | 2000-06-16 | Interventional Technologies | PROCEDURE FOR THE MANUFACTURE OF A POLYMER MATERIAL WITH IMPROVED MECHANICAL PROPERTIES. |
US5620457A (en) | 1994-11-23 | 1997-04-15 | Medinol Ltd. | Catheter balloon |
US5476589A (en) | 1995-03-10 | 1995-12-19 | W. L. Gore & Associates, Inc. | Porpous PTFE film and a manufacturing method therefor |
NL1000106C2 (en) | 1995-04-10 | 1996-10-11 | Cordis Europ | Balloon balloon balloon catheter and method of making the balloon. |
US5814405A (en) | 1995-08-04 | 1998-09-29 | W. L. Gore & Associates, Inc. | Strong, air permeable membranes of polytetrafluoroethylene |
US5868704A (en) | 1995-09-18 | 1999-02-09 | W. L. Gore & Associates, Inc. | Balloon catheter device |
US20060271091A1 (en) | 1995-09-18 | 2006-11-30 | Campbell Carey V | Balloon catheter device |
US5827304A (en) | 1995-11-16 | 1998-10-27 | Applied Medical Resources Corporation | Intraluminal extraction catheter |
NL1003178C2 (en) | 1996-05-21 | 1997-11-25 | Cordis Europ | Tubular prosthesis made of curable material. |
US5954740A (en) | 1996-09-23 | 1999-09-21 | Boston Scientific Corporation | Catheter balloon having raised radial segments |
US5913871A (en) | 1996-09-25 | 1999-06-22 | Medtronic, Inc. | Balloon modification for improved stent fixation and deployment |
US6039757A (en) | 1997-03-12 | 2000-03-21 | Cardiosynopsis, Inc. | In situ formed fenestrated stent |
GB9707725D0 (en) | 1997-04-16 | 1997-06-04 | Smiths Industries Plc | Cuffed medico-surgical tubes |
US5954745A (en) | 1997-05-16 | 1999-09-21 | Gertler; Jonathan | Catheter-filter set having a compliant seal |
IT238354Y1 (en) | 1997-09-12 | 2000-10-16 | Invatec Srl | DILATATION CATHETER FOR THE INTRODUCTION OF EXPANDABLE STENT |
US6206283B1 (en) | 1998-12-23 | 2001-03-27 | At&T Corp. | Method and apparatus for transferring money via a telephone call |
JPH11319103A (en) | 1998-05-18 | 1999-11-24 | Toray Ind Inc | Catheter for drug injection |
US6048332A (en) | 1998-10-09 | 2000-04-11 | Ave Connaught | Dimpled porous infusion balloon |
US6129706A (en) | 1998-12-10 | 2000-10-10 | Janacek; Jaroslav | Corrugated catheter balloon |
US6022359A (en) | 1999-01-13 | 2000-02-08 | Frantzen; John J. | Stent delivery system featuring a flexible balloon |
US7049380B1 (en) | 1999-01-19 | 2006-05-23 | Gore Enterprise Holdings, Inc. | Thermoplastic copolymer of tetrafluoroethylene and perfluoromethyl vinyl ether and medical devices employing the copolymer |
US6258099B1 (en) | 1999-03-31 | 2001-07-10 | Scimed Life Systems, Inc. | Stent security balloon/balloon catheter |
US6786889B1 (en) | 1999-03-31 | 2004-09-07 | Scimed Life Systems, Inc | Textured and/or marked balloon for stent delivery |
KR20020064882A (en) * | 1999-09-23 | 2002-08-10 | 어드밴스트 스텐트 테크놀로지스, 인코포레이티드 | Differentially expanding stent and method of use |
DE19952505A1 (en) | 1999-10-29 | 2001-05-03 | Gerd Hausdorf | An expandable balloon for medical use comprises a thin-walled polymer shell coated with radio-opaque material in a pattern and is expandable on introduction of liquid and increasing pressure |
DE29922454U1 (en) | 1999-12-21 | 2000-03-02 | Jomed GmbH, 72414 Rangendingen | Expandable balloon for balloon catheters |
US7479128B1 (en) | 2000-01-04 | 2009-01-20 | Boston Scientific Scimed, Inc. | Protective coatings for medical devices |
US6478807B1 (en) | 2000-06-08 | 2002-11-12 | Advanced Cardiovascular Systems, Inc. | Pre-formed expandable member having grooves |
JP4538918B2 (en) * | 2000-08-02 | 2010-09-08 | 株式会社カネカ | Medical catheter for treating part of a body tube with ionizing radiation |
US6875197B1 (en) | 2000-11-14 | 2005-04-05 | Advanced Cardiovascular Systems, Inc. | Dimensionally stable and growth controlled inflatable member for a catheter |
US6638246B1 (en) * | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
US6527739B1 (en) | 2000-12-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Spiraled balloon arrangement for treatment of a tortuous vessel |
US7572270B2 (en) | 2001-02-16 | 2009-08-11 | Cordis Corporation | Balloon catheter stent delivery system with ridges |
US20020161388A1 (en) * | 2001-02-27 | 2002-10-31 | Samuels Sam L. | Elastomeric balloon support fabric |
NL1018018C2 (en) | 2001-05-08 | 2002-11-19 | Blue Medical Devices B V | Balloon catheter and method for manufacturing thereof. |
US20030032999A1 (en) | 2001-08-07 | 2003-02-13 | Medtronic Ave, Inc. | Balloon stent assembly system and method |
US7004963B2 (en) | 2001-09-14 | 2006-02-28 | Scimed Life Systems, Inc. | Conformable balloons |
US7083639B2 (en) | 2001-09-26 | 2006-08-01 | Medtronic Vascular, Inc. | Stent delivery catheter with grooved balloon and methods of making same |
US6814730B2 (en) | 2001-10-09 | 2004-11-09 | Hong Li | Balloon catheters for non-continuous lesions |
US6541589B1 (en) | 2001-10-15 | 2003-04-01 | Gore Enterprise Holdings, Inc. | Tetrafluoroethylene copolymer |
JP2003320031A (en) | 2002-02-26 | 2003-11-11 | Buaayu:Kk | Balloon catheter |
US20050137621A1 (en) | 2002-04-08 | 2005-06-23 | Acrostak Corporation | PTCA and/or PTA balloon |
US7335184B2 (en) | 2002-07-02 | 2008-02-26 | Sentient Engineering And Technology | Balloon catheter and treatment apparatus |
US20040024448A1 (en) | 2002-08-05 | 2004-02-05 | Chang James W. | Thermoplastic fluoropolymer-coated medical devices |
US6991617B2 (en) | 2002-08-21 | 2006-01-31 | Hektner Thomas R | Vascular treatment method and device |
US6989025B2 (en) | 2002-10-04 | 2006-01-24 | Boston Scientific Scimed, Inc. | Extruded tubing with discontinuous striping |
US6835189B2 (en) | 2002-10-15 | 2004-12-28 | Scimed Life Systems, Inc. | Controlled deployment balloon |
US6841213B2 (en) | 2002-12-27 | 2005-01-11 | Scimed Life Systems, Inc | Fiber pattern printing |
US7195638B1 (en) | 2002-12-30 | 2007-03-27 | Advanced Cardiovascular Systems, Inc. | Catheter balloon |
US7625337B2 (en) * | 2003-01-17 | 2009-12-01 | Gore Enterprise Holdings, Inc. | Catheter assembly |
US7686824B2 (en) | 2003-01-21 | 2010-03-30 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
US7306616B2 (en) | 2003-05-05 | 2007-12-11 | Boston Scientific Scimed, Inc. | Balloon catheter and method of making same |
US7776078B2 (en) | 2003-05-22 | 2010-08-17 | Boston Scientfic Scimed, Inc. | Catheter balloon with improved retention |
US7008438B2 (en) | 2003-07-14 | 2006-03-07 | Scimed Life Systems, Inc. | Anchored PTCA balloon |
US8048093B2 (en) | 2003-12-19 | 2011-11-01 | Boston Scientific Scimed, Inc. | Textured balloons |
US7273471B1 (en) | 2003-12-23 | 2007-09-25 | Advanced Cardiovascular Systems, Inc. | Catheter balloon having a porous layer with ridges |
US7270673B2 (en) * | 2003-12-31 | 2007-09-18 | Boston Scientific Scimed, Inc. | Microsurgical balloon with protective reinforcement |
JP4443278B2 (en) | 2004-03-26 | 2010-03-31 | テルモ株式会社 | Catheter with expansion body |
US7566319B2 (en) | 2004-04-21 | 2009-07-28 | Boston Scientific Scimed, Inc. | Traction balloon |
JP2005349202A (en) | 2004-06-08 | 2005-12-22 | Cordis Corp | Instrument and method for delivering therapeutic agent into tissue |
US20060136032A1 (en) | 2004-12-16 | 2006-06-22 | Advanced Cardiovascular Systems, Inc. | Balloon catheter having a balloon with hybrid porosity sublayers |
US20060178685A1 (en) | 2004-12-30 | 2006-08-10 | Cook Incorporated | Balloon expandable plaque cutting device |
DK1830915T3 (en) | 2004-12-30 | 2009-02-16 | Cook Inc | Catheter construction with plaque cutting balloon |
ATE554820T1 (en) | 2005-01-24 | 2012-05-15 | Makram R Ebeid | BALLOON CATHETER FOR STENT POSITIONING IN A BLOOD VESSEL CURVE SEGMENT |
US8048028B2 (en) | 2005-02-17 | 2011-11-01 | Boston Scientific Scimed, Inc. | Reinforced medical balloon |
US8465509B2 (en) | 2005-02-28 | 2013-06-18 | Avraham Shekalim | Apparatus and method for removing deposits from tubular structure, particularly atheroma from blood vessels |
US8851294B2 (en) | 2005-05-25 | 2014-10-07 | W. L. Gore & Associates, Inc. | Aqueous delivery system for low surface energy structures |
JP5307536B2 (en) | 2005-05-25 | 2013-10-02 | ゴア エンタープライズ ホールディングス,インコーポレイティド | Multifunctional coating on microporous substrate |
US8292912B2 (en) | 2005-06-10 | 2012-10-23 | Cook Medical Technologies, LLC | Balloon catheter that resists curving |
BRPI0520387A2 (en) | 2005-06-14 | 2009-05-05 | Vayu Co Ltd | balloon catheter |
US7531611B2 (en) | 2005-07-05 | 2009-05-12 | Gore Enterprise Holdings, Inc. | Copolymers of tetrafluoroethylene |
US7306729B2 (en) | 2005-07-18 | 2007-12-11 | Gore Enterprise Holdings, Inc. | Porous PTFE materials and articles produced therefrom |
US7927362B2 (en) | 2005-07-21 | 2011-04-19 | Boston Scientific Scimed, Inc. | Laser ablated elastomer sheath profiles to enables stent securement |
US20070061006A1 (en) | 2005-09-14 | 2007-03-15 | Nathan Desatnik | Methods of making shape memory films by chemical vapor deposition and shape memory devices made thereby |
US8876763B2 (en) * | 2005-11-01 | 2014-11-04 | Boston Scientific Scimed, Inc. | Composite balloon |
US7828766B2 (en) | 2005-12-20 | 2010-11-09 | Advanced Cardiovascular Systems, Inc. | Non-compliant multilayered balloon for a catheter |
BRMU8600250Y8 (en) | 2006-02-24 | 2021-06-22 | Angiomed Imp E Exportacao Ltda Me | constructive disposition applied in balloon catheter |
US8333000B2 (en) | 2006-06-19 | 2012-12-18 | Advanced Cardiovascular Systems, Inc. | Methods for improving stent retention on a balloon catheter |
US20080125711A1 (en) | 2006-08-07 | 2008-05-29 | Alpini Alfred A | Catheter balloons with integrated non-distensible seals |
US20080140173A1 (en) | 2006-08-07 | 2008-06-12 | Sherif Eskaros | Non-shortening wrapped balloon |
US8216267B2 (en) * | 2006-09-12 | 2012-07-10 | Boston Scientific Scimed, Inc. | Multilayer balloon for bifurcated stent delivery and methods of making and using the same |
US7976497B2 (en) | 2007-09-25 | 2011-07-12 | Polyzen Inc. | Multi-layer film welded articulated balloon |
US8637144B2 (en) | 2007-10-04 | 2014-01-28 | W. L. Gore & Associates, Inc. | Expandable TFE copolymers, method of making, and porous, expended articles thereof |
EP2072065A1 (en) | 2007-12-21 | 2009-06-24 | Abbott Laboratories Vascular Enterprises Limited | Strengthening textures in medical devices |
DE102008006092A1 (en) * | 2008-01-25 | 2009-07-30 | Biotronik Vi Patent Ag | Multiple membrane balloon and method of making a multiple membrane balloon |
EP2262565A1 (en) | 2008-03-06 | 2010-12-22 | Boston Scientific Scimed, Inc. | Balloon catheter devices with sheath covering |
EP2431067A1 (en) | 2008-03-07 | 2012-03-21 | London Equitable Limited in its capacity as Trustee of the Think Tank Trust | A dilation catheter |
EP2106820A1 (en) | 2008-03-31 | 2009-10-07 | Torsten Heilmann | Expansible biocompatible coats comprising a biologically active substance |
US20090281564A1 (en) | 2008-05-09 | 2009-11-12 | Cook Incorporated | Pre-Clot Vessel Dilator |
US8771332B2 (en) | 2008-05-29 | 2014-07-08 | Boston Scientific Scimed, Inc. | Multi-layer balloon design for use in combination with catheter assemblies, and methods of making the same |
EP2320985B1 (en) | 2008-07-25 | 2020-11-11 | Cook Medical Technologies LLC | Balloon catheter and method for making the same |
US20100042198A1 (en) | 2008-08-18 | 2010-02-18 | Burton David G | Single piece double wall dilation balloon catheter |
KR101467739B1 (en) * | 2008-08-28 | 2014-12-01 | 마르코 안토니오 페나 듀크 | Directional expansion of intraluminal devices |
JP2012505050A (en) | 2008-10-10 | 2012-03-01 | インターバルブ, インコーポレイテッド | Valvuloplasty catheter and method |
US9139669B2 (en) | 2009-03-24 | 2015-09-22 | W. L. Gore & Associates, Inc. | Expandable functional TFE copolymer fine powder, the expandable functional products obtained therefrom and reaction of the expanded products |
EP2258439B1 (en) | 2009-06-04 | 2020-04-29 | Biotronik Ag | Structured drug-eluting balloon catheter |
EP2470232B1 (en) * | 2009-08-27 | 2016-03-30 | Boston Scientific Scimed, Inc. | Balloon catheter devices with drug-coated sheath |
US10086176B2 (en) | 2009-12-11 | 2018-10-02 | Hotspur Technologies, Inc. | Balloon catheter and methods for use |
US20110230946A1 (en) | 2010-03-16 | 2011-09-22 | Abbott Laboratories | Easy marker placement balloon mold |
US8808848B2 (en) | 2010-09-10 | 2014-08-19 | W. L. Gore & Associates, Inc. | Porous article |
US8961457B2 (en) * | 2010-09-30 | 2015-02-24 | Surmodics, Inc. | Catheter assembly with guard |
US8597239B2 (en) | 2011-03-01 | 2013-12-03 | Sanovas, Inc. | Abrading balloon catheter for extravasated drug delivery |
US9028444B2 (en) | 2011-04-15 | 2015-05-12 | W. L. Gore & Associates, Inc. | Pivoting ring seal |
US9370647B2 (en) | 2011-07-14 | 2016-06-21 | W. L. Gore & Associates, Inc. | Expandable medical devices |
-
2012
- 2012-10-04 US US13/645,414 patent/US9730726B2/en active Active
- 2012-10-05 CN CN201280054897.5A patent/CN103930158B/en active Active
- 2012-10-05 EP EP19151714.3A patent/EP3488892B1/en active Active
- 2012-10-05 RU RU2014118473/14A patent/RU2014118473A/en not_active Application Discontinuation
- 2012-10-05 BR BR112014008291A patent/BR112014008291A2/en not_active IP Right Cessation
- 2012-10-05 CA CA2850504A patent/CA2850504C/en active Active
- 2012-10-05 AU AU2012333084A patent/AU2012333084A1/en not_active Abandoned
- 2012-10-05 ES ES19151714T patent/ES2877118T3/en active Active
- 2012-10-05 KR KR1020147012044A patent/KR20140074378A/en not_active Application Discontinuation
- 2012-10-05 ES ES19151719T patent/ES2817498T3/en active Active
- 2012-10-05 JP JP2014534792A patent/JP6612502B2/en active Active
- 2012-10-05 WO PCT/US2012/059024 patent/WO2013066566A1/en active Application Filing
- 2012-10-05 EP EP19151719.2A patent/EP3488893B1/en active Active
- 2012-10-05 EP EP12779235.6A patent/EP2763735B1/en active Active
- 2012-10-05 EP EP20185756.2A patent/EP3789073A1/en active Pending
-
2015
- 2015-02-02 HK HK15101106.2A patent/HK1200744A1/en not_active IP Right Cessation
-
2017
- 2017-07-10 US US15/645,176 patent/US10881426B2/en active Active
- 2017-12-01 JP JP2017231826A patent/JP2018043036A/en active Pending
-
2019
- 2019-02-07 JP JP2019020867A patent/JP6680915B2/en active Active
-
2020
- 2020-03-19 JP JP2020049651A patent/JP7309643B2/en active Active
- 2020-12-29 US US17/136,570 patent/US20210186555A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020010489A1 (en) * | 2000-07-24 | 2002-01-24 | Jeffrey Grayzel | Stiffened balloon catheter for dilatation and stenting |
US20100189876A1 (en) * | 2001-01-05 | 2010-07-29 | Abbott Cardiovascular Systems Inc. | Balloon Catheter for Delivering Therapeutic Agents |
US20060241680A1 (en) * | 2005-01-03 | 2006-10-26 | Eric Johnson | Coated endoluminal filter |
US20080097301A1 (en) * | 2006-08-07 | 2008-04-24 | Alpini Alfred A | Non-shortening high angle wrapped balloons |
US20120059401A1 (en) * | 2010-03-12 | 2012-03-08 | Quatro Vascular Pe Ltd. | Device and method for compartmental vessel treatment |
Also Published As
Publication number | Publication date |
---|---|
EP2763735B1 (en) | 2019-01-16 |
US20170333075A1 (en) | 2017-11-23 |
EP3488893A1 (en) | 2019-05-29 |
JP2019088877A (en) | 2019-06-13 |
ES2817498T3 (en) | 2021-04-07 |
JP2018043036A (en) | 2018-03-22 |
HK1200744A1 (en) | 2015-08-14 |
JP7309643B2 (en) | 2023-07-18 |
BR112014008291A2 (en) | 2017-04-18 |
EP2763735A1 (en) | 2014-08-13 |
RU2014118473A (en) | 2015-11-20 |
WO2013066566A1 (en) | 2013-05-10 |
JP2014528809A (en) | 2014-10-30 |
EP3789073A1 (en) | 2021-03-10 |
CA2850504A1 (en) | 2013-05-10 |
KR20140074378A (en) | 2014-06-17 |
ES2877118T3 (en) | 2021-11-16 |
CN103930158B (en) | 2016-08-24 |
CA2850504C (en) | 2018-02-13 |
CN103930158A (en) | 2014-07-16 |
AU2012333084A1 (en) | 2014-05-29 |
US20130116655A1 (en) | 2013-05-09 |
US9730726B2 (en) | 2017-08-15 |
US10881426B2 (en) | 2021-01-05 |
JP6680915B2 (en) | 2020-04-15 |
EP3488892A1 (en) | 2019-05-29 |
EP3488892B1 (en) | 2021-03-31 |
JP2020103953A (en) | 2020-07-09 |
JP6612502B2 (en) | 2019-11-27 |
EP3488893B1 (en) | 2020-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210186555A1 (en) | Balloon assemblies having controllably variable topographies | |
AU2022204890B2 (en) | Controlled porosity devices for tissue treatments, methods of use, and methods of manufacture | |
US10786258B2 (en) | Multiple inflation endovascular medical device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |